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Chapter 1 Introduction 
 
Aging: FoxO transcription factors as interventions 
Aging is broadly understood as biological changes that occur with time and lead to 
progressive functional impairment, loss of homeostasis, and risk of mortality. Aging is a 
top risk factor for major causes of human morbidity and mortality, including 
cardiovascular disease, dementia, type 2 diabetes, osteoporosis, autoimmune disease, and 
cancer [1]. It increases susceptibility to disability and infection, and limits ability to 
perform activities of daily living. Modern technology, medicine, public health initiatives 
and lifestyle have increased life expectancy up to 30 years in many countries during the 
20th century [2]. However, the continuing expansion of the elderly population has been 
accompanied by the expected burden of age-related disease. 
Our understanding of aging has been revolutionized by the discovery that single gene 
mutations can dramatically extend the life span of the nematode Caenorhabditis elegans 
(up to 10-fold) [3]. It is now known that these findings translate to mammals and 
potentially humans. The fact that aging is under genetic control makes it possible to treat 
or prevent age-related disease by manipulating gene function pharmacologically. As 
proof of principle, drugs such as rapamycin extend life span and slow age-related changes 
in mice [4,5]. Importantly, many interventions that extend longevity in model organisms 
delay age-related disease and slow functional decline [6]. 
FoxO transcription factors have emerged as major candidates to understand the causes, 
processes and consequences of aging. Identification of specific FoxO activities that affect 
aging may yield treatments to prevent and ameliorate disease, as well as improve quality 
of life for an aging population. 
 
 2 
FoxO transcription factors  
FoxO transcription factors (TFs) comprise a subclass of the forkhead superfamily, which 
regulates gene expression, is defined by a ~100 amino-acid winged helix DNA binding 
domain, and is conserved in all metazoans [7]. Humans and other mammals possess four 
FoxO transcription factors encoded by separate genes: FoxO1, FoxO3, FoxO4, and 
FoxO6 [8]. The model organisms Drosophila melanogaster and C. elegans each possess 
single FoxO orthologs, termed dFoxO and DAF-16/FoxO respectively [9]. 
FoxO transcription factors are homeostatic regulators [10], responding to numerous 
signals concerning nutrient and energy availability, stress, and growth requirements. 
FoxO proteins integrate these signals to coordinate many gene expression programs for 
cellular survival, stress resistance, metabolism, maintenance, and proliferation. These 
allow organisms to grow, develop, and reproduce in a manner appropriate to the 
organism’s circumstances [10]. 
The functions of FoxO TFs are highly varied and context-dependent. For example, FoxO 
can promote either cell survival or cell death depending on the precise conditions of 
growth factor signaling [11]. The pleiotropy and complexity of FoxO TFs makes them 
attractive targets for manipulating complex biological processes to treat disease, but this 
requires a fundamental understanding of how FoxO controls distinct and sometimes 
opposing genetic programs. 
Role of FoxO and insulin/IGF signaling (IIS) in longevity control 
FoxO transcription factors are negatively regulated in a conserved manner by insulin and 
insulin-like growth factor (IGF) signaling (IIS) via a phosphoinositide 3-kinase and 
protein kinase B (PI3K/Akt) phosphorylation cascade [12]. IIS control of FoxO and 
longevity was initially discovered by work in the nematode C. elegans, and is now a 




A single mutation in the C. elegans daf-2 gene doubles life span and slows age-related 
decline, effects that are completely reversed by a single mutation in another gene, daf-16 
[13]. Cloning revealed that daf-2 is homologous to mammalian insulin and IGF receptors 
[14], and daf-16 is homologous to mammalian FoxO transcription factors [15,16]. These 
daf-2/IGFR and daf-16/FoxO mutations reduce or eliminate gene function, and therefore 
reduced insulin/IGF signaling (IIS) extends life span dependent on FoxO.  
Reduced IIS influences life span in a conserved manner across animal species. Mutations 
in the Drosophila insulin-like receptor pathway extend life span up to 85% [17,18]. 
Approximately a dozen studies have examined the longevity of mice with mutations 
affecting the IGF-1 or insulin signaling pathways, or the growth hormone signaling 
pathway that regulates IGF-1 production [19]. Consistent with findings in invertebrates, 
most of these studies showed that reduced IIS extends life span. There is also some 
evidence from human candidate gene association studies that the IIS pathway influences 
longevity [19]. In particular, mutations that impair IGF receptor function are associated 
with extreme longevity in Ashkenazi Jewish populations [20]. The precise mechanisms 
by which IIS influences mammalian longevity have yet to be elucidated, but dysregulated 
IIS has been linked to type 2 diabetes, cardiovascular disease, cancer, and dementia [6]. 
FoxO plays a crucial and conserved role in life span extension due to IIS reduction. 
Similar to C. elegans DAF-16/FoxO, the Drosophila FoxO ortholog is required for the 
longevity of IIS mutants [21]. DAF-16/FoxO mediates the majority of gene expression 
changes resulting from daf-2/IGFR mutation, and specific genes regulated by DAF-
16/FoxO influence life span [22,23]. Accordingly, overexpression of FoxO extends life 
span in both worms and flies [24,25]. Therefore, DAF-16/FoxO is not simply a 
permissive factor, but indeed plays an active and causative role in life span extension. 
FoxO is implicated in human longevity, given that IIS influences mammalian aging, 
mechanisms of FoxO regulation by IIS are highly conserved, and FoxO mediates IIS 
mutant longevity in invertebrates. However, a causative role for FoxO in mammalian 
longevity has not been strictly proven. At present, the strongest evidence for involvement 
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of FoxO comes from candidate gene association studies, where human FoxO 
polymorphisms have been linked to longevity in multiple and diverse human cohorts [26–
29]. Some studies also found associations with improved cardiovascular health, lower 
incidence of cancer, and improved insulin sensitivity. Regardless, FoxO possesses 
diverse functions in mammals. Uncovering the mechanisms by which FoxO promotes 
longevity in model organisms should narrow the search for candidate mechanisms that 
may be active in humans. 
 
Figure 1.1: Insulin and insulin-like signaling (IIS) controls FoxO transcription 






Role of FoxO in mammalian biology and age-related disease 
The initial discovery in C. elegans that FoxO transcription factors are regulated by IIS 
[15,16] has motivated intensive study of FoxO’s conserved role in mammalian IIS and 
numerous other biological processes [30]. Animal models and human clinical studies 
implicate dysregulation of FoxO transcription factors in age-related pathologies, 
including osteoporosis, cancer, type 2 diabetes, and more general loss of tissue integrity 
[31]. 
Deletion of FoxO1, FoxO3, and FoxO4 together (FoxO1/3/4) in adulthood increases 
mouse osteoblast apoptosis resulting in loss of bone mass, implying FoxO activity can 
protect against osteoporosis [32]. Loss of FoxO1/3/4 in mice also causes widespread 
formation of metastatic cancer, especially lymphomas and hemangiomas [33]. 
Furthermore, FoxO acts as a tumor suppressor in human breast cancer, renal cell 
carcinoma, stomach cancer, and others [34–37]. Despite these desirable influences on 
osteoporosis and cancer, a few studies have identified potentially detrimental roles for 
FoxO in these diseases [38,39], suggesting that manipulation of FoxO activity must be 
done in a targeted manner. 
FoxO activation also appears to be pathogenic in the context of diabetes. FoxO1 
haploinsufficiency in the liver reverses the diabetes-like phenotype caused by InsR 
(insulin receptor) mutation and high-fat diet [40,41], and restores deficient pancreatic 
beta cell proliferation in Irs2 (insulin-receptor substrate 2) mutants [42]. Thus, FoxO1 
can contribute to metabolic and cellular derangements of diabetes. 
Mouse studies suggest that FoxO transcription factors may protect against age-related 
disease by promoting tissue homeostasis [43], which normally declines with age resulting 
in inappropriate cell proliferation and reduced regeneration [44]. FoxO1/3/4 loss in the 
hematopoietic system causes depletion of hematopoietic stem cells and over-proliferation 
of immune cells [45]. A similar effect on neural stem cells and brain size is observed 
upon deletion of FoxO1/3/4 in the central nervous system [32]. FoxO3 appears to be 
particularly important for tissue homeostasis, as whole-body knockout of FoxO3 alone 
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causes early infertility due to premature ovarian failure, widespread organ inflammation 
secondary to immune cell abnormalities, and depletion of neural stem cells [46–48]. 
In summary, both protective and pathogenic effects of FoxO have also been described in 
age-related phenotypes. Even if FoxO does not influence longevity per se in humans, 
FoxO transcription factors are excellent candidates for intervening in age-related disease. 
However, the complexity of FoxO biology demonstrates the need to dissect specific outputs 





C. elegans: model organism for FoxO control of longevity 
The initial discovery of FoxO’s role in longevity control and its regulation by IIS was 
greatly facilitated by advantages of the C. elegans model system (Figure 1.2). In 
particular, it is easy to manipulate multiple genes simultaneously and measure life span, 
and these advantages help to further dissect the mechanism of life span extension by 
FoxO. 
Mutating genes in C. elegans to investigate function is easy, rapid and cheap, facilitating 
screening and analysis of large numbers of genes. The C. elegans genome harbors an 
estimated 20,470 protein-coding genes, and many variants (alleles) of nearly all those 
genes have already been isolated from mutagenesis screens and are readily available to 
researchers. Alternatively, gene function can be reduced by RNA interference (RNAi) 
simply by feeding RNAi to animals [49]. 
Rapid breeding of C. elegans worms harboring multiple mutations is enabled by powerful 
genetic tools and short generation time. For assays, large numbers of animals can be 
easily grown in a synchronized and uniform fashion. Wild-type C. elegans (the N2 
Bristol strain) live approximately 2-3 weeks, while daf-2/IGFR mutants live 6-9 weeks. 
Therefore, many life span experiments can be conducted in a short period of time. In 
contrast, many mouse longevity studies report the results of a single cohort of mice due to 
prohibitive cost and length (2-4 years) of experiments. 
The C. elegans model system is also particularly advantageous for study of FoxO 
transcription factors. A single IIS input from daf-2/IGFR exists in C. elegans, simplifying 
pathway analysis. Mutant strains of daf-16/FoxO are viable, while knockout of FoxO1 in 
mice results in embryonic lethality due to failure of vascular development [50]. DAF-
16/FoxO activity influences many other easily assayable traits, including development, 
stress resistance, motility, and fat stores. Finally, a well-annotated genome and 
transcriptome facilitates study of FoxO’s role as a transcription factor. 
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C. elegans is an excellent system for identifying and functionally testing specific genes 
that influence longevity. 35% of C. elegans genes have human homologs [51] and are 
similar enough that many human genes can be introduced and functionally replace their 
C. elegans counterparts. Thus, genes found to influence longevity in C. elegans are likely 
to shed light on their counterparts in humans. 
Figure 1.2. Advantages of the C. elegans model system, specifically in the fields of 
FoxO biology and longevity control.  






IIS regulation of DAF-16/FoxO in C. elegans 
The mechanisms by which IIS regulates the FoxO ortholog DAF-16 in C. elegans is 
remarkably similar to those in mammals, with all major components of the IIS pathway 
functionally and molecularly conserved. Binding of insulin-like peptides to the C. 
elegans insulin-like receptor DAF-2 [14] activates a signaling pathway comprised of the 
phosphatidylinositol-3-kinase AGE-1 [52], synthesis of phosphatidylinositol (3,4,5)-
trisphosphate (PIP3), the phosphoinositol-dependent kinase PDK-1 [53], and serine-
threonine kinases AKT-1 and AKT-2 [54]. These AKT kinases phosphorylate three 
conserved RxRxxS/T consensus motifs on DAF-16/FoxO. This promotes cytoplasmic 
sequestration of DAF-16/FoxO [55] enhanced by binding to 14-3-3 proteins [56,57], thus 
preventing DAF-16/FoxO from regulating transcription of its target genes. Loss-of-
function mutations in components of this pathway promote longevity in a DAF-16/FoxO-
dependent manner. Thus, DAF-2 insulin-like signaling inhibits the transcriptional activity 
of DAF-16/FoxO to control longevity (Figure 1.3). 
SGK-1 (serum/glucocorticoid regulated kinase) is highly related to AKT kinases and is 
predicted to inhibit DAF-16/FoxO due to similar substrate specificity (RxRxxS/T motifs). 
Indeed, mammalian Sgk inhibits FoxO transcriptional activity in cell culture [58], and 
inactivation of sgk-1 by RNA interference (RNAi) has been reported to promote DAF-
16/FoxO nuclear localization and life span extension in C. elegans [59]. However, 
several recent reports utilizing sgk-1 mutations [60–62] have called into question the 
paradigm that SGK-1 inhibits DAF-16/FoxO. It remains an open question as to how 









Multiple DAF-16/FoxO isoforms with divergent functions 
While mammals possess four FoxO isoforms encoded by distinct loci, a single C. elegans 
daf-16/FoxO genomic locus encodes multiple protein isoforms that share C-termini but 
differ in their transcriptional start sites and N-termini. There are three functional 
isoforms: DAF-16A, DAF-16B, and DAF-16F [60,63]. See Chapter 4 for greater detail. 
DAF-16A and DAF-16F share 428 carboxy-terminal amino acids and are the most 
similar to human FoxO1, FoxO3, and FoxO4. The forkhead DNA binding domain is 
highly conserved (76% identity with FoxO1) and accordingly DAF-16A binds the same 
DNA motif as mammalian FoxO in vitro [64]. Key regulatory elements are also 
conserved, including 14-3-3 binding sites and RxRxxS/T motifs phosphorylated in 
response to IIS. DAF-16B is more distantly related and differs in a portion of the DNA 
binding domain. In place of the N-terminal RxRxxT, DAF-16F has a unique QxRxxS 
motif that is present in FoxO3 and FoxO4 but not FoxO1, suggesting that regulation and 
function of specific DAF-16/FoxO isoforms may parallel that of specific mammalian 
FoxO isoforms. 
Mammalian FoxO TFs display strongly overlapping expression patterns among tissues, 
yet show dramatically distinct phenotypes when knocked out individually [31]. However, 
consistent with significant sequence homology, they also have redundant functions. For 
example, loss of FoxO1, FoxO3, and FoxO4 in adulthood causes formation of 
widespread cancer, deletion of one or two FoxO isoforms causes very mild tumorigenic 
phenotypes [33]. The divergent but overlapping functions of FoxO isoforms in mammals 
raise the strong possibility that conserved DAF-16/FoxO isoforms also have a mixture of 
unique and shared functions. 
Most data on the distinct functions of DAF-16 isoforms is based on transgenes that over-
express the isoforms in animals lacking DAF-16 activity. Experiments indicate distinct 
tissue expression, regulation by distinct kinases, and differential contributions to 
longevity, target gene regulation, development, and stress resistance [60,65]. In 
particular, rescue of either DAF-16A or DAF-16F in animals lacking DAF-16 restores 
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daf-2/IGFR longevity. DAF-16B does not appear to contribute to longevity, and DAF-
16F may play a stronger role than DAF-16A. However, the use of daf-16 isoform over-
expression and lack of isoform-specific mutants limits the interpretation of existing data. 
Thus, C. elegans isoforms possess distinct but probably overlapping functions. Only two 
isoforms, DAF-16A and DAF-16F, are capable of promoting longevity [60,66]. 
Elucidating the endogenous contributions of DAF-16A and DAF-16F may suggest 
differential contributions of mammalian FoxO to control of longevity and age-related 
disease. 
Figure 1.4: FoxO isoforms in C. elegans (worm) and Homo sapiens (human).  
Pink, green, and orange indicate unique N-termini of DAF-16/FoxO isoforms. “P” indicates 
phosphorylation sites critical for determination of subcellular localization. Yellow indicates the Forkhead 
DNA binding domain, the region of greatest homology between C. elegans DAF-16 and mammalian FoxO. 
This domain is 76% identical between DAF-16A and FoxO1. For comparison, the forkhead domain of 
FoxO1 is 86%, 83%, and 88% identical those of FoxO3, FoxO4, and FoxO6, respectively. Blue indicates 
the region of 2nd greatest homology, being 31% identical between DAF-16A and FoxO1. For comparison, 
this region in FoxO1 is 65% and 51% identical to those in FoxO3 and FoxO4, respectively. See text and 





Mechanisms of transcriptional regulation by DAF-16/FoxO 
Mammalian FoxO proteins and C. elegans DAF-16 bind highly similar sequences to 
control transcription of target genes. In vitro, FoxO1, FoxO3, FoxO4, and DAF-16 all 
bind the same core consensus sequence TTGTTTAC, named the DAF-16-binding 
element (DBE) [64], confirmed by crystal structures of FoxO1 and FoxO3 bound to the 
DBE [67]. Single nucleotide mutations in the core TGTT sequence are sufficient to 
abolish binding, and the number of promoter DBEs correlates with FoxO1-mediated 
transcription in cell culture reporter assays [64]. However, distinct FoxO proteins vary in 
their preferences for 5’ flanking sequences of the DBE [64]. A global analysis 
demonstrated that genes are most responsive to DBEs located within 300bp upstream of 
the transcriptional start site [23]. However, DAF-16/FoxO probably regulates genes 
through binding to other sequences as well, including those within introns or coding 
regions [68,69]. DAF-16/FoxO also regulates a large subset of genes indirectly [70] by 
mechanisms that may be conserved in mammals [71]. 
Other transcription factors participate in the regulation of both direct and indirect DAF-
16/FoxO targets. Some target genes are co-regulated by HSF-1 [72] and SKN-1 [65,73], 
which also contribute to the longevity of daf-2/IGFR mutants. The DAE (DAF-16-
Associated Element; CTTATCA) is a sequence enriched in the promoters of DAF-
16/FoxO-regulated genes and is the reverse complement of the mammalian GATA site 
[74]. Tissue-specific GATA factors bind the DAE and contribute to tissue-specific 
expression of DAF-16/FoxO target genes and life span control [68,75,76]. The 
transcription factor PQM-1 also regulates gene expression dependent on the DAE [23]. 
DAF-16/FoxO antagonizes PQM-1 nuclear localization and indirectly regulates genes 
through PQM-1 inhibition [23].  
Indirect regulation by DAF-16/FoxO is most striking when acting at a distance across 
tissues. Increasing DAF-16/FoxO activity in one tissue alters gene expression and aging-
related phenotypes in other tissues, presumably through systemic signals [77,68]. 
Intriguingly, DAF-16/FoxO activity limited to the intestine can retard aging of the entire 
organism, and does not require DAF-16/FoxO activity in responding tissues [68,77]. 
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In summary, DAF-16/FoxO controls gene expression through numerous mechanisms, 
exerting far-reaching effects on C. elegans biology. This complexity poses significant 
challenge to understanding the mechanisms by which DAF-16/FoxO promotes longevity. 
 
Known DAF-16/FoxO target genes 
Several studies have collectively discovered thousands of potential gene regulatory 
events mediated directly or indirectly by DAF-16/FoxO in the context of reduced IIS 
(Figure 1.5; [22,23,78]). The most common method is genome-wide RNA transcript 
profiling, for example by printed DNA microarrays, or serial analysis of gene expression 
(SAGE) [22,79]. These studies search for RNA transcripts whose abundance increases or 
decreases under conditions where DAF-16 is on (e.g. following daf-2 mutation or RNAi 
treatment) compared to conditions where DAF-16 is mostly or fully inactive (e.g. wild-
type animals or daf-16;daf-2 double mutants). This method does not distinguish between 
direct and indirect regulatory events.  
Other methods such as chromatin immunoprecipitation (ChIP) and DNA adenine 
methyltransferase identification (DamID) have identified genes directly bound by DAF-
16/FoxO, though many of the binding events do not appear to mediate transcriptional 
regulation [69,70,80]. Proteomics studies have also identified a number of genes whose 
protein levels are altered by DAF-16/FoxO activity [78]. Some protein targets are not 
changed in RNA abundance, and these may be indirectly regulated via other DAF-
16/FoxO transcriptional targets. 
DAF-16/FoxO target gene function has primarily been determined by homology and GO 
term annotation [22,79]. Many of the genes are involved in response to stresses including 
extreme temperature, osmotic stress, free radicals, toxins, physical stress, and infection. 
Others are involved in metabolism or transport of nucleic acids, lipids, protein, 
carbohydrates, and other molecules. Growth, reproduction, development, and structural 
genes are also affected. Apoptosis and cell cycle DAF-16/FoxO targets influence 
germline proliferation [81]. Direct targets of DAF-16/FoxO are enriched for signaling, 
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transcription, and translation genes that could potentially influence the expression of 
indirect targets [69,70]. Notably, DAF-16/FoxO regulates many genes of unknown 
function. FoxO regulates many of the same gene classes in mammals, especially those 
involved in oxidative stress resistance, immunity, apoptosis, metabolism, and signaling 
[10,82]. 
However, some of the existing data on DAF-16/FoxO targets is seemingly conflicting. 
An analysis by McElwee and colleagues suggests that out of ~3000 genes identified by at 
least one of three microarray studies, only ~650 are shared by two or three of the studies 
[83]. Differences in laboratory conditions, experimental conditions such as animal age 
and use of sterile strains, technology platforms, and bioinformatics may all confound the 
analysis. The data has been partially reconciled using a microarray meta-analysis to 
combine the results of all published microarray comparisons between DAF-16-on and 
DAF-16-off conditions [23]. This study found 1,633 genes upregulated by DAF-16/FoxO 
and 1,733 genes downregulated by DAF-16/FoxO, using a 5% false discovery rate. 
Interestingly, ~50% of the top 100 DAF-16/FoxO targets were not found by individual 
microarray studies [23], suggesting that statistical power and methodology may also 
explain incompleteness and differences between studies. Systematic large-scale qPCR 
validation of target genes would be helpful to identify bona fide DAF-16/FoxO targets, 
but has not yet been performed. 
In summary, identification of DAF-16/FoxO target genes remains an ongoing effort that 
has already shed light on how DAF-16/FoxO influences many aspects on animal biology. 
However, a more vexing problem remains: given the thousands of genes potentially 
regulated by DAF-16/FoxO, how do we utilize existing and future data to determine the 
mechanism by which DAF-16/FoxO promotes longevity? This question must be 
addressed before experimentally testing which conserved FoxO targets might influence 




Figure 1.5: DAF-16/FoxO transcriptionally regulates numerous genes, posing a 






An open question: How does DAF-16/FoxO promote longevity? 
A major hypothesis is that DAF-16/FoxO extends longevity through numerous gene 
expression changes, each with minor but cumulative effects on longevity. This hypothesis 
is intuitively appealing, as aging involves many different kinds of biological changes, and 
there are many potential causes of death for an organism that are exacerbated by aging. 
Therefore, it seems highly unlikely that DAF-16/FoxO could promote longevity through 
a single gene or process. 
However, it is possible that some genes may be far more important than others for 
longevity assurance and delay of age-related phenotypes. This possibility has not been 
experimentally tested due to the large number of genes regulated by DAF-16/FoxO. Even 
the hypothesis that a single target gene is responsible for DAF-16/FoxO-mediated 
longevity is difficult to strictly disprove, as this would require testing every single gene 
individually, and currently an exhaustive search is not experimentally feasible. If a small 
set of DAF-16/FoxO target genes with major effects on life span exist, then those are 
excellent candidates for understanding and intervening in the aging process.  
Role of DAF-16/FoxO target genes in life span control 
The most thorough analysis to date of the roles of DAF-16/FoxO target genes in 
promoting daf-2/IGFR longevity was performed by Murphy and colleagues [74]. They 
performed microarray analysis across many conditions to identify 514 high-confidence 
DAF-16/FoxO target genes. The authors then utilized RNAi to knock down 39 DAF-
16/FoxO-upregulated genes (termed Class 1) and 19 downregulated genes (termed Class 
2). Knockdown of nearly all the Class 1 genes modestly reduced daf-2/IGFR life span, 
implying that they normally function to promote longevity. In contrast, knockdown of 
most Class 2 genes modestly increased wild-type life span, implying they normally 
function to limit longevity. No single gene recapitulated the effect of either daf-16 or daf-
2 RNAi. Life span was altered by genes involved in stress responses, signaling, and 
metabolism, as well as genes with no known function. Other studies have expanded the 
list of target genes that influence life span, though the concordance between direction of 
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regulation by DAF-16/FoxO and effect on life span was not as strong as in the study by 
Murphy and colleagues [22,84,85]. Nevertheless, these findings are consistent with the 
hypothesis that DAF-16/FoxO target genes collectively and cumulatively influence aging 
and longevity. 
Because using mutant alleles of a gene to study gene function is far more time-consuming 
than RNAi treatment, very few DAF-16/FoxO target genes have been tested by mutation. 
Therefore, it is unknown if mutation analysis would support the hypothesis that many 
DAF-16/FoxO target genes cumulatively contribute to the longevity of daf-2/IGFR 
mutants. RNAi is prone to both false positives due to off-target effects, as well as false 
negatives due to incomplete knockdown [86]. A study of morpholinos, a system 
analogous to RNAi in zebrafish, showed that 80% of morpholino-induced phenotypes 
were not recapitulated by mutation [87]. It is conceivable that many of the small changes 
in life span upon RNAi knockdown of DAF-16/FoxO target genes are due to off-target 
effects, and the lack of any genes that recapitulated the effect of DAF-16/FoxO could be 
attributable to incomplete knockdown. 
The potential value of testing mutants is illustrated by the Class 1 gene sod-3, a 
manganese superoxide dismutase localizing to mitochondria [88]. RNAi knockdown of 
sod-3 shortens life span of daf-2/IGFR mutants [74], but mutation of sod-3 was 
separately reported to have no effect [89]. It is unclear if this discrepancy is due to off-
target effects of RNAi, or if the role of sod-3 is more complex. Therefore, it is important 
to verify RNAi life span phenotypes using mutation. 
Two recent studies used mutations in target genes to develop the idea that DAF-16/FoxO 
acts as a “regulator of regulators” [78]. aakg-4 and mdl-1 are genes directly bound and 
upregulated by DAF-16/FoxO [70,90,91]. aakg-4 is involved in signaling and mdl-1 is a 
transcription factor. aakg-4 and mdl-1 mutations both reduce daf-2 but not wild-type 
longevity, and cause a number of gene expression changes when mutated. This suggests 
that even if numerous genes contribute to longevity, a few DAF-16/FoxO target genes 
may be responsible for activating the rest, and therefore play a disproportionate role in 
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longevity control. However, as comparable studies have not rigorously tested other 
categories of target genes, the relative contribution of targets involved in signaling and 
transcription compared to other processes is not clear. For our purposes, these studies 
demonstrate that a logical strategy to determine which DAF-16/FoxO target genes are 
most likely to influence life span is valuable for selecting high-priority candidate genes 
for detailed mechanistic studies. 
In summary, the functional significance of specific DAF-16/FoxO target genes in life 
span control has not been tested in a rigorous fashion. Almost none have been tested 
using genetic mutants, and most have not been tested by RNAi except for a subset of the 
top candidates. Therefore, it is plausible that a small number of genes play a 
disproportionate effect in longevity, and we need a logical strategy to identify and test 
these genes. 
A strategy to identify and test high-priority DAF-16/FoxO targets 
The motivating question of this dissertation is: What is the mechanism by which DAF-
16/FoxO promotes longevity? The fact that DAF-16/FoxO influences the expression of 
thousands of genes [23] is a major barrier to experimentally investigating this question. 
Although multiple studies utilizing microarray approaches have identified a number of 
DAF-16/FoxO target genes that may influence life span [22,92], there is surprisingly low 
agreement among these studies [22,23,83], making it difficult to prioritize candidate 
genes for functional validation. Furthermore, more recently developed whole 
transcriptome profiling (RNA-seq) shows greater sensitivity than microarray-based 
approaches [93,94], and thus it is likely that potentially critical subsets of DAF-16/FoxO 
targets remain unidentified. Taken together, the current list of genes is experimentally 
intractable for rigorous functional validation by traditional genetic approaches (e.g. 
genetic mutants), even in spite of the advantages of the C. elegans model system 
compared to vertebrate models (Figure 1.2). A new strategy is required to narrow this list 
and determine the mechanisms of life span extension mediated by DAF-16/FoxO. 
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The overall strategy of this dissertation is to use genetic approaches to isolate and 
selectively activate distinct DAF-16/FoxO transcriptional programs. If only specific 
programs promote longevity, then the genes that comprise those programs are high-
priority candidates. Given the thousands of genes regulated by DAF-16/FoxO, the search 
for specific DAF-16 target genes that promote longevity can be likened to searching for 
needles in a haystack. Selective activation of DAF-16/FoxO programs is akin to 
separating this haystack into many different haystacks. These haystacks are then small 
enough for rigorous functional testing. 
Chapter 2 is concerned with two highly related kinases reported to have very similar 
effects on DAF-16/FoxO activity, but which have opposite effects on longevity, 
potentially representing distinct DAF-16/FoxO programs. Chapter 3 identifies a set of 
genes associated with longevity across many contexts (the “high-priority” haystack). 
Chapter 4 investigates the role of distinct DAF-16/FoxO isoforms in life span control and 
identifies genes specifically regulated by those isoforms, effectively separating target 
genes into multiple groups. Finally, Chapter 5 rigorously tests the groups of genes found 
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Chapter 2 Effects of C. elegans sgk-1 mutations on 




The AGC family serine-threonine kinases Akt and Sgk are similar in primary amino acid 
sequence and in vitro substrate specificity, and both kinases are thought to directly 
phosphorylate and inhibit FoxO transcription factors. In the nematode Caenorhabditis 
elegans, it is well established that AKT-1 controls dauer arrest and life span by regulating 
the subcellular localization of the FoxO transcription factor DAF-16. SGK-1 is thought to 
act similarly to AKT-1 in life span control by phosphorylating and inhibiting the nuclear 
translocation of DAF-16/FoxO. Using sgk-1 null and gain-of-function mutants, we now 
provide multiple lines of evidence indicating that AKT-1 and SGK-1 influence C. 
elegans life span, stress resistance, and DAF-16/FoxO activity in fundamentally different 
ways. Whereas AKT-1 shortens life span, SGK-1 promotes longevity in a DAF-16/FoxO-
dependent manner. In contrast to AKT-1, which reduces resistance to multiple stresses, 
SGK-1 promotes resistance to oxidative stress and ultraviolet radiation but inhibits 
thermotolerance. Analysis of several DAF-16/FoxO target genes that are repressed by 
AKT-1 reveals that SGK-1 represses a subset of these genes while having little influence 
on the expression of others. Accordingly, unlike AKT-1, which promotes the cytoplasmic 
sequestration of DAF-16/FoxO, SGK-1 does not influence DAF-16/FoxO subcellular 
localization. Thus, in spite of their similar in vitro substrate specificities, Akt and Sgk 
                                                
1 Originally published in Aging Cell (2013; 12(5), 932-940) with authors listed as Chen, A.T., Guo, C., 
Dumas, K.J., Ashrafi, K., and Hu, P.J. 
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influence longevity, stress resistance, and FoxO activity through distinct mechanisms in 
vivo. Our findings highlight the need for a re-evaluation of current paradigms of FoxO 
regulation by Sgk.  
 
Introduction 
Akt/Protein Kinase B (PKB) and Sgk are two highly related members of the AGC family 
of serine-threonine kinases that act in cellular signaling pathways to modulate survival, 
growth, proliferation, metabolism, and other processes [1]. Akt/PKB has evolutionarily 
conserved functions in the control of development, growth, metabolism, cell survival, and 
longevity, and dysregulation of Akt/PKB contributes to the pathogenesis of common 
human diseases such as cancer and Type 2 diabetes [2]. 
The mechanism of Akt/PKB activation is well established. In response to growth factors, 
Akt/PKB is activated in a phosphoinositide 3-kinase (PI3K)-dependent manner by 
phosphorylation at two critical regulatory sites: T308 within its kinase domain, and S473 
within a C-terminal hydrophobic motif [3]. The 3-phosphoinositide-dependent kinase 
PDK1 phosphorylates Akt/PKB at T308 [4,5], and members of the PI3K-related kinase 
(PIKK) family such as TOR complex 2 phosphorylate Akt/PKB at S473 [6–8].  
Activated Akt/PKB phosphorylates several substrates in vivo at sites that lie within 
RxRxxS/T motifs [9,10]. Among these substrates are the FoxO family of transcription 
factors that control development, metabolism, growth, and aging [11]. Akt/PKB-
dependent phosphorylation of FoxO at three conserved RxRxxS/T motifs inhibits FoxO 
activity by promoting its export from the nucleus and sequestration in the cytoplasm [12]. 
FoxO is a critical substrate of Akt/PKB in vivo, as its disinhibition in mice with reduced 
hepatic Akt/PKB signaling impairs metabolic homeostasis [13], and a null mutation in 
daf-16, which encodes the sole FoxO transcription factor in the nematode Caenorhabditis 
elegans, suppresses the dauer-constitutive and life span extension phenotypes of animals 
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with reduced Akt/PKB activity [14,15]. Thus, Akt/PKB has an evolutionarily conserved 
function as a direct inhibitor of FoxO transcription factors. 
The serum- and glucocorticoid-regulated kinase gene sgk encodes a serine-threonine 
kinase highly homologous to Akt/PKB that was first identified as a gene whose 
transcription is induced acutely by serum and glucocorticoids in a rat mammary tumor 
cell line [16]. Like Akt/PKB activation, Sgk activation by growth factors is PI3K-
dependent and involves the phosphorylation of a site in the kinase domain (T256) by 
PDK1 [17,18] and a C-terminal site within a hydrophobic motif by TOR complex 2 [19]. 
Furthermore, Sgk also phosphorylates sites that lie within RxRxxS/T motifs [20]. In spite 
of these similarities, some Akt/PKB substrates are poor substrates for Sgk in vitro and 
vice versa [21,22]; this is probably due at least in part to amino acids in the vicinity of the 
phosphoacceptor residue that confer substrate specificity [23]. The distinct substrate 
specificities of Akt/PKB and Sgk are reflected in the observation that, although both 
mammalian Akt/PKB and Sgk can promote the phosphorylation of the FoxO3 
transcription factor in cultured cells at sites within all three conserved RxRxxS/T motifs, 
they do so with distinct efficiencies within each motif [24].  
In mammalian cell culture, Sgk inhibits FoxO3 activity [24,25], and in C. elegans, SGK-
1 is thought to limit life span by inhibiting DAF-16/FoxO activity [26]. Taken together 
with the known role of Akt/PKB in FoxO regulation, these studies have established a 
paradigm whereby Akt/PKB and Sgk are thought to act via similar mechanisms to inhibit 
FoxO activity [1,27,28]. 
We and others recently reported that, in contrast to the life span extension phenotype 
observed after RNAi knockdown of sgk-1 [26], sgk-1 null mutations shorten C. elegans 
life span [15,29,30]. This phenotype is the opposite of that observed for akt-1 null 
mutations [15,29,30] and is inconsistent with prevailing models implicating Sgk as a 
FoxO inhibitor. In light of these results, we have performed a detailed phenotypic 
analysis of sgk-1 null and gain-of-function mutants. Our results indicate that in C. 
elegans, Akt/PKB and Sgk influence life span, stress resistance, and FoxO transcription 
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factor activity through distinct mechanisms. These surprising findings call into question 
current paradigms of FoxO regulation by Sgk and reveal that the interaction of Sgk and 
FoxO transcription factors may be more complex than previously appreciated. 
 
Results 
Effects of sgk-1 mutations on life span 
Three alleles of sgk-1 facilitate analysis of gene function (Figure 2.1A). We and others 
have shown that the sgk-1(mg455) mutation shortens life span [30,29]. The mg455 allele 
is a nonsense mutation that is predicted to result in truncation of SGK-1 within its kinase 
domain [29]; therefore, this is likely to be a null mutation. A third group has shown that 
the sgk-1(ok538) deletion mutation, which is predicted to remove half of the SGK-1 
kinase domain and is also probably a null mutation [26], also reduces life span [15]. We 
confirmed these results by measuring the life spans of both sgk-1(ok538) and sgk-
1(mg455) null mutants in the same assay (Figure 2.1B and Supplemental Table 2.1). sgk-
1(ok538) (heretofore referred to as “null #1”) and sgk-1(mg455) (heretofore referred to as 
“null #2”) each shorten mean life span by at least 27.5% and median life span by at least 
19.0% and 33.3% respectively (P<0.0001 by the log-rank test). The observation that two 
outcrossed strains harboring independently isolated sgk-1 null mutations both have short 
life spans compared to wild-type animals strongly suggests that these short life span 
phenotypes are a consequence of reduced SGK-1 activity. These results contrast with the 
reported life span extension induced by sgk-1 RNAi [26] and are consistent with a model 
whereby SGK-1 promotes longevity. 
One possible explanation for the discrepancy between the life spans of animals harboring 
sgk-1 loss-of-function mutations and animals subjected to sgk-1 RNAi is that strong loss-
of-function mutations could cause developmental abnormalities that shorten adult life 
span by reducing general fitness; such abnormalities can be avoided by initiating RNAi 
during late larval or early adult stages. To address this possibility, we assayed the life 
spans of animals harboring the sgk-1(ft15) gain-of-function mutation. 
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sgk-1(ft15) emerged from a genetic screen for suppressors of the developmental delay 
phenotype of animals harboring a loss-of-function mutation in lpo-6/rict-1, which 
encodes the C. elegans ortholog of the TOR complex 2 component Rictor [31,29]. sgk-
1(ft15) suppresses both the developmental delay and small body size phenotypes of lpo-
6/rict-1 loss-of-function mutants, and this suppression is abrogated by sgk-1 RNAi [31]. 
Taken together with the observations that lpo-6/rict-1 and sgk-1 act in the same genetic 
pathway [31,29] and mammalian TOR complex 2 activates Sgk by promoting its 
phosphorylation [19], these data strongly suggest that sgk-1(ft15) is a gain-of-function 
allele. 
We reasoned that, if sgk-1 null mutants are short-lived because SGK-1 plays a role in 
promoting longevity, then animals harboring sgk-1(ft15) (heretofore referred to as “sgk-
1(gf)”) should live longer than animals with wild-type sgk-1. However, if sgk-1 null 
mutants are short-lived because they are sick, then sgk-1(gf) animals would not be 
expected to live long. sgk-1(gf) animals consistently lived ~ 15-20% longer than non-
sibling wild-type animals (Supplemental Table 2.1B). When siblings harboring wild-type 
sgk-1 were used as controls, sgk-1(gf) animals exhibited a more modest but statistically 
significant extension in median and mean life span in eight of ten experimental trials 
(Figure 2.1B-E and Supplemental Table 2.1A and C). In Figure 1B, sgk-1(gf) increased 
mean and median life span by 17.5% and 9.5% respectively, compared to wild-type 
siblings (P=0.0008). This life span extension was suppressed by a null mutation in daf-
16/FoxO (Figure 2.1C and Supplemental Table 2.1A). 
In C. elegans, DAF-16/FoxO activity is regulated through at least two mechanisms. 
Phosphorylation of DAF-16/FoxO by kinases such as AKT-1 inhibits DAF-16/FoxO by 
promoting its export from the nucleus [15,30,32–34]. Other regulatory proteins such as 
HCF-1 and EAK-7 inhibit DAF-16/FoxO activity without influencing its subcellular 
localization [30,35].  To determine whether SGK-1 acts specifically in either of these 
pathways to promote longevity, we tested the effect of sgk-1 mutations on the life spans 
of akt-1 and hcf-1 null mutants. We previously reported that SGK-1 is required for the 
longevity of akt-1 mutants [30]. sgk-1(gf) did not extend the life span of akt-1(null) 
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animals (Figure 2.1D and Supplemental Table 2.1A). Similarly, in hcf-1(null) animals, 
sgk-1 was required for life span extension, but sgk-1(gf) did not further increase life span 
(Figure 2.1E and Supplemental Table 2.1A). Based on these data, whether SGK-1 acts 
specifically with AKT-1 or HCF-1 to influence life span is not clear. It is possible that 
DAF-16/FoxO activation by SGK-1 is attenuated in backgrounds such as akt-1(null) and 
hcf-1(null) in which DAF-16/FoxO is already activated. 
As the E. coli HB101-derived HT115 strain used in experiments demonstrating that sgk-1 
RNAi extends life span [26] differs from the OP50 strain used in our experiments (Figure 
2.1B-E), we sought to determine the influence of E. coli strain differences on the life 
spans of sgk-1 mutants. Therefore, we assayed the life spans of sgk-1(null) and sgk-1(gf) 
mutants grown on HT115. As observed in experiments using OP50 as a food source, sgk-
1(null) shortened and sgk-1(gf) extended life span in animals feeding on either HT115 or 
HB101 (Figure 2.1F and Supplemental Table 2.1C). Therefore, the pro-longevity activity 
of SGK-1 is not significantly influenced by differences between E. coli OP50 and 
HT115/HB101. 
Taken together, these results suggest that, in contrast to existing paradigms of FoxO 





Figure 2.1: Effects of sgk-1 mutations on life span. 
(A) Schematic of the sgk-1 genomic locus (not to scale). Locations of the ft15 missense gain-of-function, 
ok538 deletion, and mg455 nonsense mutations are shown. Exons encoding the kinase domain are colored 
red. (B) Life spans of sgk-1 mutants ft15 (gf), ok538 (null #1), and mg455 (null #2). (C) Effect of the daf-
16(mu86) null mutation on the life spans of sgk-1(gf) animals. (D) Effect of sgk-1(gf) on the life span of 
akt-1(mg306) null mutant animals. (E) Effect of sgk-1(gf) on the life span of hcf-1(pk924) null mutant 
animals. (F) Life spans of sgk-1 mutants on HT115 E. coli. Raw data and statistics are presented in 








Effects of sgk-1 mutations on dauer arrest 
Since DAF-16/FoxO promotes developmental arrest in the dauer larval stage in animals 
with reduced DAF-2 insulin-like signaling [36,37], we tested the effect of sgk-1(null) and 
sgk-1(gf) on dauer arrest. In agreement with a previous report [26], neither sgk-1(null) 
nor sgk-1(gf) had significant effects on dauer arrest at 27°C (Table 2.1A). Although a 
significant percentage of sgk-1(null) animals arrested during larval development (Table 
2.1A), analysis of these animals using Nomarski microscopy revealed no evidence of 
dauer alae or pharyngeal constriction (Supplemental Figure 2.3), indicating that these 
animals were non-dauer larvae. In contrast and as previously reported [38], an akt-1 null 
mutation had a strongly penetrant DAF-16/FoxO-dependent dauer-constitutive phenotype 
under the same assay conditions. Neither sgk-1(null) nor sgk-1(gf) significantly 
influenced the dauer-constitutive phenotype of daf-2(e1368) (Table 2.1B). Therefore, 




Table 2.1. Effects of sgk-1 mutations on dauer arrest. 
(A) Dauer formation of sgk-1 and akt-1 mutants at 27°C. (B) Effect of sgk-1 mutations on daf-2(e1368) 

























Wildtype 0.0 0.0 0.0 0.0 0.0 2.3 0-(0) 0.8-(1.3) 991
akt$1&(null) 97.7 0.6 94.5 5.0 89.1 10.9 93.8-(4.3) 5.5-(5.2) 705
daf$16(null);akt$1 0.0 1.8 0.0 9.3 0.0 15.2 0-(0) 8.8-(6.7) 811
sgk$1(gf) 0.0 0.0 0.0 0.0 0.0 10.3 0-(0) 3.4-(5.9) 968
daf$16;sgk$1(gf) 0.0 0.3 0.0 1.9 0.0 23.6 0-(0) 8.6-(13.0) 893
sgk$1(null)&#1 0.0 26.7 0.0 52.8 0.0 90.0 0-(0) 56.5-(31.8) 1144











wildtype 0.0 0.0 0.0 0!(0) 768
sgk$1(gf) 0.0 0.0 0.0 0!(0) 1007
daf$2(e1368) 81.2 90.7 46.8 72.9!(23.1) 882
daf$2;sgk$1(gf) 83.1 86.8 50.3 73.1!(20.1) 596
wildtype 0.0 0.0 0.0 0!(0) 1018
sgk$1(null)4#1 0.0 0.0 0.0 0!(0) 1498
daf$2(e1368) 87.0 90.8 87.1 88.3!(2.2) 1128
daf$2;sgk$1(null)4#1 89.8 95.6 94.3 93.2!(3.0) 1016
wildtype 0.0 0.0 0.0 0!(0) 861
sgk$1(null)4#2 0.0 0.0 0.0 0!(0) 1508
daf$2(e1368) 93.5 90.6 83.2 89.1!(5.3) 1064
daf$2;sgk$1(null)4#2 93.2 89.5 88.9 90.5!(2.3) 958
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Effects of sgk-1 mutations on stress resistance 
In light of our observations on the effects of sgk-1 mutations on life span (Figure 2.1), we 
tested sgk-1(null) and sgk-1(gf) for their sensitivity to oxidative stress, ultraviolet 
radiation (UVR), and heat. akt-1 null mutants were slightly more resistant to hydrogen 
peroxide than wild-type animals, although this difference was only statistically 
significant in one of four assays (Figure 2.2A-B and Supplemental Table 2.2). akt-1 null 
mutants were significantly more resistant to UVR and heat than wild-type animals 
(Figure 2.2C-F, Supplemental Table 2.3, Supplemental Table 2.4). In contrast, both sgk-1 
null mutants were more sensitive to hydrogen peroxide (statistically significant in 2 of 3 
trials for each mutant) and UVR (statistically significant in 3 of 3 trials) than wild-type 
animals (Figure 2.2A and C, Supplemental Table 2.2, Supplemental Table 2.3), 
consistent with their short life spans. sgk-1(gf) did not significantly influence sensitivity 
to any of the three stressors tested (Figure 2.2B, D, and F). 
Both sgk-1 null mutations enhanced thermotolerance to at least the same extent that an 
akt-1 null mutation did (Figure 2.2E and Supplemental Table 2.4). This result is 
consistent with a previous report examining thermotolerance of the sgk-1(ok538) null 
mutant (Hertweck et al. 2004). Taken together with our observation that the sgk-1(gf) 
mutation extends life span, this enhanced thermotolerance phenotype of sgk-1 null 
mutants strengthens the argument that the short-lived phenotype of sgk-1 null mutants is 
not simply a consequence of frailty secondary to developmental abnormalities. In contrast 
to AKT-1, which promotes general sensitivity to environmental stress, SGK-1 is 
protective against oxidative stress and UVR but enhances sensitivity to heat. 
As the thermotolerance of sgk-1(ok538) is thought to require DAF-16/FoxO [26], we 
tested the effect of a daf-16 null mutation on the thermotolerance of both sgk-1 null 
mutants. Surprisingly, daf-16 null mutation did not significantly influence the 
thermotolerance of either sgk-1 null mutant (Figure 2.2G and Supplemental Table 2.4). 




Figure 2.2. Effects of sgk-1 mutations on stress resistance. 
(A-F) Stress resistance assays exposing animals to hydrogen peroxide (A-B), UV radiation (C-D), and heat 
(E-F). Assays were performed on sgk-1(ok538) (null #1), sgk-1(mg455) (null #2) (A, C, E), and sgk-1(ft15) 
(gf) (B, D, F). (G) Effect of daf-16(mu86) null mutation on the thermotolerance of sgk-1 null mutants. Raw 












Effects of sgk-1 mutations on DAF-16A::GFP subcellular localization 
As our life span data are consistent with a model in which SGK-1 promotes longevity by 
activating DAF-16/FoxO, we sought to determine the influence of sgk-1 mutations on the 
subcellular localization of DAF-16/FoxO.  Sgk promotes the nuclear export and 
cytoplasmic sequestration of FoxO in mammalian cells [24]; however, based on 
conflicting reports in the literature [15,26], the role of C. elegans SGK-1 in regulating 
DAF-16/FoxO localization remains unclear. We constructed sgk-1(null) and sgk-1(gf) 
strains expressing a functional DAF-16A::GFP fusion protein as the sole source of DAF-
16/FoxO in the animal and determined DAF-16A::GFP subcellular localization in young 
adult animals raised in the same conditions used for life span assays (Figure 2.3A). Under 
these conditions, akt-1 null mutation promoted the translocation of DAF-16A::GFP from 
the cytoplasm to the nucleus, as previously shown [30,33,34]. Neither the sgk-1(ok538) 
null mutation nor sgk-1(gf) had a significant influence on the nucleocytoplasmic 
distribution of DAF-16A::GFP. These data suggest that, unlike AKT-1, SGK-1 does not 
control DAF-16/FoxO activity in vivo by regulating its subcellular localization.  
Effects of sgk-1 mutations on DAF-16/FoxO target gene expression 
The dependence of sgk-1(gf) life span extension on daf-16/FoxO (Figure 2.1C) suggests 
that SGK-1 may increase life span by activating DAF-16/FoxO, even in the absence of a 
significant effect on DAF-16A::GFP localization (Figure 2.3A). Therefore, we quantified 
the expression of five DAF-16/FoxO target genes [15,30,34,39,40] in young adult sgk-
1(null) and sgk-1(gf) animals. 
As expected for bona fide DAF-16/FoxO target genes, the expression of all five of these 
genes is increased in a DAF-16/FoxO-dependent manner in the context of akt-1 null 
mutation (Figure 2.3B-F and Supplemental Table 2.6) [30,34]. In contrast, sgk-1 
mutations had varying influences on the expression of these five genes. sod-3 expression 
was not influenced by sgk-1(gf) but was reduced in sgk-1 null mutants Figure 2.3B and 
Supplemental Table 2.6). Thus, null mutations in sgk-1 and akt-1 have opposite effects on 
sod-3 expression. Neither sgk-1 null mutation nor sgk-1(gf) reproducibly influenced the 
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expression of nnt-1 and sip-1 (Figure 2.3C-D and Supplemental Table 2.6). Expression of 
both dod-3 and mtl-1 was elevated in a DAF-16/FoxO-dependent manner in the context 
of sgk-1 null mutation in five of six trials (Figure 2.3E-F and Supplemental Table 2.6), 
suggesting that SGK-1 and AKT-1 may act similarly to regulate these two DAF-16/FoxO 
target genes.  
In aggregate, these data indicate that AKT-1 and SGK-1 control DAF-16/FoxO target 
gene expression through distinct mechanisms. The heterogeneity of the influence of sgk-1 
mutations on DAF-16/FoxO target gene expression suggests that the molecular basis for 
SGK-1 regulation of DAF-16/FoxO activity is significantly more complex than has been 
appreciated. 
Figure 2.3. Effects of sgk-1 mutations on DAF-16A::GFP subcellular localization 
and DAF-16/FoxO target gene expression (next page). 
(A) Subcellular localization of DAF-16A::GFP in akt-1 and sgk-1 mutants. Nuclear localization is 
increased by akt-1(mg306) null mutation (two-way ANOVA, F=14.47, P<0.0001), but not by sgk-1(ok538) 
null mutation (F=1.825, P=0.1733) or by sgk-1(ft15) gain-of-function mutation (F=0.869, P=0.5037). Error 
bars represent SEM for 3 cohorts of 20-30 animals per genotype imaged separately. All animals also 
harbored the daf-16(mu86) null allele, so no endogenous DAF-16/FoxO is present. Representative images 
are shown in Supplemental Figure 2.2. Raw data and statistics are presented in Table S5. (B-F) 
Representative experiments measuring sod-3 (B), nnt-1 (C), sip-1 (D), dod-3 (E), and mtl-1 (F) transcript 
levels using quantitative RT-PCR on total RNA isolated from young adult animals. Values are normalized 
to expression levels in wild-type animals. Columns represent mean +/- SEM of three technical replicates. 
Raw data and statistics for biological replicates are summarized in Supplemental Table 2.6. (G) Summary 
of statistically significant gene expression changes (P<0.05; Supplemental Table 2.6; unpaired two-tailed t-
test with Welch’s correction) in akt-1 and sgk-1 mutants and their dependence on DAF-16/FoxO. The 
asterisk indicates that dod-3 expression was increased significantly in eight of twelve trials. The number 
sign indicates that daf-16(null) significantly reduced expression of dod-3 and mtl-1 in sgk-1(null) mutants 
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Akt/PKB inhibits FoxO transcription factors via a well-established and evolutionarily 
conserved mechanism involving phosphorylation of FoxO at three sites that lie within 
conserved RxRxxS/T motifs [2,10]. Based on both its similarity in primary structure [16] 
and substrate specificity [20] to Akt/PKB as well as data from mammalian cell culture 
[24,25] and C. elegans [26], Sgk is also thought to inhibit FoxO by promoting its 
phosphorylation at RxRxxS/T motifs. Our data challenge this model of FoxO regulation 
by Sgk and support the notion that in C. elegans, Akt/PKB and Sgk regulate FoxO 
activity in fundamentally different ways. 
Our conclusions are at odds with those of the only study in the literature that has focused 
on Sgk action in C. elegans life span control and FoxO regulation [26]. This study 
showed that sgk-1 RNAi extends life span in a DAF-16/FoxO-dependent manner. One 
possible explanation for this discrepancy is that the E. coli strain used for RNAi (the 
HB101-related strain HT115) is different from the standard strain used for growth and 
maintenance of C. elegans (the E. coli B-related OP50) that we used in our experiments. 
Indeed, wild-type C. elegans grown on HT115 live nearly 20% longer than wild-type 
animals grown on OP50 [41]. However, we have shown that sgk-1(null) and sgk-1(gf) 
animals are respectively short-lived and long-lived when cultured on E. coli OP50, 
HT115, or HB101 (Figure 2.1 and Supplemental Table 2.1), indicating that the life span 
phenotypes of sgk-1(null) and sgk-1(gf) are not significantly influenced by differences 
between OP50 and HT115/HB101 per se. 
We did confirm the previously reported finding that sgk-1 null mutant animals are 
thermotolerant compared to wild-type animals [26]. This suggests that sgk-1 null mutant 
animals are not short-lived due to general frailty or sickness, as such animals would be 
expected to be generally hypersensitive to environmental stresses. Intriguingly, daf-
16/FoxO was not required for thermotolerance in sgk-1(null) animals, suggesting that, 
although AKT-1 and SGK-1 both promote thermosensitivity, they likely do so through 
distinct mechanisms. Our results dissociate thermotolerance from longevity and suggest 
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that divergent molecular pathways act downstream of SGK-1 to influence life span and 
responses to increased ambient temperature. 
Our results also contrast with a detailed analysis of mammalian FoxO3 regulation 
demonstrating that both Sgk and Akt/PKB can inhibit FoxO3 activity in cell culture by 
promoting the phosphorylation of all three conserved sites that lie within RxRxxS/T 
motifs [24]. This discrepancy may be due in part to differences in experimental context; 
these experiments were performed in cell culture, where growth factors are frequently 
added in excess of physiologic concentrations and overexpressed proteins may exhibit 
activities that are not discernible when they are expressed at endogenous levels. The 
effect of Sgk knockdown or deletion on the activity of endogenous FoxO transcription 
factors has not been investigated in mammals. Although it is conceivable that Sgk 
regulates FoxO activity through distinct mechanisms in mammals and C. elegans, this is 
unlikely in light of the conservation of mechanisms of FoxO regulation by insulin-like 
growth factor signaling pathways [42]. 
Although the increased life span phenotypes caused by akt-1 null mutation and the sgk-
1(gf) both require daf-16/FoxO (Figure 2.1C and Supplemental Table 2.1), the expression 
of DAF-16/FoxO target genes was influenced by these two mutations in starkly 
discordant ways (Figure 2.3B-F). Whereas the expression of five DAF-16/FoxO target 
genes is induced in a DAF-16/FoxO-dependent manner in akt-1 null mutants, sgk-1(null) 
and sgk-1(gf) mutations had distinct and varying influences on the expression of specific 
DAF-16/FoxO target genes. This difference is likely a reflection of underlying 
differences in the molecular basis for DAF-16/FoxO regulation by AKT-1 and SGK-1. 
These observations suggest that the underlying mechanisms of life span control by AKT-
1 and SGK-1 are fundamentally different. In contrast to AKT-1, which inhibits DAF-
16/FoxO by promoting its nuclear export and cytoplasmic retention [26,30,33,34], SGK-1 
may promote longevity by regulating other proteins that functionally and/or physically 
interact with DAF-16/FoxO, such as SKN-1, HSF-1, or HCF-1 [35,43,44]. In this regard, 
DAF-16/FoxO may play a permissive role in life span control by SGK-1 without being 
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directly regulated by SGK-1. Alternatively, SGK-1 may directly regulate DAF-16/FoxO 
activity in a small number of cells, which in turn could control life span by influencing 
other cells in a DAF-16/FoxO-independent manner. 
In summary, we have shown that the AGC kinase family members Akt/PKB and Sgk 
control C. elegans life span and stress resistance in fundamentally different ways, and 
they likely influence FoxO transcription factor activity through distinct mechanisms in 
vivo. Our findings challenge existing paradigms of FoxO regulation by Sgk and should 




Materials and Methods 
Strains and reagents 
The following strains were used: N2 Bristol (wild-type), sgk-1(ft15) [31], akt-1(mg306) 
[38], sgk-1(ok538) [26], sgk-1(mg455) [29], daf-16(mu86) [45], hcf-1(pk924) [35] and 
TJ356 (zIs356) [46]. Since sgk-1(ft15) was isolated after mutagenesis of animals 
harboring the linked akt-2(tm812) mutation [31], we confirmed the absence of akt-
2(tm812) prior to further analysis. Throughout the manuscript, sgk-1(ft15) is referred to 
as “sgk-1(gf),” akt-1(mg306) as “akt-1(null),” sgk-1(ok538) as “sgk-1(null) #1,” and sgk-
1(mg455) as “sgk-1(null) #2.” sgk-1 mutant strains were outcrossed with N2 at least 
seven times prior to phenotypic analysis. Wild-type siblings of sgk-1(ft15) from the 
seventh outcross with N2 Bristol were used as controls for phenotypic comparison to sgk-
1(ft15). This sibling is labeled “wild-type” in all figures, in contrast to “N2 wild-type.” 
Double and triple mutants were generated using standard genetic techniques. For 
maintenance and all assays, animals were grown in Percival I-30NL or I-36NL incubators 
(Percival Scientific, Inc., Perry, IA). 
Life span assays 
Life span assays were performed at 20°C as described [30,34]. Briefly, animals were 
treated with alkaline hypochlorite and grown for at least three generations at 15°C. A 
synchronized egglay was then performed to yield animals for the life span assay. These 
were grown at 20°C until the L4 larval stage, at which time they were picked to separate 
plates and grown until they were Day 2 adults. They were then transferred to NGM plates 
(10-15 animals per plate) containing 25 µg/mL (100 µM) 5-fluoro-2’-deoxyuridine 
(FUDR; Sigma-Aldrich, St. Louis, MO, USA) and 10 µg/mL nystatin (Sigma-Aldrich) 
and seeded with 20X concentrated OP50. Animals were incubated at 20°C and scored 
every 1-2 days. Animals that were not moving, did not respond to prodding, and did not 
exhibit pharyngeal pumping were scored as dead and removed. Animals that died due to 
desiccation on the side of the plate, a compromise in vulval integrity, or bagging were 
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censored. Statistical significance was assessed using the standard chi-square-based log-
rank test in GraphPad Prism (GraphPad Software; La Jolla, CA, USA). 
Dauer assays 
Dauer assays were performed at 25° or 27°C as previously described [38]. Briefly, 
animals were synchronized in a 4-6 hour egglay and grown at 25° or 27°C on NGM 
plates. Dauers were scored when wild-type animals were gravid adults and daf-2(e1368) 
or akt-1(mg306) mutant animals were arrested as dauers (approximately 60-84 hours after 
egglay). sgk-1 null mutant animals were plated twelve hours prior to other strains to 
compensate for developmental delay. Plates were observed for two additional days after 
initial scoring to account for possible dauer arrest in animals with severe developmental 
delay. 
Stress resistance assays 
Animals were grown at 20°C for 48 hours after a 4-6 hour egglay until most animals 
were L4 larvae. sgk-1(null) animals were grown starting 12 hours earlier than other 
strains for L4 synchronization due to developmental delay [26,29,31]. Young adults, L3 
larvae, and males were removed by suction. Cohorts were sufficiently large to allow for 
thermotolerance, oxidative stress, and UV assays to be performed in parallel. All assays 
were performed in triplicate. 
For oxidative stress assays, L4 larvae were transferred to fresh seeded NGM plates, 
grown for an additional 18 hours, washed two or three times with M9 buffer, and diluted 
to a concentration of ~ 50 animals/mL of M9. 0.5 mL of animals was dispensed to 
Eppendorf tubes and rocked for ~ 20 minutes to allow animals to digest E. coli. Four 
tubes were used per genotype per concentration of H2O2. 0.5 mL of H2O2 dissolved in 
M9 was then added to each tube to the final concentration, followed by rocking for 2 
hours protected from light. The H2O2 solution was then removed and the animals were 
washed with M9. Animals were then pipetted back onto fresh NGM plates and scored 
after an 18-hour recovery period at 20°C. Two-way ANOVA was conducted using 
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GraphPad Prism, with survival of animals on each plate as the dependent variable and 
H2O2 dose and genotype as independent variables. 
UV stress assays were performed as described [47]. Briefly, animals were transferred to 
plates containing 25 µg/mL FUDR on Day 1 of adulthood. After four days, they were 
transferred to plates lacking bacteria and irradiated with 1200 J/m2 UV-C using a 
Stratalinker 2400 UV crosslinker (Stratagene, La Jolla, CA). They were then transferred 
onto NGM plates with food and scored daily for survival. Statistical significance was 
assessed using the standard chi-square-based log-rank test. 
Thermotolerance assays were performed essentially as described [15]. Briefly, L4 larvae 
were transferred to fresh seeded NGM plates (~20 per plate), and then grown for an 
additional 18 hours prior to shifting them to an incubator set at 35°C. Four plates were 
used per genotype per time point. At each time point, plates to be scored were removed 
and incubated further for 18 hours at 20°C, after which living and dead animals were 
scored. Two-way ANOVA was conducted using GraphPad Prism, with survival of 
animals on each plate as the dependent variable and time at 35°C and genotype as 
independent variables. 
DAF-16A::GFP localization assays 
Animals were mounted onto slides in M9 with 10 mM sodium azide. Approximately ten 
young adults were picked to each slide, and the anterior segment of each animal was 
imaged within five minutes after mounting. Images were scored according to the criteria 
shown in Figure S1. Both imaging and scoring were performed in a blinded fashion. 
Two-way ANOVA was used to assess statistical significance in GraphPad Prism. 
Quantitative RT-PCR 
Animals from a 4.5 hour egglay were grown at 20°C for 48 hours until most animals 
were L4 larvae. sgk-1(null) animals were grown starting 12 hours earlier than other 
strains for L4 synchronization due to developmental delay [26,29,31]. Young adults and 
 
 47 
L3 larvae were removed by suction, and the remaining animals were grown for an 
additional 12 hours. Total RNA was isolated from 600-1000 young adults per strain per 
biological replicate using TRIzol (Invitrogen; Carlsbad, CA, USA) and purified using an 
RNeasy Kit (QIAGEN Inc.; Valencia, CA, USA). cDNA was synthesized using a 
Superscript III Reverse Transcriptase Kit (Invitrogen). SYBR Green (Applied 
Biosystems, Warrington, UK) Real Time PCR was then performed using primers 
corresponding to the DAF-16/FoxO target genes sod-3, nnt-1, sip-1, dod-3, and mtl-1. 
act-1 was used as an internal control. Quantitative PCR primer sequences are listed in 
Supplemental Table 2.7. Statistical analysis was performed in GraphPad Prism by 






Supplemental Figure 2.1. Criteria for blind scoring of DAF-16::GFP subcellular 
localization.  
daf-16(mu86) mutant animals carrying high-copy DAF-16::GFP (TJ356) and sgk-1 or akt-1 alleles (see 
Supplemental Figure 2.2) were grown at 20°C and picked to slides as young adults. The anterior of each 













Supplemental Figure 2.2. Example photographs of wildtype, sgk-1(null), sgk-1(gf), 
and akt-1(null) animals expressing DAF-16::GFP.  
daf-16(mu86);DAF-16::GFP (TJ356) were built with wildtype (A), akt-1(mg306) null (B), sgk-1(ft15) gain-
of-function (C), sgk-1(ok538) null (D) alleles, and imaged and scored as described in Fig. S1. sgk-1(ok538) 
null animals showed autofluorescent granules (inset) in their intestines that were too small to be nuclei and 
were present in non-GFP animals, as early as the L2 larval stage (E), and thus were not scored as nuclei in 











Supplemental Figure 2.3. Example photograph of the pharynx of an arrested sgk-
1(null) larva at 27°C (lower panel). 
















Supplemental Table 2.1. Life span raw data and statistics 
Life span data and statistics for (A) each replicate of Figure 2.1, (B) replicates using N2 wild-type as a 
control, and (C) replicates feeding HB101 or HT115 bacteria. All assays were conducted at 20°C. We used 
GraphPad Prism (GraphPad Software; La Jolla, CA, USA) to perform statistical analysis, including the log-

































Figure&1B wildtype'sib'of'ft15 93(3) 20.0 7.0 21 n/a n/a n/a n/a
replicate'1 sgk(1(ft15) 98(1) 23.5 7.8 23 0.0008 wildtype'sib'of'ft15 +17.5 +9.5
*shown&figure sgk(1(ok538) 101(0) 14.5 5.4 17 <0.0001 wildtype'sib'of'ft15 +27.5 +19.0
sgk(1(mg455) 100(1) 14.5 5.9 14 <0.0001 wildtype'sib'of'ft15 +27.5 +33.3 0.35 sgk(1(ok538) 0 +17.6
Figure&1B wildtype'sib'of'ft15 64(2) 25.1 5.9 26 n/a n/a n/a n/a
replicate'2 sgk(1(ft15) 56(4) 28.5 9.0 27 0.0005 wildtype'sib'of'ft15 +13.5 +3.8
Figure&1C sgk(1(ok538) 63(0) 12.3 3.6 12 <0.0001 wildtype'sib'of'ft15 +51.0 +53.8
replicate'1 sgk(1(mg455) 65(0) 12.1 1.4 12 <0.0001 wildtype'sib'of'ft15 +51.2 +53.8 0.8091 sgk(1(ok538) +1.6 0
*shown&figure daf(16(mu86);sgk(1(ft15) 45(2) 17.6 2.7 16 <0.0001 sgk(1(ft15)
akt(1(mg306) 59(2) 30.0 7.6 28 <0.0001 wildtype'sib'of'ft15 +19.5 +7.7
daf(16;akt(1 54(4) 15.3 2.1 16 <0.0001 akt(1(mg306) 0.0001 daf(16;sgk(1(ft15) +13.0 0
Figure&1B wildtype'sib'of'ft15 97(2) 20.7 5.5 21 n/a n/a n/a n/a
replicate'3 sgk(1(ft15) 91(8) 21.5 5.1 21 0.5082 wildtype'sib'of'ft15 +3.9 0
Figure&1C sgk(1(ok538) 98(0) 10.9 4.0 10 <0.0001 wildtype'sib'of'ft15 +47.3 +52.4
replicate'2 sgk(1(mg455) 100(0) 11.1 3.6 11 <0.0001 wildtype'sib'of'ft15 +46.4 +47.6 0.7079 sgk(1(ok538) +1.8 +10.0
daf(16(mu86);sgk(1(ft15) 96(5) 13.1 1.5 13 <0.0001 sgk(1(ft15)
akt(1(mg306) 61(4) 32.2 5.8 34 <0.0001 wildtype'sib'of'ft15 +55.5 +61.9
daf(16;akt(1 95(4) 13.5 1.5 14 <0.0001 akt(1(mg306) 0.5116 daf(16;sgk(1(ft15) +3.1 +7.7
Figure&1C wildtype'sib'of6ft15 61(39) 17.2 2.8 18 n/a n/a n/a n/a
replicate'3 N2'wildtype 65(35) 16.6 2.8 17 0.857 wildtype'sib'of'ft15 +3.5 +5.6
sgk(1(ft15) 55(45) 15.9 3.7 15 0.0659 wildtype'sib'of'ft15 +7.6 +16.6
daf(16(mu86) 61(43) 13.3 1.9 13 <0.0001 wildtype'sib'of'ft15 +22.7 +28.2
daf(16(mu86);sgk(1(ft15) 77(24) 13.3 1.6 13 <0.0001 sgk(1(ft15) +16.3 +13.3 0.217 daf(16(mu86) 0 0
Figure&1D wildtype 91(10) 21.1 2.6 20 n/a n/a n/a n/a
all'are'siblings sgk(1(ft15) 79(21) 23.1 4.2 23 <0.0001 wildtype +9.5 +15.0
replicate'1 akt(1(mg306) 87(13) 23.7 3.2 24 <0.0001 wildtype +12.3 +20.0
*shown&figure akt(1;sgk(1 74(26) 22.8 3.7 23 0.4614 sgk(1(ft15) +1.3 0 0.3489 akt(1(mg306) +1.3 +4.2
Figure&1D wildtype 82(18) 20.3 3.1 21 n/a n/a n/a n/a
all'are'siblings sgk(1(ft15) 79(21) 21.9 3.1 22 0.0031 wildtype +7.9 +4.8
replicate'2 akt(1(mg306) 85(15) 24.1 2.8 24 <0.0001 wildtype +18.7 +14.3
akt(1;sgk(1 73(27) 24.5 5.0 24 <0.0001 sgk(1(ft15) +11.9 +9.1 0.0375 akt(1(mg306) +1.7 0
Figure&1E wildtype 70(8) 18.0 3.1 19
first'four'are sgk(1(ft15) 56(53) 20.1 3.7 19 <0.0001 wildtype +11.7 0
siblings hcf(1(pk924) 73(27) 21.3 5.4 21 <0.0001 wildtype +18.3 +10.5
replicate'1 hcf(1;sgk(1(ft15) 81(19) 20.5 5.0 21 0.413 sgk(1(ft15) +2.0 +10.5 0.4130 hcf(1(pk924) +3.8 0
*shown&figure hcf(1;sgk(1(ok538) 96(4) 10.8 1.5 11 <0.0001 wildtype +40.0 +42.1 <0.0001 hcf(1(pk924) +49.3 +47.6
hcf(1;sgk(1(mg455) 100(0) 10.9 1.4 10 <0.0001 wildtype +39.4 +47.4 <0.0001 hcf(1(pk924) +48.8 +52.4
Figure&1E wildtype 91(10) 18.7 3.0 18 n/a n/a n/a n/a
first'four'are sgk(1(ft15) 67(28) 19.8 5.9 19 0.0309 wildtype +5.9 +5.6
siblings hcf(1(pk924) 79(21) 20.6 5.8 21 <0.0001 wildtype +10.2 +16.7
replicate'2 hcf(1;sgk(1(ft15) 75(24) 22.0 5.5 22 0.0642 sgk(1(ft15) +11.1 +15.8 0.2348 hcf(1(pk924) +6.8 +4.8
hcf(1;sgk(1(ok538) 100(0) 11.2 1.8 11 <0.0001 wildtype +40.1 +38.9 <0.0001 hcf(1(pk924) +45.6 +47.6
hcf(1;sgk(1(mg455) 93(7) 11.5 1.6 11 <0.0001 wildtype +38.5 +38.9 <0.0001 hcf(1(pk924) +44.2 +47.6
Table&S1B.&Additional&life&span&data&using&N2&wildtype
Figure&1B N2'wildtype 69(31) 14.3 1.5 14.5 n/a n/a n/a n/a
sgk(1(ft15) 71(29) 17.8 3.8 17 <0.0001 N2'wildtype +24.5 +17.2
Figure&1B N2'wildtype 77(23) 16.6 2.3 16.5 n/a n/a n/a n/a
sgk(1(ft15) 96(4) 21.4 3.7 20 <0.0001 N2'wildtype +28.9 +21.2
Figure&1B N2'wildtype 63(37) 14.3 2.0 14.5 n/a n/a n/a n/a
sgk(1(ft15) 73(29) 17.0 3.6 17 <0.0001 N2'wildtype +18.9 +17.2
Figure&1B N2'wildtype 70(30) 14.9 1.8 14.5 n/a n/a n/a n/a
Figure&1C sgk(1(ft15) 84(16) 18.4 4.7 17.5 <0.0001 N2'wildtype +23.5 +20.7
daf(16(mu86) 93(8) 14.2 1.8 14.5 0.0313 N2'wildtype +4.7 0
daf(16;sgk(1 84(16) 13.6 2.0 13.5 0.0002 N2'wildtype +8.7 +6.9 0.0584 daf(16(mu86) +4.2 +6.9
Table&S1C.&Additional&life&span&data&on&different&E.#coli&strains
Figure&1B wildtype'sib'of6ft15 94(8) 22.8 2.8 22 n/a n/a n/a n/a
replicate'4 sgk(1(ft15) 84(20) 24.4 3.3 25 0.0005 wildtype'sib'of'ft15 +7.0 +13.6
HT115 sgk(1(ok538) 101(3) 13.0 2.5 13 <0.0001 wildtype'sib'of'ft15 +43.0 +40.9
bacteria sgk(1(mg455) 100(0) 12.5 2.2 13 <0.0001 wildtype'sib'of'ft15 +45.2 +40.9 0.0999 sgk(1(ok538) +3.8 0
Figure&1B N2'wildtype 69(31) 18.1 2.9 18.5 n/a n/a n/a n/a
HB101 sgk(1(ft15) 90(10) 21.5 3.1 21.5 <0.0001 N2'wildtype +18.8 +16.2
bacteria sgk(1(ok538) 100(0) 13.9 2.4 13.5 <0.0001 N2'wildtype +23.2 +27.0




Supplemental Table 2.2. H2O2 survival data and statistics 
Young adult animals were subjected to H2O2 treatment in M9 for 2 hours in Eppendorf tubes, allowed to 
recover for 18 hours, and then scored for survival. Animal counts listed for each genotype are split among 5 
treatments ranging from 200 to 400 µM and between 4 tubes per genotype per treatment. Survival for each 
tube was calculated, allowing mean and median lethal dose to be calculated. Pairing by H2O2 
concentration was used to conduct a Student’s t-test in GraphPad Prism. Data used in Figures 2A and 2D 
are labeled as ‘*.’ 
 
Supplemental Table 2.3. UV survival data and statistics 
Synchronized animals were maintained on FUDR plates until they were 4 days old, transferred to plates 
without food and exposed to ultraviolet radiation (1200 J/m2 UV-C) using a Stratalinker UV Crosslinker. 
Survival was scored daily for each animal from time of UV exposure until death, similar to life span assays. 
We used GraphPad Prism to perform statistical analysis, including the log-rank (Mantel-Cox) test. Data 

































Figure(2A N2$wildtype 188 322 44 300 n/a n/a n/a n/a
replicate$1 sgk$1(ok538) 274 262 42 250 0.0002 N2$wildtype /18.6 /16.7
*shown(figure sgk$1(mg455) 266 285 47 300 0.0012 N2$wildtype /11.5 0 0.0689 sgk$1(ok538) +8.8 +20.0
akt$1(mg306) 328 345 62 350 0.1299 N2$wildtype +7.1 +16.7
Figure(2A N2$wildtype 656 315 65 300 n/a n/a n/a n/a
replicate$2 sgk$1(ok538) 685 276 69 250 0.0911 N2$wildtype /12.4 /16.7
sgk$1(mg455) 610 260 77 250 0.0250 N2$wildtype /17.5 /16.7 0.4749 sgk$1(ok538) /5.8 0
akt$1(mg306) 678 327 64 300 0.3666 N2$wildtype +3.8 0
Figure(2A N2$wildtype 476 304 57 300 n/a n/a n/a n/a
replicate$3 sgk$1(ok538) 932 242 39 250 <0.0001 N2$wildtype /20.4 /16.7
sgk$1(mg455) 738 313 65 300 0.4804 N2$wildtype +3.0 0 <0.0001 sgk$1(ok538) +29.3 +20.0
akt$1(mg306) 496 317 64 300 0.3462 N2$wildtype +4.3 0
Figure(2B wildtype$sib$of$ft15 319 348 53 350 n/a n/a n/a n/a
replicate$1 sgk$1(ft15) 306 343 42 350 0.6429 wildtype$sib$of$ft15 /1.4 0
*shown(figure akt$1(mg306) 304 >400 43 >400 <0.0001 wildtype$sib$of$ft15 >$+14.9 >$+14.3
Figure(2B wildtype$sib$of$ft15 398 335 51 350 n/a n/a n/a n/a
replicate$2 sgk$1(ft15) 516 321 62 350 0.0401 wildtype$sib$of$ft15 /4.2 0
Figure(2B wildtype$sib$of$ft15 596 353 74 350 n/a n/a n/a n/a






























Figure(2C N2!wildtype 100 162.3 35.5 167 n/a n/a n/a n/a
replicate!1 sgk$1(mg455) 99 80.0 27.3 69 <0.0001 N2!wildtype +50.7 +41.3
*shown(figure sgk$1(ok538) 98 82.1 29.8 69 <0.0001 N2!wildtype +49.4 +41.3 0.3953 sgk$1(mg455) +2.6 0
akt$1(mg306) 100 175.5 29.5 190 <0.0001 N2!wildtype +8.1 +13.8
Figure(2C N2!wildtype 65 135.2 26.7 144 n/a n/a n/a n/a
replicate!2 sgk$1(mg455) 34 112.8 25.4 118 0.0044 N2!wildtype +16.6 +18.1
sgk$1(ok538) 69 94.4 34.8 95 <0.0001 N2!wildtype +30.2 +34.0 0.0019 sgk$1(mg455) +16.3 +34.0
Figure(2C N2!wildtype 87 121.1 21.4 122 n/a n/a n/a n/a
replicate!3 sgk$1(mg455) 97 89.8 23.9 96 <0.0001 N2!wildtype +25.8 +21.3
Figure(2D sgk$1(ok538) 100 82.2 21.4 66 <0.0001 N2!wildtype +32.1 +45.9 0.0023 sgk$1(mg455) +8.5 +31.2
replicate!1 sgk$1(ft15) 100 115.6 22.1 122 0.8032 N2!wildtype +4.5 0
akt$1(mg306) 73 131.9 15.0 >142 <0.0001 N2!wildtype +8.9 >!16.4
Figure(2D wildtype!sib!of3ft15 100 145.5 35.1 149 n/a n/a n/a n/a
replicate!2 sgk$1(ft15) 99 134.9 26.1 149 0.0057 wildtype!sib!of3ft15 +7.3 0
*shown(figure akt+1(mg306) 99 170.0 37.3 164 <0.0001 wildtype!sib!of3ft15 +16.8 +10.1
Figure(2D wildtype!sib!of3ft15 60 174.7 37.3 196 n/a n/a n/a n/a
replicate!3 sgk$1(ft15) 51 160.9 40.2 176 0.0163 wildtype!sib!of3ft15 +7.9 +10.2




Supplemental Table 2.4. Thermotolerance data and statistics  
Young adult animals were subjected to 35°C for 3 to 6 hours on NGM plates, allowed to recover for 18 
hours, and then scored for survival. Animal counts listed for each genotype are split among 6 or 7 time 
points and between 4 plates per genotype per time point. Survival for each plate was calculated, allowing 
mean and median lethal time exposure to be calculated. Pairing by time point was used to conduct a 































Figure(2E N2'wildtype 414 3.57 0.37 3.42 n/a n/a n/a n/a
replicate'1 sgk$1(ok538) 504 4.09 0.37 4.25 <0.0001 N2'wildtype +14.6 +24.3
*shown(figure sgk$1(mg455) 551 4.15 0.36 3.83 0.0040 N2'wildtype +16.2 +7.3 0.0561 sgk$1(ok538) +1.5 09.9
akt$1(mg306) 432 3.88 0.48 4.25 <0.0001 N2'wildtype +8.7 +24.3
Figure(2E N2'wildtype 485 3.94 0.69 3.5 n/a n/a n/a n/a
replicate'2 sgk$1(ok538) 445 5.15 0.70 5.17 <0.0001 N2'wildtype +30.7 +47.7
sgk$1(mg455) 424 5.15 0.67 5.17 <0.0001 N2'wildtype +30.7 +47.7 0.3041 sgk$1(ok538) 0 0
akt$1(mg306) 439 4.79 0.80 4.83 <0.0001 N2'wildtype +21.6 +38.0
Figure(2E N2'wildtype 649 3.39 0.38 3.83 n/a n/a n/a n/a
replicate'3 sgk$1(ok538) 558 3.92 0.43 4.25 0.0046 N2'wildtype +15.6 +11.0
sgk$1(mg455) 634 3.73 0.49 4.25 0.0045 N2'wildtype +10.0 +11.0 0.6014 sgk$1(ok538) 04.8 0
akt$1(mg306) 603 3.72 0.50 3.83 0.0125 N2'wildtype +9.7 0
Figure(2F wildtype'sib'of'ft15 567 3.89 0.59 4 n/a n/a n/a n/a
replicate'1 sgk$1(ft15) 671 3.97 0.60 4 0.5288 wildtype'sib'of'ft15 +2.1 0
*shown(figure akt$1(mg306) 645 4.62 0.62 4.5 <0.0001 wildtype'sib'of'ft15 +18.8 +12.5
Figure(2F wildtype'sib'of'ft15 407 4.21 0.55 4 n/a n/a n/a n/a
replicate'2 sgk$1(ft15) 490 4.34 0.67 4.67 0.1980 wildtype'sib'of'ft15 +3.1 +20
akt$1(mg306) 460 4.42 0.66 4.67 0.1309 wildtype'sib'of'ft15 +5.0 +20
Figure(2F wildtype'sib'of'ft15 634 4.14 0.44 4.25 n/a n/a n/a n/a
replicate'3 sgk$1(ft15) 520 4.26 0.50 4.25 0.2377 wildtype'sib'of'ft15 +2.9 0
akt$1(mg306) 563 4.45 0.44 4.25 0.0157 wildtype'sib'of'ft15 +7.5 0
Figure(2G N2'wildtype 190 2.92 0.26 3 n/a n/a n/a n/a
replicate'1 daf$16(mu86) 197 3.04 0.22 3 0.0635 N2'wildtype +4.1 0
*shown(figure sgk$1(ok538) 170 3.30 0.18 3.33 <0.0001 N2'wildtype +13.0 +11.1
Figure(2E daf$16;sgk$1(ok538) 156 3.26 0.29 3.33 0.7658 sgk$1(ok538) 01.2 0 0.0185 daf$16(mu86) +7.2 +11.1
sgk$1(mg455) 164 3.29 0.19 3.33 0.0005 N2'wildtype +12.7 +11.1
daf$16;sgk$1(mg455) 155 3.37 0.21 3.33 0.4355 sgk$1(mg455) +2.4 0 0.0078 daf$16(mu86) +10.9 +11.1
Figure(2G N2'wildtype 228 3.92 0.49 4.25 n/a n/a n/a n/a
replicate'2 daf$16(mu86) 304 4.12 0.46 4.25 0.0087 N2'wildtype +5.1 0
Figure(2E sgk$1(ok538) 216 4.49 0.15 4.5 <0.0001 N2'wildtype +14.5 +5.9
daf$16;sgk$1(ok538) 218 4.48 0.14 4.5 0.8540 sgk$1(ok538) 00.2 0 0.0022 daf$16(mu86) +8.7 +5.9
Figure(2G N2'wildtype 254 3.67 0.46 3.67 n/a n/a n/a n/a
replicate'3 daf$16(mu86) 240 3.87 0.49 4 0.0204 N2'wildtype +5.4 +9.0
Figure(2E sgk$1(ok538) 245 4.04 0.35 4.25 0.1259 N2'wildtype +10.1 +15.8
daf$16;sgk$1(ok538) 209 4.31 0.27 4.25 0.1571 sgk$1(ok538) +6.7 0 0.0027 daf$16(mu86) +11.4 +6.3
Figure(2G N2'wildtype 260 3.39 0.35 3.33 n/a n/a n/a n/a
replicate'4 daf$16(mu86) 284 3.45 0.29 3.33 0.6399 N2'wildtype +1.8 0
Figure(2E sgk$1(mg455) 204 3.84 0.25 3.83 0.0011 N2'wildtype +13.3 +15.0
daf$16;sgk$1(mg455) 202 3.73 0.33 3.83 0.4184 sgk$1(mg455) 02.9 0 0.0427 daf$16(mu86) +8.1 +15.0
Figure(2G N2'wildtype 274 3.52 0.27 3.33 n/a n/a n/a n/a
replicate'5 daf$16(mu86) 246 3.56 0.24 3.58 0.6990 N2'wildtype +1.1 +7.5
Figure(2E sgk$1(mg455) 224 3.83 0.06 3.58 0.0015 N2'wildtype +8.8 +7.5
daf$16;sgk$1(mg455) 229 3.70 0.24 3.83 0.1781 sgk$1(mg455) 03.4 +7.0 0.2681 daf$16(mu86) +3.9 +7.0
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Supplemental Table 2.5. DAF-16A::GFP subcellular localization data. 
daf-16(mu86) mutant animals carrying a DAF-16A::GFP (TJ356, Henderson and Johnson, 2001) and sgk-1 
or akt-1 alleles were grown, imaged, and scored as described in Figure S2. 
 
Supplemental Table 2.6. qPCR data and statistics 
Five DAF-16/FoxO targets were each measured in six independent biological replicates, although not all 
genotypes were included in every replicate. All animals listed in the same column were grown and 
harvested at the same time under identical conditions. Three technical replicate measurements were 
performed per target/genotype/biological replicate and compared to three technical replicate measurements 
of act-1. All data is normalized to wildtype within the same cohort. An unpaired two-tailed t-test with 
Welch’s correction (P < 0.05) was performed to make relevant comparisons, and statistically significant 
changes are bolded. Note that sgk-1 null mutant changes in dod-3 and mtl-1 gene expression did not always 








Localization*Score wildtype akt$1(mg306) sgk$1(ok538) sgk$1(ft15)
1 38 0 23 40
2 27 6 30 20
3 8 39 19 21
4 2 25 3 3
5 0 0 0 0
N 75 70 75 84


















wildtype 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.00 n/a n/a n/a n/a
akt$1(mg306) 2.00 4.20 n/a 2.41 4.23 2.62 3.09 1.05 0.0112 wildtype 3.09 5'of'5
daf$16(mu86);akt$1(mg306) 0.52 0.70 n/a 0.54 0.72 0.37 0.57 0.14 0.0054 akt$1(mg306) 0.18 5'of'5
sgk$1(ft15) 0.57 1.04 1.09 0.69 1.02 0.51 0.82 0.26 0.1506 wildtype 0.82 37of76
daf$16;sgk$1(ft15) 0.44 0.52 0.54 0.43 0.49 0.22 0.44 0.11 0.0140 sgk$1(ft15) 0.53 6'of'6
sgk$1(ok538) 0.25 0.41 0.60 0.67 0.27 0.33 0.42 0.18 0.0005 wildtype 0.42 6'of'6
daf$16;sgk$1(ok538) 0.20 0.16 0.10 n/a n/a n/a 0.15 0.05 0.0126 sgk$1(ok538) 0.37 3'of'3
sgk$1(mg455) 0.48 0.43 0.54 0.45 0.48 0.28 0.44 0.09 <0.0001 wildtype 0.44 6'of'6
daf$16;sgk$1(mg455) 0.26 0.16 0.19 n/a n/a n/a 0.20 0.05 0.0016 sgk$1(mg455) 0.45 3'of'3
nnt$1
wildtype 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.00 n/a n/a n/a n/a
akt$1(mg306) 4.29 1.95 n/a 1.01 3.89 3.20 2.87 1.37 0.0378 wildtype 2.87 4'of'5
daf$16(mu86);akt$1(mg306) 0.72 1.33 n/a 0.26 0.80 0.45 0.71 0.41 0.0216 akt$1(mg306) 0.25 5'of'5
sgk$1(ft15) 1.05 1.09 0.80 0.55 1.08 0.47 0.84 0.28 0.2172 wildtype 0.84 27of76
daf$16;sgk$1(ft15) 0.59 0.84 0.56 0.50 0.69 0.36 0.59 0.16 0.0945 sgk$1(ft15) 0.70 67of76
sgk$1(ok538) 0.72 1.60 0.72 0.70 1.27 0.82 0.97 0.38 0.8676 wildtype 0.97 n/a
daf$16;sgk$1(ok538) 0.42 0.59 0.34 n/a n/a n/a 0.45 0.13 0.0192 sgk$1(ok538) 0.46 3'of'3
sgk$1(mg455) 1.13 1.16 0.57 0.74 1.24 0.91 0.96 0.26 0.7127 wildtype 0.96 n/a
daf$16;sgk$1(mg455) 0.62 0.39 0.24 n/a n/a n/a 0.42 0.19 0.0143 sgk$1(mg455) 0.44 3'of'3
sip$1
wildtype 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.00 n/a n/a n/a n/a
akt$1(mg306) 3.61 3.48 n/a 1.82 2.08 2.13 2.62 0.85 0.0129 wildtype 2.62 5'of'5
daf$16(mu86);akt$1(mg306) 0.69 0.29 n/a 0.34 0.44 0.52 0.46 0.16 0.0040 akt$1(mg306) 0.17 5'of'5
sgk$1(ft15) 1.14 1.15 1.42 1.21 0.91 0.97 1.13 0.18 0.1369 wildtype 1.13 27of76
daf$16;sgk$1(ft15) 0.64 0.73 0.75 0.61 0.52 0.51 0.63 0.10 0.0004 sgk$1(ft15) 0.55 6'of'6
sgk$1(ok538) 1.41 3.36 2.04 1.16 1.06 1.05 1.68 0.90 0.1239 wildtype 1.68 37of76
daf$16;sgk$1(ok538) 0.73 0.99 0.62 n/a n/a n/a 0.78 0.19 0.0590 sgk$1(ok538) 0.46 37of73
sgk$1(mg455) 0.76 2.00 2.69 1.54 1.03 1.25 1.54 0.71 0.1174 wildtype 1.54 47of76
daf$16;sgk$1(mg455) 1.59 1.48 0.80 n/a n/a n/a 1.29 0.43 0.5260 sgk$1(mg455) 0.84 27of73
dod$3
wildtype 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.00 n/a n/a n/a n/a
akt$1(mg306) 8.06 4.17 n/a 2.38 5.50 5.58 5.14 2.09 0.0114 wildtype 5.14 5'of'5
daf$16(mu86);akt$1(mg306) 0.78 0.22 n/a 0.50 0.55 0.92 0.59 0.27 0.0078 akt$1(mg306) 0.12 5'of'5
sgk$1(ft15) 0.43 0.33 0.52 0.66 0.54 0.30 0.46 0.14 0.0002 wildtype 0.46 6'of'6
daf$16;sgk$1(ft15) 0.28 0.38 0.50 0.34 0.59 0.36 0.41 0.11 0.4645 sgk$1(ft15) 0.88 27of76
sgk$1(ok538) 3.43 11.00 4.26 1.01 2.81 0.76 3.88 3.75 0.1186 wildtype 3.88 47of76
daf$16;sgk$1(ok538) 1.21 4.08 1.29 n/a n/a n/a 2.20 1.63 0.3798 sgk$1(ok538) 0.57 37of73
sgk$1(mg455) 0.86 6.50 3.89 0.90 3.86 1.77 2.96 2.20 0.0809 wildtype 2.96 47of76
daf$16;sgk$1(mg455) 1.05 3.92 1.13 n/a n/a n/a 2.03 1.63 0.5050 sgk$1(mg455) 0.69 27of73
mtl$1
wildtype 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.00 n/a n/a n/a n/a
akt$1(mg306) 6.73 6.15 n/a 2.33 2.68 3.03 4.18 2.08 0.0269 wildtype 4.18 5'of'5
daf$16(mu86);akt$1(mg306) 0.41 0.28 n/a 0.25 0.18 0.21 0.27 0.09 0.0136 akt$1(mg306) 0.06 5'of'5
sgk$1(ft15) 0.51 0.95 0.81 1.05 1.15 0.63 0.85 0.25 0.1968 wildtype 0.85 37of76
daf$16;sgk$1(ft15) 0.17 0.29 0.23 0.18 0.26 0.09 0.20 0.07 0.0009 sgk$1(ft15) 0.24 6'of'6
sgk$1(ok538) 1.31 4.50 2.83 5.82 2.95 0.85 3.04 1.88 0.0450 wildtype 3.04 5'of'6
daf$16;sgk$1(ok538) 1.75 0.85 0.39 n/a n/a n/a 1.00 0.69 0.0511 sgk$1(ok538) 0.33 2'of'3
sgk$1(mg455) 2.14 3.31 4.76 5.78 1.79 2.27 3.34 1.61 0.0162 wildtype 3.34 6'of'6





Supplemental Table 2.7. qPCR primers. 
 
  
Target Forward primer (5' to 3') Reverse primer (5' to 3') Reference
act-1 CCAGGAATTGCTGATCGTATGCAGAA TGGAGAGGGAAGCGAGGATAGA Alam et al. 2010
sod-3 TATTAAGCGCGACTTCGGTTCCCT CGTGCTCCCAAACGTCAATTCCAA Alam et al. 2010
nnt-1 CAGTAGAAACTGCTGACATGCTTC GAGCGATGGGATATTGTGCCTGAG Ghazi et al. 2009
sip-1 AAGAGATCGTTCACTCGCCAG AGCCAAGTCGACGTCCTTTG Kwon et al. 2010
dod-3 AAAAAGCCATGTTCCCGAAT GCTGCGAAAAGCAAGAAAAT Alam et al. 2010
mtl-1 ATGGCTTGCAAGTGTGACTG CACATTTGTCTCCGCACTTG Alam et al. 2010
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Chapter 3 Identification of DAF-16/FoxO target 
genes highly associated with longevity 
 
Abstract 
FoxO transcription factors modulate age-related disease in mammals and promote 
longevity in invertebrates. In C. elegans, reduced DAF-2 insulin-like signaling and 
germline ablation both extend life span by activating the FoxO ortholog DAF-16, but 
their mechanisms of life span extension downstream of DAF-16/FoxO have not been 
directly compared. Combining whole transcriptome profiling (RNA-seq) with a unique 
genetic filter, we find that half of the longevity-associated DAF-16/FoxO target genes 
regulated by the germline are shared with reduced IIS. We further identify a core set of 
46 genes regulated by DAF-16/FoxO highly correlated with longevity in multiple 
contexts. This set is tractable for rigorous functional validation, and we used qPCR to 
validate genes not previously identified in microarray-based studies. As the majority of 
these genes likely have functions conserved in humans, understanding the biological 
function of these genes may help develop strategies to promote healthy aging.  
Introduction 
FoxO transcription factors promote longevity in invertebrates [1–3] and modulate 
phenotypes related to age-related disease in mammals [4–9]. FoxO may be involved in 
human life span control, as FoxO1 and FoxO3 polymorphisms are associated with 
longevity in multiple cohorts of human centenarians [10–12]. Thus, identifying conserved 
genes regulated by FoxO to control life span promises to elucidate mechanisms of aging 
that can be targeted to treat and prevent age-related disease. However, a major challenge 
in identifying and studying FoxO target genes that influence longevity is that thousands 
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of genes are regulated by FoxO, many of which may be unrelated to aging and longevity 
[13,14]. 
The role of FoxO in life span control is best understood in C. elegans, where the FoxO 
ortholog DAF-16 promotes longevity in the contexts of reduced IIS (insulin and insulin-
like signaling) and germline ablation [1,15]. DAF-16/FoxO activation by reduced IIS is 
well-understood and conserved in mammals. Reduced activation of the insulin-like 
growth factor receptor DAF-2/IGFR turns off a conserved PI3K/Akt cascade, resulting in 
hypophosphorylation and nuclear localization of DAF-16/FoxO. In this context, both 
DAF-16 and mammalian FoxO proteins regulate gene expression by binding to a 
conserved DNA motif (TTGTTTAC) [16]. Indeed, classes of target genes are shared 
between DAF-16 and mammalian FoxO, strongly suggesting that understanding DAF-
16/FoxO-mediated life span extension will shed light on human aging [13,17,18]. 
Less is known about the mechanism of DAF-16 activation by germline ablation, but it is 
at least partially divergent from activation by IIS reduction. Germline ablation extends 
the life span of daf-2 mutants [15,19], but this interaction is complicated by the fact that 
daf-2 alleles are hypomorphic rather than null. Specific molecular components such as 
KRI-1 and TCER-1 are required for DAF-16/FoxO to extend life span in germline-
ablated animals but are dispensable for daf-2/IGFR mutant longevity [20–22]. 
It is clear that IIS and signals from the germline converge on DAF-16/FoxO, but it is not 
known if DAF-16/FoxO regulates the same set of target genes to extend life span upon 
reduction of those signals. An ad hoc comparison between two rigorous microarray 
studies of DAF-16/FoxO targets in reduced IIS and germline ablation only identifies ~30 
shared targets out of ~600. However, two separate studies of daf-2 mutants only found 
~160 out of ~1700 genes in common [23–25]. Technical differences in laboratory 
conditions, technological platforms, and bioinformatic analysis pipelines complicate 
direct comparisons between studies. Therefore, direct comparison should ideally be 
performed using identical conditions and procedures. 
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Recently, new efforts have begun to identify DAF-16/FoxO targets by sequencing-based 
whole transcriptome profiling (RNA-seq). RNA-seq is superior to microarray-based 
approaches for detecting expression changes in high- and low-abundance transcripts, 
unannotated transcripts, and non-coding RNAs [26,27]. RNA-seq displays greater 
sensitivity, specificity and quantification than tiling arrays in direct comparisons in C. 
elegans [28]. Thus, employing RNA-seq increases the chances of identifying novel bona 
fide targets of DAF-16/FoxO. 
We reasoned that if there do exist similar mechanisms downstream of DAF-16/FoxO in 
both daf-2/IGFR mutants and animals lacking germlines, these would be strongly 
associated with longevity and therefore high-priority candidates for functional testing. 
Here, we use RNA-seq profiling technology to perform the first head-to-head comparison 
of insulin-like signaling and germline ablation. We further demonstrate that in both these 
contexts, the list of longevity-associated genes can be filtered using alleles of daf-16 with 
distinct effects on gene expression. 
Results 
Design of genetic filter to identify DAF-16 targets associated with longevity 
The daf-16 genomic locus encodes multiple isoforms that share C-termini but differ in 
their N-termini [29,30]. All published profiling experiments to identify DAF-16 target 
genes have utilized either mutations or RNAi constructs that affect all daf-16 isoforms. 
We reasoned that the large list of DAF-16 targets could be filtered if daf-16 isoforms 
controlled different targets. 
The roles of endogenous DAF-16 isoforms are unclear due to lack of isoform-specific 
mutants. However, according to previous reports utilizing animals harboring multiple 
copies of DAF-16 isoform-specific transgenes, DAF-16A and F are both capable of 
promoting longevity in the context of daf-2 mutation, while DAF-16B can only promote 
longevity if over-expressed at very high copy number [29–31]. More detailed analysis 
will be required to understand the individual contributions of endogenous DAF-16A and 
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DAF-16F. Importantly, DAF-16B is reported to have unique functions in pharyngeal 
remodeling and neurite outgrowth [32,33] and therefore is likely to have unique targets. 
As DAF-16B does not appear to contribute to life span extension, exclusion of its targets 
could be useful for filtering. 
Furthermore, we noted that the mg54 allele is predicted to introduce an early stop codon 
specifically into daf-16a and daf-16f, but not daf-16b. mg54 will henceforth be referred to 
as daf-16a/f. Therefore, if DAF-16B does not promote longevity, then daf-16a/f mutation 
should have the same effect on longevity as daf-16 null mutation. Indeed, it was reported 
that daf-16a/f suppresses longevity to the same extent as daf-16 null mutation (mgDf47 
allele) in the context of the daf-2(e1370) Class 2 mutation [33]. We confirmed this result 
(Figure 3.1A) using the daf-16(mu86) null allele (henceforth referred to as “daf-16” or 
“daf-16 null” for our purposes). We further measured the longevity of daf-16a/f;daf-
2(e1368) and daf-16;daf-2(e1368) in the same assay and found they had identical life 
spans (Figure 3.1B). Finally, we found the same result in the context of germline 
ablation, utilizing the temperature-sensitive glp-1(e2141) mutation (Figure 3.1C). 
Therefore, endogenous DAF-16B, in the absence of DAF-16A and F, is not sufficient for 
longevity in the contexts of daf-2 mutation or germline ablation. 
Since daf-16a/f and daf-16 null mutation both suppress longevity to the same extent 
(Figure 3.1), DAF-16B targets are far less likely to contribute to life span extension. We 




Figure 3.1. daf-16a/f and null daf-16 mutation suppress longevity to the same extent 
in (A) daf-2(e1370) animals, (B) daf-2(e1368) animals, and (C) germline-ablated 
animals. 
Data from 5 pooled cohorts are shown. Animals used for these life span cohorts were derived from 




daf-16a/f and daf-16 null mutation cause distinct changes in global gene expression  
To our knowledge, daf-16a/f mutants have not been previously profiled. To determine if 
the difference between daf-16 null and daf-16a/f mutation can be used as a genetic filter, 
we performed whole transcriptome profiling on adult daf-2(e1370), daf-2(e1368), and 
glp-1(e2141) animals with wild-type daf-16, daf-16a/f, or daf-16 null mutations. For each 
strain, 5 cohorts were utilized for experimental replicates, and we measured the life spans 
of a subset of each cohort to confirm that they had the expected phenotypes (Figure 3.1). 
We performed pair-wise comparisons based on fold-change and false discovery rate 
criteria (see Materials and Methods for precise criteria). 
We will use terminology introduced by Murphy and colleagues [24] to indicate direction 
of gene expression change. The term “Class 1” denotes genes upregulated by DAF-16 
and therefore are reduced upon daf-16 mutation. “Class 2” denotes genes downregulated 
by DAF-16 and increased upon daf-16 mutation. 
We first examined comparisons between daf-2(e1368) and either daf-16;daf-2 or daf-
16a/f;daf-2 (Figure 3.2). daf-16 null mutation yielded 270 Class 1 transcripts and 211 
Class 2 transcripts. daf-16a/f mutation yielded 248 Class 1 transcripts and 117 Class 2 
transcripts. We noticed the disparity in the number of Class 2 transcripts, and examined 
the overlap in Class 2 transcripts. Indeed, only 20% of the Class 2 transcripts (55/273) 
found in either comparison are shared, while the overlap for Class 1 transcripts is 50% 
(172/346). Thus, daf-16 null mutation affects Class 2 transcripts more than daf-16a/f 
mutation, suggesting that DAF-16B may be disproportionately responsible for Class 2 
transcript expression changes. 
We confirmed that daf-16a/f and null daf-16 mutation have distinct effects in two other 
contexts: (1) daf-2(e1370) mutation which is stronger than daf-2(e1368), and (2) 
germline ablation (Figure 3.2). In daf-2(e1370) mutants, daf-16 null mutation affected 
577 Class 1 transcripts and 594 Class 2 transcripts, while daf-16a/f mutation affected 704 
Class 1 transcripts and 496 Class 2 transcripts. The overlap was 50% for both classes 
(Class 1: 429/852; Class 2: 362/728). In glp-1 germlineless animals, daf-16a/f again 
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altered the expression of more Class 1 targets compared to Class 2 (284 vs. 169), while 
daf-16 null mutation affected approximately equal numbers of Class 1 and 2 targets (252 
vs. 227). 46% (169/367) of Class 1 transcripts were shared between daf-16a/f and daf-16 
null, while only 20% (67/329) of Class 2 transcripts were shared. Thus, DAF-16B also 
appears to be disproportionately responsible for Class 2 transcript expression changes in 
daf-2(e1370) mutants and germline-ablated animals. 
In summary, the daf-16a/f mutation is useful for identifying targets associated with 
longevity. At the very least, it serves as an additional daf-16 allele, allowing us to control 
for genetic background, as well as technical and biological noise. However, the data are 
consistent with DAF-16B activity remaining intact in daf-16a/f mutants. As DAF-16B 
does not contribute to life span extension, we are able to enrich for targets that are 
required for longevity. 
 
Figure 3.2. daf-16a/f and null daf-16 mutation have distinct effects on global gene 






Identification of common DAF-16 targets regulated by IIS and germline ablation 
We sought to compare gene expression changes mediated by DAF-16A/F in the contexts 
of reduced IIS and germline ablation.  
We defined two separate sets of DAF-16A/F targets that are regulated by DAF-2 insulin-
like signaling (Figure 3.3A, B): (1) in the context of daf-2(e1370) tyrosine kinase domain 
mutation, and (2) in the context of daf-2(e1368) ligand-binding domain mutation. daf-
2(e1370) is often considered a stronger loss-of-function allele than daf-2(e1368) due 
because of its larger magnitude of life span extension, higher penetrance of dauer arrest, 
and additional phenotypes [30,34]. Thus, to define two sets of DAF-2-regulated 
transcripts, we identified transcripts whose expression is altered in either daf-2(e1368) or 
daf-2(e1370) compared to wild-type. We then applied the genetic filter previously 
described to identify those transcripts changed in the opposite direction by both null daf-
16 and daf-16a/f mutation. Consistent with stronger loss-of-function, daf-2(e1370) 
affected most of the same DAF-16A/F targets daf-2(e1368) did (110 out of 150), as well 
as almost 600 additional targets (Figure 3.3D). 
For the DAF-16A/F targets regulated by germline ablation (Figure 3.3C), a wild-type 
strain was not included due to potential confounding caused by germline transcripts in 
wild-type animals. Therefore, we simply applied our genetic filter to define the 236 
transcripts changed by both null daf-16 and daf-16a/f mutation. Interestingly, this set 
does not overlap much with daf-2(e1368) (47 out of 236), but shows stronger overlap 
with daf-2(e1370) (110 out of 236). Overall, DAF-16A/F has a larger influence on global 
transcriptional regulation in the context of daf-2(e1370) mutation than daf-2(e1368) or 
germline ablation (Figure 3.3D), consistent with the greater longevity of daf-2(e1370) 
mutants. 
We then identified 44 transcripts that correlate with longevity in all three contexts. The 
effects of mu86 and mg54 alleles on the expression of these 44 transcripts were strongly 
correlated (R2 = 0.9642), consistent with specific regulation by DAF-16A/F (Figure 3.3E). 
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Of these 44, four constitute operons composed of two genes each, and two transcripts 
corresponded to the same gene. Therefore, we identified a total of 47 genes (Table 3.1).  
We performed global validation of our data set by quantitative PCR in wild-type and daf-
2(e1370) animals (Figure 3.4A). 46 of 47 genes showed the expected change in expression. 
The only exception was ceh-89 which is part of the akt-2 transcript and therefore constitutes 
a bioinformatic artifact. Importantly, the magnitude of change measured by qPCR and by 
RNA-seq was highly correlated (R2 = 0.900), demonstrating that RNA-seq gives reliable 
quantitative measurements. One major advantage of RNA-seq over microarray is larger 
dynamic range and lower background noise, allowing for more precise quantification [27]. 
More thorough validation of three targets showed the expected changes with both daf-2 
mutations and both daf-16 mutations (Figure 3.4B-D). 
We compared our set of 46 validated targets to DAF-16/FoxO targets previously 
identified by microarrays (Table 3.1). Our set includes “gold standard” DAF-16/FoxO 
targets such as sod-3, mtl-1, dod-3, and hsp-12.6 [13,24,35,36]. Only 11 out of 46 genes 
were found in a previous microarray-based analysis of germline-regulated DAF-16/FoxO 
target genes [37]. 32 were found in at least one previous microarray study of DAF-2-
regulated DAF-16/FoxO target genes, which is much higher than the 6 genes expected by 
chance [23–25,38]. DAF-16/FoxO was previously shown to directly bind to the promoters of 
16 of the genes (by DamID and ChIP-seq) [39,40]. A GO term analysis using DAVID 
bioinformatics software indicated the only enriched terms were “aging”, “multicellular 
organismal aging”, and “determination of adult life span” (false discovery rate less than 
0.0001) [41], consistent with the overlap with previous microarray studies of DAF-16 
targets.  
15 genes were not previously identified by any individual microarray study. Of those, 8 were 
suggested by a meta-analysis of all existing DAF-2-related microarrays [36], suggesting that 
individual microarray studies are not sufficiently powered to detect some of the genes we 
found. Of the remaining six, four were not present on previous microarray chips [36]. 
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Taken together, it is highly likely that most of the 46 genes are bona fide DAF-16/FoxO 
targets, and this gene set represents an opportunity to identify genes with novel roles in 
life span control. Only 11 were previously tested for roles in life span extension by RNAi 
[13,24,25,42], but none of those were confirmed by mutation (Table 3.1). 9 of the genes 
have clear human homologs, and another 20 have domains conserved in humans. In 





Figure 3.3. Identification of 44 transcripts (47 genes) that correlate with longevity in 
8 different long- vs. short-lived comparisons. 
(A-C) We applied our genetic filter to identify DAF-16A/F targets in the contexts of (A) daf-2(e1370) 
mutation, (B) daf-2(e1368) mutation, and (C) germline ablation. These sets of DAF-16A/F targets were 
compared in (D) which identified 44 transcripts common to all three sets. (E) shows fold-change due to 
daf-16 null (mu86) or daf-16a/f (mg54) in the daf-2(e1370) background. The trend is similar in daf-





Figure 3.4. Validation of 
DAF-16/FoxO targets.  
(A) Comparison of relative expression 
measured by qPCR and absolute 
expression measured by RNA-seq 
(FPKM = fragments per kilobase of 
exon per million fragments mapped). 
(B-D) Detailed comparisons between 
qPCR and RNA-seq for three different 
DAF-16/FoxO targets. On the left, 
average measurements for three 
independent cohorts are plotted. Error 
bars correspond to SD, and p < 0.05 
for all relevant comparisons. On the 
right, average measurements for five 
independent cohorts are plotted. FDR 
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glp-1 daf-2 meta
F56D6.9 63 aa protein inf X ✔
T12D8.5 135 aa protein inf ✔ ✔ ✔
T02B5.1 esterase/lipase domain 207 ✔ ✔
Y6G8.9 F-box-associated domain domain 118 X
dct-8 69 aa protein 90 ✔ ✔
Y39G8B.7 ShK domain 82 ✔ ✔
R05H10.7 63 ✔
mtl-1 Metallothionein domain 58 ✔ ✔ ✔ ✔*
F15B9.6 53 ✔ ✔
F21C10.11 80 aa protein 38 ✔
K03D3.2 144 aa protein 26 ✔ ✔
lipl-2 Triacylglycerol lipase homolog 24 ✔ ✔
sdz-24 RPA2 fold domain 24 ✔ ✔
C08E8.4 DUF1768 23 ✔ ✔ ✔
dod-3 106 aa protein 22 ✔ ✔ ✔ ✔ ✔*
T23F4.3 Dienelactone hydrolase homolog 18 ✔ ✔ ✔
C08F11.3 16 ✔ ✔
sod-3 Superoxide dismutase homolog 15 ✔ ✔ ✔ ✔ ✔*
Y20C6A.1 F-box domain 15 ✔ ✔
Y6G8.2 domain 15 ✔ ✔
gst-29 Glutathione S-transferase homolog 13 ✔ ✔ ✔
lys-7 Lysozyme domain 13 ✔ ✔ ✔*
hen-1 LDL receptor motif domain 13 ✔ ✔
ftn-1 Ferritin heavy chain homolog 13 ✔ ✔ ✔ ✔ ✔
sru-40 Serpentine receptor domain 10 ✔ ✔
glb-1 Globin domain 8 ✔ ✔ ✔ ✔ ✔
spp-2 Antimicrobial peptide domain 7 ✔ ✔
Y34F4.2 Claudin 3 superfamily domain 7 ✔ ✔ ✔
btb-16 BTB domain domain 7 ✔ ✔
M01B2.13 
Phytanoyl-CoA 2-hydroxylase 
interacting protein-like domain 6 X
btb-17 BTB domain domain 5 ✔ ✔ ✔
cpg-7 116 aa protein 4 ✔ ✔
cutl-24 Zona pellucida domain domain 4 ✔
Y38C1AA.6 4 ✔
ttr-44 DUF290 domain 4 ✔ ✔
icl-1 Isocitrate lyase homolog 4 ✔ ✔ ✔ ✔*
F48D6.4 98 aa protein 4 ✔ ✔ ✔ ✔
hsp-12.6 Heat shock protein homolog 3 ✔ ✔ ✔ ✔*
hda-5 Histone deacetylase homolog 3 ✔
ttr-5 Transthyretin-like domain domain 3 ✔ ✔
akt-2 Akt/Protein Kinase B homolog 3 ✔ ✔ ✔
ceh-89 Homeodomain 3
Y2H9A.4 DUF713 2 ✔
dod-23 168 aa protein 0.30 ✔ ✔ ✔
srh-70 Serpentine receptor domain 0.25 ✔
F35E12.5 CUB domain domain 0.18 ✔ ✔ ✔ ✔*














Table 3.1. List of genes regulated by DAF-16/FoxO in both contexts of reduced 
insulin-like signaling and germline ablation. 
For the conservation column, “homolog” indicates the gene is unambiguously homologous to a human 
protein, while “domain” indicates that the gene possesses a domain conserved in human proteins. Fold-
change indicates expression in daf-2(e1370) divided by N2 wild-type. For comparison to previous 
microarrays, “glp-1” refers to McCormick et al. 2012, “daf-2” refers to combined results of Murphy et al. 
2003, McElwee et al. 2003, and Troemel et al. 2006, and “meta” refers to the meta-analysis performed by 
Tepper et al. 2013. See text for details. “DAF-16 bind” indicates genes bound DAF-16 in vivo identified by 
either ChIP-seq (Contrino et al. 2012) or DamID (Schuster et al. 2010). See text for details. Previous LS 
test indicates genes previously tested by RNAi for roles in life span control, and * indicates those that had a 
statistically significant effect. Note that only ceh-89 was eliminated by qPCR validation. 
 
Discussion 
The mechanism of DAF-16/FoxO-mediated life span extension remains elusive. One 
strategy to uncover mechanism is to observe multiple long-lived mutants that rely on 
DAF-16/FoxO activity for longevity and ask what is common between them. In this 
study, we combined three novel approaches to identify longevity-associated targets of 
DAF-16/FoxO: (1) direct comparison of DAF-16/FoxO targets in the contexts of reduced 
IIS and germline ablation, (2) RNA-sequencing technology and (3) a unique genetic filter 
based on the fact that only the DAF-16A and DAF-16F isoforms promote longevity. Our 
results both add to and greatly refine the sets of daf-2/IGFR- and germline-dependent 
DAF-16/FoxO target genes have previously been identified [24,36,37]. The end result 
was a set of 46 genes validated by qPCR that is tractable for rigorous testing. 
We have chosen the most stringent criteria to select our 46 genes: genes must show clear 
evidence of differential expression in all 8 long- vs. short-lived comparisons. Therefore, it 
is possible other genes in our RNA-seq data set also correlate with longevity but are 
subject to more subtle regulation by DAF-16/FoxO. However, the 46 genes already 
identified should be sufficient for functional analysis in Chapter 5. 
The filtering itself yielded novel insights into DAF-16/FoxO target gene regulation. The 
daf-16a/f mutation reliably produced distinct sets of target genes compared with daf-16 
null mutation, strongly implying that endogenous DAF-16 isoforms diverge in their 
transcriptional activity. This is consistent with previous measurements of 10 target genes 
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in transgenic animals over-expressing DAF-16 isoforms individually [29]. Gene 
regulatory events reversed by daf-16 mutation but not by daf-16a/f mutation are not 
sufficient for life span extension. We separately found that daf-16b mutation does not 
reduce daf-2 longevity (data not shown), raising the possibility that these gene regulatory 
events are also not required.  
Confirmation that disparities between daf-16a/f and null daf-16 correspond to DAF-16B 
targets will require profiling the daf-16b-specific mutant. The other possibilities to 
explain strain-specific differences include: (1) genetic background and (2) biological and 
technical noise. However, these are not likely to explain why DAF-16-downregulated 
genes (Class 2) are disproportionately filtered out by mg54/mu86 comparisons, indicating 
a biologically significant difference. Thus, it is far more likely that mg54 filters out DAF-
16B-specific targets, which are enriched in Class 2 genes. 
We also compared the gene expression profiles of germline-ablated animals and two 
types of IIS mutants. First, daf-2(e1370) exhibited gene expression changes that included 
nearly all those seen in daf-2(e1368), and many more. This is consistent with daf-
2(e1370) being a stronger loss-of-function allele that causes more marked longevity and 
developmental phenotypes. Second, many regulatory events that occur in daf-2(e1370), 
but not daf-2(e1368), are shared with germline-ablated animals. Thus, the extraordinary 
longevity of daf-2(e1370) may result from longevity assurance mechanisms shared by 
both daf-2(e1368) and germline-ablated animals, as well as additional mechanisms. 
Finally, the 123 gene regulatory events unique to germline-ablated animals may explain 
why germline ablation extends the longevity of both daf-2 mutants [15,19]. 
Our identification of significant overlap (~110 transcripts) between germline ablation and 
reduced IIS is important. Thus, nearly half of the DAF-16/FoxO targets controlled by the 
germline are shared with reduced IIS. This is much higher than the 30 genes found in one 
rigorous IIS study that are included the set of 230 DAF-16/FoxO targets found by another 
rigorous germline-ablation study [24,37]. This is surprising because germline ablation 
and reduced IIS constitute significantly divergent contexts for DAF-16/FoxO action. 
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Germline ablation only activates intestinal DAF-16/FoxO to promote longevity, while 
reduced IIS engages system-wide insulin-like ligand networks to activate DAF-16/FoxO 
in many tissues, especially the intestine, hypodermis, and neurons [43–45]. Furthermore, 
germline ablation and reduced IIS activate distinct sets of transcription factors that work 
in concert with DAF-16/FoxO to promote longevity. HSF-1 and SKN-1 are activated by 
reduced IIS, are required for the longevity of daf-2/IGFR mutants, and co-regulate at 
least some target genes with DAF-16/FoxO [46–48]. In contrast, NHR-80, PHA-4, DAF-
12, and TCER-1 transcriptional regulators are critical for longevity in animals lacking a 
germline [21,49,50]. Finally, the germline constitutes half the mass of adult C. elegans 
[51], and therefore germline ablation itself is likely to dramatically alter the organism-
wide transcriptome. Thus, it is intriguing that DAF-16/FoxO controls many of the same 
genes in these two very different contexts, and these similarities may explain their 
common life span extension. 
To test whether DAF-16/FoxO promotes longevity through overlapping mechanisms in 
germline-ablated animals and IIS mutants, we will need to determine the contributions of 
the 46 shared DAF-16/FoxO target genes (Table 3.1) to life span control. In Chapter 5, 
we will functionally test these genes as well as those found in Chapter 4. It is plausible 
that these simply correlate with DAF-16/FoxO activation. However, given that almost no 
DAF-16/FoxO targets have been rigorously tested using genetic mutants, even ruling out 
individual contributions within these 46 genes would yield novel insight into the 
mechanism of DAF-16/FoxO-mediated life span extension. More likely, some of these 46 
genes are required for longevity across many contexts. Given that at least 29 of these 
likely possess functions conserved in humans, identification of these genes may shed 




Materials and Methods 
C. elegans strains and maintenance 
Strains used in this study are listed in Table 3.2. Animals were maintained at 15°C on 
nematode growth media (NGM) plates seeded with Escherichia coli OP50. Double 
mutants were constructed using standard genetic techniques. Percival I-36NL incubators 
(Percival Scientific, Inc., Perry, IA) were employed for maintenance and life span assays. 
 
Table 3.2. List of strains used in Chapter 3. 
Life span assays 
Life span assays were performed as previously described [52], with minor modifications. 
Wild-type and daf-2 animals derived from a synchronized 4 hr egglay were grown at 
15°C until the early L4 larval stage and then shifted to 20°C. Plates harboring any males 
were discarded. Animals were grown for an additional 20-24hr to day 1 of adulthood and 
then placed on life span plates containing 25µg/mL 5-fluoro-2’-deoxyuridine (FUDR; 
Sigma-Aldrich, St. Louis, MO) to prevent progeny growth. Egglay of daf-2(e1370) was 
performed 6 hours earlier to adjust for slower growth. Preparation of glp-1 mutant 
animals was similar except they were raised at the restrictive temperature (25°C) for 48 
hrs to ablate the germline. Statistical significance was assessed using the standard chi-
square-based log-rank test in GraphPad Prism. 
RNA isolation 
The remaining animals from populations raised for life span assays were washed twice in 
M9 buffer. Total RNA was isolated using TRIzol® reagent (Invitrogen) and purified 
Strain Genotype Outcrossed Reference
N25Bristol wild9type
DR1572 daf$2(e1368) 6X Kimura5et.al..1997
CB1370 daf$2(e1370) 6X Kimura5et.al..1997
CB4037 glp$1(e2141) 6X Priess5et.al.51987
CF1038 daf$16(mu86) 6X Lin5et.al.51997
GR1308 daf$16(mg54) 6X Ogg5et.al.51997
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using an RNeasy kit (QIAGEN Inc., Valencia, CA) according to manufacturers’ 
instructions. 
Quantitative real-time reverse-transcriptase PCR (qPCR) 
cDNA was synthesized using a SuperScript® III Reverse Transcriptase kit and random 
hexamers (Invitrogen, Carlsbad, CA). Real-time PCR was then performed in triplicate 
using Power SYBR® Green PCR master mix (Applied Biosystems, Warrington, UK) and 
a Mastercycler® ep realplex thermal cycler (Eppendorf North America, Westbury, NY). 
10ng of cDNA was used as a template in 15µl reaction volume. Relative expression 
levels and technical error were determined by the ΔΔ2Ct method [53]. Gene expression 
levels were normalized to actin (act-1), and the ratio of expression relative to act-1 was 
then compared to the same ratio in N2 Bristol wild-type. Statistical analysis was 
performed in GraphPad Prism (GraphPad Software, La Jolla, CA) using the paired ratio t-
test. 
Whole transcriptome profiling (RNA-seq) 
5 biological replicates were collected for every genotype. The Agilent TapeStation was 
used to assess RNA quality. Samples with RINs (RNA Integrity Numbers) of eight or 
greater were prepped using the Illumina TruSeq mRNA Sample Prep v2 kit (Catalog 
#RS-122-2001 and RS-122-2002). mRNA was isolated from 0.1-3 µg of total RNA by 
polyA+ purification, fragmented, and copied into first strand cDNA using reverse 
transcriptase and random primers. 3’ cDNA ends were then adenylated and adapters 
ligated. One of the adapters contained a 6-nucleotide barcode to enable multiplexing of 
samples. Products were purified and enriched by PCR to create the final cDNA library. 
Libraries were checked for quality and quantity by Agilent TapeStation and qPCR using 
a library quantification kit for Illumina sequencing platforms (catalog #KK4835, Kapa 
Biosystems, Wilmington, MA). Clonal clusters were generated using cBot (Illumina, Inc., 
San Diego, CA). Quadriplexed samples were sequenced using the HiSeq 2000 system 
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(Illumina) with a 100-cycle paired-end run in high output mode using Version 3 
reagents according to manufacturer’s protocols. 
Individual reads files for each sample were concatenated into a single .fastq file. Raw 
reads data for each sample were checked using FastQC (Version 0.10.0, Babraham 
Bioinformatics, Cambridge, United Kingdom; 
http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc/) to identify features potentially 
indicative of quality issues (e.g. low quality scores, over-represented sequences, and 
inappropriate GC content). We used the Tuxedo Suite [54–56] for alignment, differential 
expression analysis, and post-analysis diagnostics. Briefly, reads were aligned to the 
reference genome (UCSC ce10; http://genome.ucsc.edu/) using TopHat (version 2.0.9) 
[54] and Bowtie (version 2.1.0.0) [57]. We used default parameter settings for alignment, 
with the exception of: “--b2-very-sensitive” and “--no-coverage-search.” A second round 
of quality control was then performed using FastQC to ensure that only high quality data 
was analyzed further. Cufflinks/CuffDiff (Version 2.1.1) [54] was used for quantification 
of expression and differential expression analysis, using UCSC ce10.fa as the reference 
genome and UCSC ce10.gtf as the reference transcriptome (http://genome.ucsc.edu/). For 
this analysis, we used parameter settings: “--multi-read-correct” to adjust expression 
calculations for reads that map to more than one locus, as well as “--compatible-hits-
norm” and “--upper-quartile –norm” for normalization of expression values. We 
generated diagnostic plots using the CummeRbund package [55] to confirm that each 
experiment yielded high quality data. 
We used locally developed scripts to format and annotate the differential expression data 
output from CuffDiff. Genes and isoforms were annotated using NCBI Entrez GeneIDs 
and text descriptions.  
RNA-seq analysis 
Gene expression data output from CuffDiff comprised 8 comparisons in 3 groups: (1) 
daf-2(e1370) compared to wild-type, daf-16(mu86);daf-2(e1370), and daf-16(mg54);daf-
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2(e1370), (2) daf-2(e1368) compared to wild-type, daf-16(mu86);daf-2(e1368), and daf-
16(mg54);daf-2(e1368), and (3) glp-1(e2141) compared to daf-16(mu86);glp-1 and daf-
16(mg54);glp-1. We defined DAF-16A/F targets in the daf-2 context as meeting all of the 
following criteria: (1) test status = “OK”, (2) fold change (FC) ≥ ±1.5 for wild-type vs. 
daf-2, (3) FC ≥ 1.5 in the opposite direction as wild-type for daf-2 vs. daf-16(mu86);daf-
2, (4) FC ≥ 1.5 in the opposite direction as wild-type for daf-2 vs. daf-16a/f(mg54);daf-2, 
and (5) FDR < 0.05 for all three comparisons. The criteria for glp-1 animals was similar 
except there was no wild-type comparison. We noted that many genes previously 
validated as DAF-16/FoxO targets did not meet our FDR criteria, and that RNA-seq is 
biased against short, low-expressed genes even if normalized for length [58]. Therefore, 
we also included genes that did not meet the FDR requirement but did fulfill a more 
stringent FC > 3 criterion for all comparisons. 4 genes in our final list did not meet the 
FDR cutoff for any of the 8 comparisons. 19 genes in our final list did not meet the FDR 
cutoff for one or more of the 8 comparisons. However, all of our genes met the fold 
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Chapter 4 Hierarchical Action of DAF-16/FoxO 
Isoforms in C. elegans Life Span Control 
 
Abstract 
FoxO transcription factors control development, metabolism, and aging across taxa. The 
Caenorhabditis elegans FoxO transcription factor DAF-16 promotes longevity in the 
contexts of reduced DAF-2 insulin-like growth factor receptor (IGFR) signaling and 
germline ablation. How it does so is poorly understood. The daf-16 genomic locus 
encodes four distinct isoforms (DAF-16A, D, F, and H) that are capable of extending life 
span. Using isoform-specific daf-16/FoxO mutant alleles, we show that the D, F, and H 
isoforms of DAF-16/FoxO are collectively not required for longevity in animals either 
with reduced DAF-2/IGFR signaling or lacking a germline, but function redundantly with 
DAF-16A to prolong life. In contrast, DAF-16A is necessary for full life span extension 
in these same contexts. Whole transcriptome profiling in animals with reduced DAF-
2/IGFR activity reveals a dominant role for DAF-16A over DAF-16D/F/H in the 
regulation of target gene expression. Our results unveil a hierarchy of isoform action in 
DAF-16/FoxO-dependent life span control and gene regulation, establishing DAF-16A as 
the primary C. elegans FoxO isoform that controls aging. As FoxO transcription factors 
have conserved functions in promoting longevity and may be dysregulated in aging-
related diseases, these findings promise to illuminate fundamental principles underlying 





FoxO transcription factors control development, metabolism, stress responses, and aging 
in diverse animal species [1-4]. FoxO promotes longevity in invertebrates with reduced 
insulin-like signaling [5-9]. Phenotypic analysis of knockout mice implicates FoxO 
transcription factors in the pathogenesis of aging-related diseases such as cancer [10-12], 
Type 2 diabetes [13-16], osteoporosis [17,18], and atherosclerosis [19,20]. In humans, 
FoxO1 and FoxO3 polymorphisms are associated with extreme longevity in multiple 
independent cohorts of centenarians [21-26], suggesting that the role of FoxO in 
controlling aging may be conserved in mammals. Therefore, understanding the molecular 
basis for FoxO transcription factor action will likely illuminate fundamental mechanisms 
that govern aging in animals. 
The well-established role of FoxO transcription factors as targets of insulin-like signaling 
first came to light from studies in C. elegans, where the insulin/insulin-like growth factor 
receptor (IGFR) ortholog DAF-2 promotes reproductive development and limits adult life 
span by inhibiting the FoxO transcription factor DAF-16 via a conserved 
phosphoinositide 3-kinase (PI3K)/Akt pathway-dependent mechanism. Engagement of 
DAF-2/IGFR by agonist insulin-like ligands activates the PI3K/Akt pathway, resulting in 
Akt-dependent phosphorylation of three DAF-16/FoxO amino acid residues that lie 
within conserved RxRxxS/T motifs. Phosphorylated DAF-16/FoxO is subsequently 
exported from the nucleus and sequestered in the cytoplasm. When DAF-2/IGFR 
pathway activity is reduced, unphosphorylated DAF-16/FoxO translocates to the nucleus, 
where it regulates the expression of numerous genes, including those that control 
metabolism, immunity, and detoxification [27]. The inhibition of FoxO by insulin-like 
signaling is evolutionarily conserved, as reduction of FoxO activity ameliorates 
biological phenotypes associated with reduced insulin-like signaling in flies [8,9,28] and 
mice [13-16]. 
DAF-16/FoxO also promotes life span extension in animals lacking a germline [29]. 
Although DAF-2/IGFR and the germline both control DAF-16/FoxO activity by 
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regulating its subcellular localization [30-32], they may do so through distinct 
mechanisms, as the molecular requirements for DAF-16/FoxO regulation by DAF-
2/IGFR signaling and the germline differ [33,34]. 
The daf-16 genomic locus encodes three groups of transcripts (a, b, and d/f/h) that are 
transcribed from distinct promoters [6,7,35]. daf-16d, f, and h are transcribed from the 
same promoter but have distinct 5’ ends and translational start sites [Supplemental Figure 
4.1,Supplemental Figure 4.2]; WormBase (www.wormbase.org)] [27,35]. For clarity, we 
refer to the d/f/h group of transcripts and polypeptides collectively as daf-16f and DAF-
16F, respectively. 
In animals with diminished DAF-2/IGFR signaling, mutations that reduce daf-16a and f 
but not daf-16b activity shorten life span to the same extent as daf-16 null mutations [31]. 
Furthermore, overexpression of DAF-16B under the control of its endogenous promoter 
does not extend the life span of daf-16/FoxO null mutants [31,35]. These data implicate 
DAF-16A and DAF-16F as the critical targets of DAF-2/IGFR in life span control. 
DAF-16A and DAF-16F share their C-terminal 428 amino acids, including the Forkhead 
DNA binding domain and two of the three conserved Akt-dependent phosphorylation 
motifs (Figure 4.1A) [27,35]. However, the A and F isoforms diverge in their N-termini 
(Figure 4.1A). Whereas DAF-16A contains a conserved RxRxxS/T motif likely to be 
recognized by Akt and/or Akt-related kinases [36], the N-terminus of DAF-16F lacks this 
motif but harbors a QxRxxS/T motif that is phosphorylated in vivo (Figure 4.1B) 
[27,35,37]. Since phosphorylation of the N-terminal RxRxxS/T site in murine FoxO1 is 
important in controlling FoxO subcellular localization [38], this difference suggests that 
nucleocytoplasmic shuttling of DAF-16A and DAF-16F may be controlled by distinct 
upstream inputs.  
Comparative sequence analysis indicates that DAF-16F is conserved in the related 
nematode C. briggsae [39]. Intriguingly, Drosophila and mammalian FoxO transcription 
factors possess both RxRxxS/T and QxRxxS/T motifs in their N-termini (Figure 4.1B), 
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and these sites are phosphorylated in intact cells [40,41], suggesting that conserved 
upstream inputs that regulate distinct FoxO isoforms in Caenorhabditis species may 
converge on a single FoxO isoform in flies and mammals. 
Transgene-based experiments demonstrate that, whereas both DAF-16A and DAF-16F 
are capable of extending life span in animals harboring a daf-16/FoxO null mutation 
when overexpressed under the control of their native promoters, overexpression of either 
isoform using the daf-16f promoter increases life span to a greater extent than 
overexpression of the same isoforms using the daf-16a promoter [35]. These findings 
have led to the conclusion that DAF-16F is the major FoxO isoform that controls C. 
elegans life span [35,42]. However, the lack of mutant alleles that specifically inactivate 
either daf-16a or daf-16f has precluded an analysis of the functions of each isoform in the 
presence of physiologic levels of expression of the other isoform. In this study, we use 
isoform-specific daf-16/FoxO mutant alleles to establish the roles of DAF-16A and DAF-
16F in the control of C. elegans development, longevity, and gene expression. 
 
 
Figure 4.1. daf-16/FoxO isoforms and isoform-specific mutations (next page). 
(A) Protein schematic comparing C. elegans DAF-16A and DAF-16F isoforms with human FoxO1 and 
FoxO3 proteins. The identical C-termini of DAF-16A and DAF-16F share two highly conserved RxRxxS/T 
Akt-family consensus phosphorylation motifs (yellow) with human FoxO.  The N-terminus of DAF-16A 
includes an RxRxxS/T phosphorylation motif (orange) conserved in human FoxO1 and FoxO3, while the 
unique N-terminus of DAF-16F harbors a QxRxxS motif (green) conserved in FoxO3. (B) N-terminal 
phosphorylation motifs in DAF-16A and DAF-16F are conserved in Drosophila dFoxO and human FoxO1, 
FoxO3, and FoxO4. Asterisks indicate conserved phosphoacceptor sites. Residues known to be 
phosphorylated in vivo (DAF-16F) or in intact cells (dFoxO, FoxO3, and FoxO4) are emboldened and 
underlined. See text for details. (C) C. elegans daf-16/FoxO genomic structure with isoform-specific 
mutations. Colors indicate unique N-terminal exons and Forkhead domains that correspond to DAF-






























Molecular characterization of isoform-specific daf-16/FoxO mutants 
To isolate daf-16a- and daf-16f-specific mutant alleles, we screened for mutants with 
deletions in the unique N-terminal exons of each isoform [43]. Two independent alleles, 
tm5030 and tm5032, are deletions in the daf-16a-specific exon (Figure 4.1C-D). 5’ rapid 
amplification of cDNA ends (RACE) analysis shows that these mutations result in 
frameshifts and predicted early translation termination (Figure 4.1D and Supplemental 
Figure 4.3-5). As expected, both tm5030 and tm5032 significantly reduced daf-16a 
transcript levels as measured by quantitative real-time reverse transcriptase PCR (qPCR; 
Supplemental Figure 4.6A-B; Supplemental Table 4.1), consistent with nonsense-
mediated decay secondary to premature translation termination. Neither mutation 
influenced the integrity or quantity of daf-16b or daf-16f transcripts (Supplemental Figure 
4.6C-D; Supplemental Table 4.1). 
tm6659 is a deletion that spans all four daf-16f-specific exons, including all three putative 
transcriptional and translational start sites (Figure 4.1C-D and Supplemental Table 4.1) 
[27,35]. daf-16f transcripts were undetectable in animals harboring tm6659 by 5’ RACE 
and qPCR (Supplemental Figure 4.3,6D; Supplemental Table 4.1), and neither daf-16a 
nor daf-16b transcripts were affected (Supplemental Figure 4.6A-C; Supplemental Table 
4.1). Total daf-16 levels are sharply reduced in tm6659 mutants (Supplemental Figure 
4.6E-F; Supplemental Table 4.1). Examination of tm6659 RNA-sequencing data shows 
no reads originating from the daf-16f-specific exons. Importantly, our data show no 
compensatory increase in daf-16f transcripts in either daf-16a(tm5030) or daf-
16a(tm5032) (Supplemental Figure 4.6D), and no increase in daf-16a transcripts in daf-
16f(tm6659) (Supplemental Figure 4.6A-B). 
Taken together, these data strongly suggest that tm5030, tm5032, and tm6659 are bona 
fide isoform-specific loss-of-function alleles. These isoform-specific alleles are 




DAF-16A promotes dauer arrest in animals with reduced DAF-2/IGFR signaling 
In response to adverse environmental conditions, C. elegans larvae undergo 
developmental arrest in an alternative larval stage known as dauer [44]. daf-2/IGFR and 
daf-16/FoxO mutants were first isolated in genetic screens for animals with dauer-
constitutive (Daf-c) and dauer-defective (Daf-d) phenotypes, respectively [45]. daf-
2/IGFR mutants constitutively arrest as dauers at 25°C in a daf-16/FoxO-dependent 
manner [45-47].  
To examine the roles of distinct DAF-16/FoxO isoforms in dauer regulation, we 
determined the influence of isoform-specific daf-16/FoxO mutations on dauer-
constitutive phenotypes in two daf-2/IGFR mutant backgrounds: e1368, a missense 
mutation in the DAF-2/IGFR extracellular ligand-binding domain, and e1370, a missense 
mutation in the cytoplasmic tyrosine kinase domain [48]. e1370 may be a stronger loss-
of-function allele than e1368, as it causes a more penetrant dauer-constitutive phenotype 
and extends life span to a greater extent than e1368 (Figure 4.2-3) [49]. 
As previously shown, the dauer-constitutive phenotype caused by both daf-2/IGFR 
mutations is fully suppressed by the null daf-16/FoxO allele mu86 [6] as well as by mg54 
(Figure 4.2; Supplemental Table 4.2), a nonsense mutation that affects daf-16a and daf-
16f but not daf-16b (Figure 4.1C-D) [7,31]. daf-16(mu86) and daf-16(mg54) are 
henceforth referred to as “daf-16 null” and “daf-16a/f mutation” for purposes of clarity. 
These results indicate that DAF-16B does not suffice to promote dauer arrest in animals 
with reduced DAF-2/IGFR signaling, implicating DAF-16A and/or DAF-16F in dauer 
regulation. 
Both daf-16a mutations completely suppress the dauer-constitutive phenotype of daf-
2(e1368) mutants, whereas daf-16f mutation does not influence daf-2(e1368) dauer arrest 
(Figure 4.2A; Supplemental Table 4.2; Supplemental Table 4.3). Thus, in this context, 
DAF-16A is the critical isoform that regulates dauer arrest. In daf-2(e1370) mutants, daf-
16a #1 and #2 mutations suppress dauer arrest by 22% (p = 0.0204) and 24% (p = 
0.0408) respectively, whereas daf-16f mutation has no effect on dauer arrest (Figure 
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4.2B; Supplemental Table 4.2). Since daf-16a/f mutation fully suppresses daf-2(e1370) 
dauer arrest (Figure 4.2B; Supplemental Table 4.2), DAF-16A and DAF-16F act 
redundantly to promote dauer arrest in daf-2(e1370) mutant animals. 
 
Figure 4.2. daf-16a-specific mutations suppress dauer arrest in daf-2/IGFR mutants.  
(A) The dauer-constitutive phenotype of daf-2(e1368) animals is fully suppressed by daf-16a/f mutation 
and both daf-16a mutations but is unaffected by daf-16f mutation. (B) The dauer-constitutive phenotype of 
daf-2(e1370) animals is fully suppressed by daf-16a/f mutation, partially suppressed by both daf-16a 
mutations, and unaffected by daf-16f mutation. Mean and standard deviation for at least three biological 
replicates are presented. Statistics and raw data are presented in Supplemental Table 4.2, Supplemental 






DAF-16A promotes longevity in animals with reduced DAF-2/IGFR signaling  
DAF-16/FoxO is required for life span extension both in animals with reduced DAF-
2/IGFR activity [5] and in animals lacking a germline [29]. Experiments involving 
RNAi-based knockdown and transgenic overexpression of DAF-16/FoxO isoforms 
suggest that both DAF-16A and DAF-16F promote longevity in daf-2/IGFR mutants 
[35]. We determined the effect of daf-16a and daf-16f mutations on life span in daf-
2(e1368) and daf-2(e1370) mutants. As previously shown, life span extension induced by 
daf-2/IGFR mutation was fully suppressed by daf-16 null mutation as well as by daf-
16a/f mutation (Figure 4.3A-D; Supplemental Table 4.5-6) [31,32]. 
In daf-2(e1368) mutants, daf-16a #1 and #2 mutations reduced mean life span by 19.3% 
and 17.3% respectively (p<0.0001), whereas daf-16a/f mutation decreased mean life span 
by 39.5% (Figure 4.3A; Supplemental Table 4.5-6). Thus, on average, daf-16a mutations 
shortened daf-2(e1368) life span ~46% as much as daf-16a/f mutation did (18.3/39.5). 
Similarly, in daf-2(e1370) mutants, daf-16a #1 and #2 mutations shortened mean life 
span by 26.3% and 26.6% respectively (p<0.0001), whereas daf-16a/f mutation reduced 
mean life span by 65.6% (Figure 4.3C; Supplemental Table 4.5-6). Therefore, daf-16a 
mutation was on average 40% as potent as daf-16a/f mutation in decreasing daf-2(e1370) 
life span (26.45/65.6). These results indicate that DAF-16A is partially required for the 
longevity of daf-2/IGFR mutants. In contrast, daf-16f mutation did not reproducibly 
influence life span in either daf-2/IGFR mutant background, shortening daf-2(e1368) 
mean life span by 5% and 9% in two of three trials (p = 0.0356, 0.0013) while having no 
significant effect on daf-2(e1370) life span in three trials (Figure 4.3B,D; Supplemental 
Table 4.5-6). This finding was unexpected in light of previous studies implicating DAF-
16F in life span control by the DAF-2/IGFR pathway [35,42]. Taken with our finding that 
the tm6659 mutation likely fully eliminates daf-16f activity (Figure 4.1, Supplemental 
Figure 4.1, Supplemental Figure 4.6D), our data are consistent with a hierarchical model 
of DAF-16/FoxO isoform function in promoting longevity in the context of reduced 
DAF-2/IGFR signaling. DAF-16A is necessary for full life span extension, as daf-16a-
specific mutation reduces life span extension by ~40-50%. However, DAF-16F is 
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dispensable for longevity, as DAF-16A is sufficient to fully extend life span even when 
daf-16f is mutated. 
Given that daf-16a/f mutation shortens life span in animals with reduced DAF-2/IGFR 
activity to a much greater extent than daf-16a mutation alone, we tested the possibility 
that DAF-16F is required for life span extension in the absence of DAF-16A. Thus, we 
performed isoform-specific daf-16/FoxO RNAi [35]. As previously shown, inactivation 
of either daf-16a or daf-16f alone by RNAi had a modest effect on the longevity of daf-
2/IGFR mutant animals compared to RNAi of all daf-16/FoxO isoforms (“pan-daf-16 
RNAi”) [35]. daf-2(e1370) mean life span is reduced 25% by daf-16a RNAi and 16.7% 
by daf-16f RNAi, corresponding to 45% and 30% of the effect of pan-daf-16 RNAi 
(55.0% reduction of mean life span; Figure 4.3E; Supplemental Table 4.7). However, 
daf-16f RNAi shortened the mean life span of daf-16a;daf-2 double mutant animals by 
46%, which is 93% of the effect of pan-daf-16 RNAi (49.5%; Figure 4.3F; Supplemental 
Table 4.7). Therefore, although DAF-16F is dispensable for longevity in the presence of 
DAF-16A, it is required for life span extension in animals lacking DAF-16A. The life-
span-shortening effect of daf-16a RNAi in daf-16a;daf-2 double mutants (10.8% 
reduction in mean life span) may be a consequence of off-target RNAi effects [50]. 
We also wished to determine the extent to which longevity in daf-16f;daf-2 double 
mutants requires DAF-16A. To address this question, we performed isoform-specific daf-
16/FoxO RNAi on daf-16f;daf-2 double mutants. daf-16a RNAi shortened the mean life 
span of daf-16f;daf-2 double mutant animals by 53.8%, constituting 90% of the effect of 
pan-daf-16 RNAi (59.9%; Figure 4.3G; Supplemental Table 4.7). In contrast, daf-16f 
RNAi increased daf-16f;daf-2 mean life span by 1.1%.  
Therefore, when DAF-16F is absent, DAF-16A is likely the sole FoxO isoform that 
promotes longevity. DAF-16A is the primary isoform that controls C. elegans aging in 
the context of reduced DAF-2/IGFR signaling. DAF-16F is not required for longevity 




Figure 4.3. DAF-16A, but not DAF-16F, is sufficient for full life span extension in 
daf-2/IGFR mutants.  
(A-D) Effects of daf-16a (A, C) and daf-16f (B, D) mutations on life spans of daf-2(e1368) (A-B) and daf-
2(e1370) (C-D). (E-G) daf-16a is required for daf-16f;daf-2 longevity and vice versa. Survival curves are 
presented for (E) daf-2(e1370), (F) daf-16a;daf-2, (G) daf-16f;daf-2 mutant animals upon exposure to 
isoform-specific daf-16 RNAi. (H) Single-copy daf-16f rescue in daf-16a/f;daf-2 recapitulates daf-16a;daf-
2 longevity, and doubling the gene dosage of daf-16f extends life span. See text for details. Statistics and 








Rescue using daf-16a and daf-16f single-copy transgenes 
Our analysis demonstrates that DAF-16A promotes longevity in daf-2/IGFR mutants 
more strongly than DAF-16F, but previous studies suggested that DAF-16F plays a 
stronger role [35,42]. These studies employed transgenic strains harboring multiple 
cDNA copies of either daf-16a or daf-16f. Thus, we generated single-copy transgenic 
strains with the aim of achieving endogenous levels of expression of daf-16a and daf-16f. 
A daf-16a/f;daf-2 mutant with a daf-16f single-copy transgene exhibited the same life 
span as the daf-16a;daf-2 mutant (Figure 4.3H), providing further evidence that daf-16a 
is required for full life span extension of daf-2/IGFR mutants. Furthermore, daf-16f 
rescue in a daf-16a;daf-2 mutant effectively doubles the gene dosage of daf-16f in the 
absence of daf-16a, and this mutant with four daf-16f copies lived longer than a strain 
with two daf-16f copies (Figure 4.3H). This strongly suggests that multi-copy expression 
of daf-16f in previous studies over-stated the role of daf-16f. However, our daf-16a 
single-copy transgene only partially rescued the dauer and life span phenotypes of daf-
16a mutation (Supplemental Discussion). Taken together, these results likely reconcile 
the previous study by Kwon et al. and our results- see Supplemental Discussion for 
further details. 
DAF-16A promotes stress resistance 
Given the lack of effect of daf-16f mutation on daf-2/IGFR mutant dauer arrest (Figure 
4.2) and longevity (Figure 4.3) when daf-16a is intact, we attempted to identify a daf-16f 
phenotype. DAF-16/FoxO promotes resistance to a wide variety of stresses [2]. We found 
that daf-16a mutation partially reduces the resistance of daf-2(e1370) mutants to 
ultraviolet (UV), oxidative, and heat stress (Supplemental Figure 4.7, Supplemental Table 
4.10), similar to the effect of daf-16a mutation on longevity. In contrast, daf-16f mutation 
does not have any significant effect on resistance to these same stresses (Supplemental 




DAF-16A promotes longevity in animals lacking a germline 
Although DAF-16/FoxO is also required for longevity in animals lacking a germline [29], 
life span extension caused by germline ablation requires molecules such as KRI-1 and 
TCER-1 that are not necessary for longevity in daf-2/IGFR mutants [33,34]. These 
observations suggest that DAF-2/IGFR and the germline could control life span by 
coupling to distinct DAF-16/FoxO isoforms. To test this hypothesis, we determined the 
effect of isoform-specific daf-16/FoxO mutations on life span in animals harboring a 
temperature-sensitive glp-1 mutation that develop without a germline when grown at 
25°C [51]. As we observed in animals with reduced DAF-2/IGFR activity, the life spans 
of germline-ablated animals were modestly reduced by daf-16a mutation; daf-16a #1 and 
#2 mutations shortened mean life spans of germline-ablated animals by 17.5% and 18.2% 
respectively (p<0.0001), compared to a 45.2% reduction in mean life span due to daf-
16a/f mutation (Figure 4.4A; Supplemental Table 4.8). Therefore, the effect of daf-16a 
mutation on mean life span is 39% of the effect of combined daf-16a/f mutation on mean 
life span of animals lacking a germline. daf-16f mutation did not influence the life span of 
germline-ablated animals in a consistent manner, increasing mean life span by 11% in 
one of three trials (p = 0.0454; Figure 4.4B; Supplemental Table 4.8).  
We also tested whether DAF-16F is required for life span extension of germline-ablated 
animals in the absence of DAF-16A and vice versa, similar to requirements in the context 
of daf-2/IGFR mutation. In germline-ablated animals where all daf-16 isoforms are 
intact, mean life span is reduced 13.8% by daf-16a RNAi and 4.8% by daf-16f RNAi, 
corresponding to 40% and 14% of the effect of pan-daf-16 RNAi (34.7% reduction of 
mean life span; Figure 4.4C; Supplemental Table 4.9). However, daf-16f RNAi shortened 
the mean life span of daf-16a;daf-2 double mutant animals by 21.8%, which is 84% of 
the effect of pan-daf-16 RNAi (26.0%; Figure 4.4D; Supplemental Table 4.9). daf-16a 
RNAi shortened the mean life span of daf-16f;daf-2 double mutant animals by 25.3%, 
constituting 83% of the effect of pan-daf-16 RNAi (30.6%, Figure 4.4E; Supplemental 
Table 4.9). Intriguingly, daf-16a and daf-16f RNAi appears to modify life span variation 
in germline-ablated animals, where a subset of the population experiences early death 
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[29]. This may reflect dosage-dependent effects of daf-16/FoxO, or it may be the result of 
off-target effects of RNAi. 
Therefore, DAF-16A is also the main FoxO isoform that promotes longevity in animals 
lacking a germline, and DAF-16F is not required for life span extension in this context. 
Furthermore, the distinct molecular requirements for life span extension in daf-2/IGFR 
mutants and germline-ablated animals cannot be explained by the coupling of these 
upstream pathways to disparate DAF-16/FoxO isoform outputs. 
 
 
Figure 4.4. DAF-16A, but not DAF-16F, is sufficient for full life span extension in 
animals lacking a germline. 
(A-B) Effects of daf-16a (A) and daf-16f (B) mutations on life spans of glp-1(e2141) animals raised at the 
restrictive temperature to ablate the germline (C-E) daf-16a is required for daf-16f;glp-1 longevity and vice 
versa. Survival curves are presented for (E) glp-1(e2141), (F) daf-16a;glp-1, (G) daf-16f;glp-1 mutant 
animals upon exposure to isoform-specific daf-16 RNAi. See text for details. Statistics and raw data are 







DAF-16/FoxO target gene regulation by DAF-16A and DAF-16F 
In order to illuminate the mechanistic basis for DAF-16/FoxO isoform-specific functions 
in life span control, we performed whole transcriptome profiling of young adult daf-
2(e1370) mutant animals in the context of wild-type daf-16/FoxO and isoform-specific 
daf-16/FoxO mutant alleles. A subset of animals from each experimental replicate was 
subjected to life span assays to confirm that all mutants from which RNA was isolated 
had the expected life span phenotypes. Identification of genes that were differentially 
expressed in wild-type and daf-2(e1370) and differentially expressed in the opposite 
direction in both daf-16(null);daf-2 and daf-16a/f;daf-2 double mutants compared to daf-
2 mutants defined a set of 399 genes that are targets of DAF-16A and/or DAF-16F 
(Figure 4.5; henceforth referred to as “DAF-16A/F target genes”). We validated our 
profiling results by measuring transcript levels corresponding to twelve genes that 
emerged from this analysis using qPCR. DAF-16/FoxO-dependent regulation was 
confirmed for all twelve of these genes (Figure 4.6; Supplemental Figure 4.8; 
Supplemental Table 4.11). 
To gain insight into the relative magnitude of DAF-16A- and DAF-16F-specific 
contributions to the regulation of individual DAF-16A/F target genes, we compared the 
effect of either daf-16a or daf-16f mutation on DAF-2/IGFR-dependent gene regulation 
to the effect of daf-16a/f mutation on DAF-2/IGFR-dependent gene regulation, thus 
calculating an “A-index” (IA) and “F-index” (IF) for each DAF-16A/F target gene (see 
Materials and Methods). Hypothetically, an idealized DAF-16A-specific target gene 
would have IA = 1.0 and IF = 0, whereas a DAF-16F-specific target gene would have IA = 
0 and IF = 1.0 (Figure 4.5A). IA and IF calculated using fragments per kilobase per million 
reads (FPKM) values from whole transcriptome profiling correlated well with IA and IF 
derived from qPCR data for twelve genes tested (Supplemental Table 4.12). 
We first generated a scatter plot of IA and IF for the entire set of 399 DAF-16A/F target 
genes (Figure 4.5B). This depiction indicates that IA > IF for most genes, suggesting that 
DAF-16A plays a larger role in gene regulation than DAF-16F. 
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To further explore this question, we plotted IA and IF of the entire set of DAF-16A/F 
target genes from lowest to highest IA (Figure 4.5C) and IF (Figure 4.5D). This allowed 
us to visualize the magnitude of isoform-specific regulation for both DAF-16A and DAF-
16F across the entire set of target genes while potentially revealing relationships between 
the isoforms in target gene regulation. These illustrations confirm that for most target 
genes, DAF-16A has a greater impact on expression than DAF-16F. Furthermore, they 
reveal no obvious global relationship between the degree of regulation of any single gene 




Figure 4.5. DAF-16A and DAF-16F target genes identified by whole transcriptome 
profiling (next page). 
(A) Depiction of the A-index (IA) for three hypothetical target genes with IA = 0, 0.5, and 1.0. Idealized 
expression profiles in daf-2(e1370), daf-16a/f;daf-2, and daf-16a;daf-2 are shown for all three genes. (B) 
Scatterplot comparing IA and IF for DAF-16A/F target genes. Dashed lines indicate IA and IF = 0 or 1. Only 
genes with indices from -0.2 to 1.2 are shown; a scatter plot with a wider range of indices is shown in 
Supplemental Figure 4.9. (C-D) Plots of IA and IF for all DAF-16A/F target genes from lowest to highest IA 
(C) or IF (D). Solid lines correspond to indices of 0 and 1. Three genes with indices greater than 2.2 or less 
than -1.2 were omitted for presentation purposes. (E) Tree diagram summarizing the categorization system 
for DAF-16A and DAF-16F target genes. See text and Materials and Methods for details. (F) Scatterplot 
from (B), with individual genes color-coded according to category. Dashed lines indicate IA or IF values of 













Categorization of DAF-16A/F target genes 
The life span phenotypes of daf-16a/f, daf-16a, and daf-16f mutants (Figure 4.3 and 
Figure 4.4) suggested that sorting of DAF-16A/F target genes into categories based on 
their regulation by DAF-16A and/or DAF-16F might shed light on which genes are likely 
to contribute significantly to longevity. Therefore, we placed each DAF-16A/F target 
gene into one of four categories based on the impact of each isoform on expression: 
DAF-16A-specific (IA > 0.8 and IF < 0.2), DAF-16F-specific (IF > 0.8 and IA < 0.2), 
redundant (IA and IF both < 0.2), and shared (all others). We further subdivided genes in 
the “shared” category into three subgroups: genes for which DAF-16A plays a greater 
role than DAF-16F in regulation (shared A > F; IA/IF > 2.0), genes for which DAF-16F 
has a greater impact on regulation than DAF-16A (shared F > A; IF/IA > 2.0), and genes 
that are regulated by both isoforms (shared A = F; 0.5 ≤ IA/IF ≤ 2.0; Figure 4.5E-F). 
57 genes are DAF-16A-specific targets (Figure 4.5E-F). This group includes far-3 
(Figure 4.6A; Supplemental Table 4.11), which encodes a fatty acid/retinol binding 
protein [52], as well as the lipl-1 gene encoding a lysosomal acid lipase, which is 
transcriptionally upregulated and promotes the mobilization of lipid stores in response to 
starvation [53]. Eight genes are DAF-16F-specific targets (Figure 4.5E-F), including lea-
1 (Figure 4.6B; Supplemental Table 4.11), which encodes a homolog of human perilipin-
4 that promotes resistance to dehydration stress [54]. 
Most DAF-16A/F target genes are regulated by both DAF-16A and DAF-16F (Figure 
4.5E-F). 35 genes are redundantly regulated by DAF-16A and DAF-16F (Figure 4.5E-F), 
including hen-1 (Figure 4.6C; Supplemental Table 4.11), a secreted protein required for 
sensory integration and learning [55], and the established DAF-16/FoxO target genes lys-
7 and dod-17 (Supplemental Figure 4.8) [56]. 
The remaining 299 DAF-16A/F target genes are categorized as those with “shared” 
regulation by DAF-16A and DAF-16F (Figure 4.5E-F). 73 percent of these (219/299) are 
primarily regulated by DAF-16A (Figure 4.5E-F). This subgroup comprises the largest 
subset of target genes and includes the established DAF-16/FoxO targets sod-3 (Figure 
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4.6D, Supplemental Table 4.11), mtl-1 (Figure 4.6E), fat-7 (Supplemental Figure 4.8), 
hsp-12.6, dod-3, dod-23, and dod-24 [56] and the lipase-like gene lipl-2 (Supplemental 
Figure 4.8). It also includes aakg-4, which encodes an atypical AMP kinase gamma 
subunit that participates in a positive feedback loop to promote DAF-16/FoxO activity 
[57]. Among the 20 “shared” target genes that are primarily regulated by DAF-16F are 
the S-adenosyl methionine synthase gene sams-5 (Figure 4.6F) and six collagen genes 
(Figure 4.5E-F). Finally, 60 target genes are regulated to a comparable extent by DAF-
16A and DAF-16F (Figure 4.5E-F). Within this subgroup are lipl-3 and lipl-4, which 
encode lipases that, along with the DAF-16A-specific target lipl-1, are transcriptionally 
induced in response to fasting [53]. 
Collectively, these classifications indicate that DAF-16A plays an important role in 
regulating 93% of DAF-16A/F target genes (“DAF-16A-specific,” “redundant,” “shared 
A > F,” and “shared A = F” categories; 371/399 genes), whereas DAF-16F strongly 
influences the expression of 30% of target genes (“DAF-16F-specific,” “redundant,” 




Figure 4.6. qPCR validation of target gene regulation by DAF-16A and DAF-16F.  
(A-F) Expression of six DAF-16A/F target genes quantified by qPCR using RNA isolated from Day 1 
young adult animals. Values represent the mean from three biological replicates. Error bars represent 
standard deviation. Asterisks indicate statistically significant changes (p < 0.05 by paired ratio t-test). IA 
and IF were calculated using mean expression values measured by qPCR. Statistics and data are 









We have used isoform-specific daf-16/FoxO mutant alleles to elucidate the biological 
functions of specific DAF-16/FoxO isoforms in development, life span control, and gene 
regulation. Our results indicate that DAF-16A is the major FoxO isoform that controls 
dauer arrest (Figure 4.2) and longevity (Figure 4.3) in the context of reduced DAF-
2/IGFR signaling. Furthermore, we show for the first time that DAF-16A is also the 
primary FoxO isoform that promotes longevity in animals lacking a germline (Figure 
4.4). Importantly, a deletion mutant that lacks all exons specific to daf-16f does not 
significantly influence dauer arrest (Figure 4.2) or longevity in either daf-2/IGFR mutants 
or in germline-ablated animals (Figure 4.3 and Figure 4.4). These results indicate that in 
the presence of physiologic levels of DAF-16A, DAF-16F is dispensable for dauer 
regulation and life span control. In the absence of DAF-16A, DAF-16F promotes dauer 
arrest and longevity, as demonstrated by the incomplete suppression of dauer-constitutive 
(Figure 4.2B) and life span extension phenotypes by daf-16a mutation (Figure 4.3A,C 
and Figure 4.4A) and the influence of daf-16f RNAi on life span in daf-2/IGFR mutants 
and germline-ablated animals that lack daf-16a (Figure 4.3F and Figure 4.4D).  
Our data are in agreement with a previous study implicating both DAF-16A and DAF-
16F in dauer regulation and stress resistance in the daf-2(e1370) mutant background [35]. 
However, our results contradict the contention that DAF-16F plays a more prominent role 
in life span control than DAF-16A [35,42]. This discrepancy is likely a consequence of 
distinct experimental strategies used to assess the function of specific DAF-16/FoxO 
isoforms in life span control. We used isoform-specific deletion mutants in which other 
daf-16/FoxO isoforms remained under the control of endogenous regulatory elements and 
continued to be expressed at physiological levels (Supplemental Figure 4.6). In contrast, 
Kwon et al. based their analysis on strains harboring a daf-16/FoxO null mutation in 
which cDNAs encoding individual daf-16/FoxO isoforms were overexpressed 
transgenically [35]. Results utilizing single-copy transgenes to rescue the isoform-
specific mutants likely reconcile these seemingly conflicting results- see Supplemental 
Discussion for further details. 
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The expression profiling experiments presented here are the first to define the relative 
contributions of specific DAF-16/FoxO isoforms to the regulation of DAF-16/FoxO 
target genes. They reveal a dominant role for DAF-16A relative to DAF-16F in 
regulating gene expression in young adult animals (Figure 4.5) that is commensurate with 
the relative influence of DAF-16A and DAF-16F on adult life span (Figure 4.3). These 
results further support the conclusion that DAF-16A is the major FoxO isoform that 
promotes longevity in C. elegans. 
Although the prolongevity function of DAF-16/FoxO is well established, the question of 
which DAF-16/FoxO target genes are important in life span control remains unanswered. 
Multiple studies have identified thousands of DAF-16/FoxO target genes that are 
regulated by DAF-2/IGFR signaling and the germline [56,58-66]. In light of these data, a 
commonly accepted model is that DAF-16/FoxO promotes longevity by controlling the 
expression of several hundreds of genes, the products of which collectively contribute to 
life span extension. Although this model may be intuitively appealing, it remains 
untested; the possibility exists that a relatively small subset of DAF-16/FoxO target genes 
plays a disproportionately prominent role in influencing longevity. 
Few DAF-16/FoxO target genes have been rigorously analyzed for roles in life span 
control. This is likely a consequence of the large number of genes that are regulated by 
DAF-16/FoxO [64]. Our phenotypic analysis and transcriptional profiling data define 
subsets of DAF-16/FoxO targets that may be more or less likely to include genes that 
contribute significantly to longevity. Since daf-16f mutation does not influence life span 
in the presence of DAF-16A (Figure 4.3B,D and Figure 4.4B), genes that are primarily 
regulated by DAF-16F (i.e., genes in the “DAF-16F-specific” and “shared F > A” 
categories; Figure 4.5E-F) are unlikely to play prominent roles in promoting longevity. 
Conversely, since daf-16a mutation significantly shortens life span and daf-16a/f 
mutation suppresses longevity to the same extent as daf-16/FoxO null mutation (Figure 
4.3A,C and Figure 4.4A), genes that are primarily regulated by DAF-16A (i.e., “DAF-
16A-specific” and “shared A > F” genes; Figure 4.5E-F) or that are redundantly regulated 
by both DAF-16A and DAF-16F (“redundant” genes) may be more likely to function as 
 
 106 
DAF-16/FoxO effectors in promoting longevity. Consistent with this notion, aakg-4, 
which emerged from our analysis as a “shared A > F” gene, was recently shown to be 
important for life span extension in daf-2/IGFR mutants [57]. Thus, our analysis provides 
a useful framework for prioritizing the evaluation of specific DAF-16/FoxO target genes 
for potential roles in life span control. 
Based on our results, we propose a hierarchical model of DAF-16/FoxO isoform function 
in life span control (Figure 4.7). DAF-2/IGFR inhibits both DAF-16A and DAF-16F 
[35]. In the context of reduced DAF-2/IGFR signaling, both DAF-16A and DAF-16F 
contribute to longevity and the regulation of DAF-16/FoxO target genes. In the absence 
of DAF-16A, the altered expression of genes regulated mainly by DAF-16A shortens life 
span. When DAF-16F is inactive, genes regulated primarily by DAF-16F are 
misregulated, but this does not influence life span. When neither DAF-16A nor DAF-16F 
is present, DAF-2/IGFR mutation does not promote longevity due to the misregulation of 
both DAF-16A-specific target genes as well as genes that are regulated by both DAF-
16A and DAF-16F. 
The vital role of IGFR signaling and FoxO transcription factors in life span control was 
discovered in C. elegans decades ago [5,67-69]. IGFR signaling is now known to 
influence aging in mammals [70,71] and possibly humans [72,73], and the prolongevity 
function of FoxO that is conserved in invertebrates [5,8,9,74,75] is likely relevant to 
mammalian aging and aging-related diseases. In establishing the primacy of DAF-16A in 
C. elegans life span control and gene regulation, we provide a foundation for 





Figure 4.7. Model of life span control and gene regulation by DAF-16A and DAF-






Materials and Methods 
C. elegans strains and maintenance 
Strains used in this study are listed in Supplemental Table 4.13. Animals were maintained 
at 15°C on nematode growth media (NGM) plates seeded with Escherichia coli OP50. 
Double mutants were constructed using standard genetic techniques. Genotypes were 
confirmed by PCR amplification to detect restriction fragment length or PCR 
polymorphisms. Percival I-36NL incubators (Percival Scientific, Inc., Perry, IA) were 
used for maintenance, dauer arrest assays, and life span assays. 
RNA isolation 
Animals were washed twice in M9 buffer. Total RNA was isolated using TRIzol® 
reagent (Invitrogen) and purified using an RNeasy kit (QIAGEN Inc., Valencia, CA) 
according to manufacturers’ instructions. 
Quantitative real-time reverse-transcriptase PCR (qPCR) 
cDNA was synthesized using a SuperScript® III Reverse Transcriptase kit  and random 
hexamers (Invitrogen, Carlsbad, CA). Real-time PCR was then performed in triplicate 
using Power SYBR® Green PCR master mix (Applied Biosystems, Warrington, UK) and 
a Mastercycler® ep realplex thermal cycler (Eppendorf North America, Westbury, NY). 
10ng of cDNA was used as a template in 15µl reaction volume. Primers were selected 
initially using GETPrime [76] and Primer-BLAST 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) and subsequently validated by 
melt curve analysis and agarose gel electrophoresis. Primer sequences are listed in 
Supplemental Table 4.14. Relative expression levels and technical error were determined 
by the ΔΔ2Ct method [77]. Gene expression levels were normalized to actin (act-1), and 
the ratio of expression relative to act-1 was then compared to the same ratio in N2 Bristol 
wild-type. Statistical analysis was performed in GraphPad Prism (GraphPad Software, La 
Jolla, CA) using the paired ratio t-test. 
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Rapid amplification of cDNA ends (RACE) 
Total RNA was isolated from young adult animals. daf-16a and daf-16f cDNA was 
prepared using a 5’ RACE System Version 2.0 (Invitrogen). First-strand cDNA was 
synthesized using a daf-16a/f gene-specific primer and SuperScriptTM II. The original 
mRNA template was degraded by RNase H and RNase T1. After purification, a 
homopolymeric tail was added using terminal deoxynucleotidyl transferase to the 3’ end 
of cDNA. Standard PCR was performed using Taq DNA polymerase, a nested daf-16a or 
daf-16f-specific primer, and the abridged anchor primer complementary to the 
homopolymeric tail. After visualization of products on a standard agarose gel, the 
reaction mix was cloned into pCRTM4-TOPO® vector using a TOPO TA Cloning® kit 
(Invitrogen) and transformed into chemically competent E. coli DH5α. Clones were 
selected on LB plates containing 50µg/mL ampicillin, and plasmids were analyzed by 
Sanger sequencing. Numbers of clones analyzed for each strain are indicated in 
Supplemental Table 4.15. 
Dauer arrest assays  
Dauer assays were performed at 25°C as previously described [78]. Briefly, animals were 
synchronized in a 4 hr egglay at 15°C and grown at 25°C on NGM plates. Animals were 
scored when wild-type animals were gravid adults and daf-2 animals had arrested as 
dauers (~60-72 hours after egglay). Statistical significance was assessed using a two-




Life span assays 
Life span assays were performed as previously described [79], with minor modifications. 
Animals derived from a synchronized 4 hr egglay were grown at 15°C until the L4 larval 
stage and then shifted to 20°C. Plates harboring any males were discarded. Animals were 
grown for an additional 20-24 hr to day 1 of adulthood and then placed on life span plates 
containing 25µg/mL 5-fluoro-2’-deoxyuridine (FUDR; Sigma-Aldrich, St. Louis, MO) to 
prevent progeny growth. glp-1 mutant animals were raised at the restrictive temperature 
to ablate the germline. Statistical significance was assessed using the standard chi-square-
based log-rank test in GraphPad Prism. 
RNAi 
RNAi clones were constructed to coincide with previously published isoform-specific 
and pan-daf-16 RNAi clones [35]. The daf-16a/f clone was obtained from Addgene. 
Feeding RNAi was performed using standard procedures [80]. All RNAi NGM plates 
contained 5mM IPTG and 25µg/mL carbenicillin. NGM plates were seeded with an 
overnight culture of E. coli HT115 with either control L4440 vector or RNAi plasmid. 
For RNAi life span assays, HT115 was concentrated 5X. Plasmids from E. coli clones 
were sequenced for every experimental replicate to confirm their identity. 
Stress assays 
For all stress assays, animals derived from a synchronized 4 hr egglay were grown at 
15°C until the late L3 larval stage and then shifted to 20°C and grown for an additional 
12 hours until the L4 larval stage. Plates harboring any males were discarded.  
For oxidative stress, animals were transferred to plates containing 7.5mM tert-Butyl 
hydroperoxide (t-BOOH) (Sigma-Aldrich) and scored ~3 times per day for survival. For 
ultraviolet (UV) stress, animals were transferred to plates lacking bacteria and irradiated 
with 1200 J/m2 UV-C using a Stratalinker 2400 UV crosslinker (Stratagene, La Jolla, 
CA). UV-treated animals were then transferred to seeded plates containing 25 µg/mL 
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FUDR  and scored daily for survival. For thermotolerance, animals were transferred to 
seeded plates containing 25 µg/mL FUDR, grown for an additional 12 hours at 20°C, 
shifted to 33°C, and scored ~4 times per day for survival.  
For all assays, animals that desiccated on the side of plates were censored. Statistical 
significance was assessed in GraphPad Prism using the standard chi-square-based log-
rank test. 
Whole transcriptome profiling (RNA-Seq) 
Animals were grown as described for life span assays. After picking a subset of the 
population for life span assays, the remaining animals were harvested for isolation of 
total RNA. The Agilent TapeStation was used to assess RNA quality. Samples with RINs 
(RNA Integrity Numbers) of eight or greater were prepped using the Illumina TruSeq 
mRNA Sample Prep v2 kit (Catalog #RS-122-2001 and RS-122-2002). mRNA was 
isolated from 0.1-3 µg of total RNA by polyA+ purification, fragmented, and copied into 
first strand cDNA using reverse transcriptase and random primers. 3’ cDNA ends were 
then adenylated and adapters ligated. One of the adapters contained a 6-nucleotide 
barcode to enable multiplexing of samples. Products were purified and enriched by PCR 
to create the final cDNA library. Libraries were checked for quality and quantity by 
Agilent TapeStation and qPCR using a library quantification kit for Illumina sequencing 
platforms (catalog #KK4835, Kapa Biosystems, Wilmington, MA). Clonal clusters were 
generated using cBot (Illumina, Inc., San Diego, CA). Quadriplexed samples were 
sequenced using the HiSeq 2000 system (Illumina) with a 100-cycle paired-end run in 
high output mode using Version 3 reagents according to manufacturer’s protocols. 
Individual reads files for each sample were concatenated into a single .fastq file. Raw 
reads data for each sample were checked using FastQC (Version 0.10.0, Babraham 
Bioinformatics, Cambridge, United Kingdom; 
http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc/) to identify features potentially 
indicative of quality issues (e.g. low quality scores, over-represented sequences, and 
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inappropriate GC content). We used the Tuxedo Suite [81-83] for alignment, differential 
expression analysis, and post-analysis diagnostics. Briefly, reads were aligned to the 
reference genome (UCSC ce10; http://genome.ucsc.edu/) using TopHat (version 2.0.9) 
[83] and Bowtie (version 2.1.0.0) [84]. We used default parameter settings for alignment, 
with the exception of: “--b2-very-sensitive” and “--no-coverage-search.” A second round 
of quality control was then performed using FastQC to ensure that only high quality data 
was analyzed further. Cufflinks/CuffDiff (Version 2.1.1) [82] was used for quantification 
of expression and differential expression analysis, using UCSC ce10.fa as the reference 
genome and UCSC ce10.gtf as the reference transcriptome (http://genome.ucsc.edu/). For 
this analysis, we used parameter settings: “--multi-read-correct” to adjust expression 
calculations for reads that map to more than one locus, as well as “--compatible-hits-
norm” and “--upper-quartile –norm” for normalization of expression values. We 
generated diagnostic plots using the CummeRbund package [85] to confirm that each 
experiment yielded high quality data. 
We used locally developed scripts to format and annotate the differential expression data 
output from CuffDiff. Genes and isoforms were annotated using NCBI Entrez GeneIDs 
and text descriptions. Differentially expressed genes were further annotated with Gene 
Ontology (GO) terms (http://www.geneontology.org/) using NCBI annotation. 
RNA-Seq analysis 
The annotated gene expression data output from CuffDiff was read into R (http://www.r-
project.org/) for six comparisons: daf-2(e1370) compared to wild-type, daf-
16(mu86);daf-2, daf-16a/f(mg54);daf-2, daf-16a(tm5030);daf-2, daf-16a(tm5032);daf-2, 
and daf-16f(tm6659);daf-2. We defined 399 DAF-16A/F targets as meeting all of the 
following criteria: (1) test status = “OK” for all six comparisons, (2) fold change (FC) ≥ 
±1.5 for wild-type vs. daf-2, (3) FC ≥ 2 in the opposite direction as wild-type for daf-2 vs. 
daf-16(mu86);daf-2, (4) FC ≥ 2 in the opposite direction as wild-type for daf-2 vs. daf-
16a/f(mg54);daf-2, and (5) FDR < 0.05 for at least one of the three comparisons of daf-2 
vs. wild-type, daf-16(mu86);daf-2, or daf-16(mg54);daf-2. We required FDR < 0.05 for 
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only one of the three comparisons for three reasons: (1) nearly all genes showed 
concordance in fold-change for all three comparisons even if they did not satisfy FDR < 
0.05 for all three; (2) some known DAF-16/FoxO targets only satisfied FDR < 0.05 in 
one or two comparisons; and (3) the choice of requiring FDR < 0.05 for one, two, or 
three comparisons did not significantly affect the categorization of DAF-16A/F target 
genes (Supplemental Table 4.16; see below). FC ≥ 2 instead of 1.5 was chosen for the 
daf-2 vs. daf-16;daf-2 comparisons to improve quantification of the effects of daf-16a 
and daf-16f mutations on gene expression. 
To define classes of DAF-16A/F targets, A- and F-indices (IA and IF) were calculated for 
399 DAF-16A/F targets. Given high correlation in gene expression between daf-
16a(tm5030);daf-2 and daf-16a(tm5032);daf-2 (Supplemental Figure 4.10), a combined 
daf-16a;daf-2 gene expression profile was generated by calculating the mean FPKM for 
each gene. IA for each gene was defined as the absolute FPKM difference between daf-
2(e1370) and daf-16a;daf-2, divided by the absolute FPKM difference between daf-
2(e1370) and daf-16a/f(mg54);daf-2. Likewise, IF for each gene was defined as the 
FPKM difference between daf-2(e1370) and daf-16f(tm6659);daf-2, divided by the 
FPKM difference between daf-2(e1370) and daf-16a/f(mg54);daf-2. 
Classes of DAF-16A/F targets were defined by the following criteria: DAF-16A-specific, 
IA > 0.8 and IF < 0.2; DAF-16F-specific, IF > 0.8 and IA < 0.2; and redundantly regulated, 
IA < 0.2 and IF < 0.2. Genes not binned into these three categories were partitioned into 
one of the following three groups: shared A-dominant (shared A>F), IA/IF > 2; shared F-






Supplemental Figure 4.1. Distinction between daf-16d, daf-16f, and daf-16h, 
collectively referred to as daf-16f in this study.  
daf-16d/f/h transcripts (arrows) differ slightly in their 5’ ends. DAF-16D/F/H proteins are translated from 
distinct translational start sites (arrowheads). Importantly, daf-16(tm6659) eliminates all three isoforms, 




Supplemental Figure 4.2. daf-16f N-terminal cDNA sequence  
Legend 
Green: Unique daf-16d N-terminal exon. Start codon is underlined. 
Blue: 7 nucleotides included in two RACE clones due to alternative trans-splicing 
Bold: C. elegans SL1 trans-spliced leader 
Italics: 5’UTR 
| exon-exon junction 
No daf-16h transcripts were detected by 5’ RACE. 


























Supplemental Figure 4.3. Overview of strategy for characterizing daf-16/FoxO 
transcripts in isoform-specific mutants.  
Spliced transcripts are shown, and exons are separated by black lines. Note that daf-16a(tm5032) disrupts a 
5’ splice site and therefore intronic sequence is included. 
 
For 5’ RACE, a semi-synchronized population of young adults was harvested for RNA. RNA was purified 
and analyzed as described in Methods. The A/F-RACE primer was used for first-strand cDNA synthesis. 
PCR amplification was performed using either the A30-RACE primer, A32-RACE primer, or the F-RACE 
primer, in combination with the Abridged Anchor Primer from the Invitrogen RACE kit. For daf-









Supplemental Figure 4.4. Effects of daf-16a mutations on daf-16a N-terminal cDNA 
sequence 
Legend 
Orange: Unique daf-16a N-terminal exon. Start codon is underlined. 
Red: early stop codon in daf-16a(tm5030) and daf-16a(tm5032) transcripts 
Blue: 6 nucleotides included in R13H8.1c but not R13H8.1b by alternative splicing that do not affect the 
reading frame. R13H8.1c and R13H8.1b are both daf-16a transcripts. 
Bold: C. elegans SL1 trans-spliced leader 
Italics: 5’UTR 
| exon-exon junction 
 
A. daf-16a(tm5030) cDNA sequence – first 3 exons, including 5’UTR 
wild-type GGTTTAATTACCCAAGTTTGAGAGAACTCACTGATCTTTCAAGCCGAAGCAATCAAGACC 
   tm5030 GGTTTAATTACCCAAGTTTGAGAGAACTCACTGATCTTTCAAGCCGAAGCAATCAAGACC 
 
wild-type TCAAAGCCAATCAACTCTACTCACTTTTCTTCAGAACCTTAACTTTTTGTGTCACTTTCC 
   tm5030 TCAAAGCCAATCAACTCTACTCACTTTTCTTCAGAACCTTAACTTTTTGTGTCACTTTCC 
 
wild-type CCAAAAACCGTTCAAGCTGCTGCCTTCACTCTCATCCCCTCCTCTTACTCCTTCTTTCTC 
   tm5030 CCAAAAACCGTTCAAGCTGCTGCCTTCACTCTCATCCCCTCCTCTTACTCCTTCTTTCTC 
 
wild-type GTCCGCTACTACTGTATCTTCTGGACATCTACCTGTATACACACCAGTGGCCAGTCATCT 
   tm5030 GTCCGCTACTACTGTATCTTCTGGACATCTACCTGTATACACACCAGTGGCCAGTCATCT 
 
wild-type GCCATTACAATTTCATCAATTGACACTTCTTCAACAACAACCGCCGTCCTCATTCACTCC 
   tm5030 GCCATTACAATTTCATCAATTGACACTTCTTCAACAACAACCGCCGTCCTCATTCACTCC 
 
wild-type CGATTCTTCCTCATCCTCAACATCGTCGTCTTTGGCTGAAATTCCCGAAGACGTTATGAT 
   tm5030 CGATTCTTCCTCATCCTCAACATCGTCGTCTTTGGCTGAAATTCCCGAAGACGTTATGAT 
 
wild-type GGAGATGCTGGTAGATCAGGGAACTGATGCATCGTCATCCGCCTCCACGTCCACCTCATC 
   tm5030 GGAGATGCTGGTAGAT-------------------------------------------- 
 
wild-type TGTTTCGAGATTCGGAGCGGACACGTTCATGAATACACCGGATGATGTGATGATGAATGA 
   tm5030 ------------------------------------------------------------ 
 
wild-type TGATATGGAACCGATTCCTCGTGATCGGTGCAATACGTGGCCAATGCGTAGGCCGCAACT 
   tm5030 ------------------------------------------------------------ 
 
wild-type CGAACCACCACTCAACTCGAGTCCCATTATTCATGAACAAATTCCTGAAGAAGATGCTGA 
   tm5030 -----------------------------TTCATGAACAAATTCCTGAAGAAGATGCTGA 
 
wild-type |CCTATACGGGAGCAATGAGCAATGTGGACAGCTCGGCGGAGCATCTTCAAACGGGTCGA 
   tm5030 |CCTATACGGGAGCAATGAGCAATGTGGACAGCTCGGCGGAGCATCTTCAAACGGGTCGA 
 
wild-type CAGCAATGCTTCATACTCCAGATGGAAGCAATTCTCATCAGACATCGTTTCCTTCGGA| 
   tm5030 CAGCAATGCTTCATACTCCAGATGGAAGCAATTCTCATCAGACATCGTTTCCTTCGGA| 
 
wild-type TTTACGAATGTCCGAATCGCCAGACGATACCGTATCGGGAAAAAAGACAACGACCAGACG 
   tm5030 TTTACGAATGTCCGAATCGCCAGACGATACCGTATCGGGAAAAAAGACAACGACCAGACG 
 
wild-type GAACGCTTGGGGAAATATGTCATATGCTGAACTTATCACTACAGCCATTATGGCTAGTCC 
   tm5030 GAACGCTTGGGGAAATATGTCATATGCTGAACTTATCACTACAGCCATTATGGCTAGTCC 
 
wild-type AGAGAAACGGTTAACTCTTGCACAAG|... 
   tm5030 AGAGAAACGGTTAACTCTTGCACAAG|... 




Additional legend- specific to daf-16a(tm5032) 
lower-case: intronic sequence introduced by tm5032 mutation 
tm5032 #1 vs. #2: Two products detected by cDNA sequencing. #1 is the major product, formed by cryptic 
splice site activation. * denotes cryptic splice site. 
B. daf-16a(tm5032) cDNA sequence – first exon and intron 
wild-type GGTTTAATTACCCAAGTTTGAGAGAACTCACTGATCTTTCAAGCCGAAGCAATCAAGACC 
tm5032 #1 GGTTTAATTACCCAAGTTTGAGAGAACTCACTGATCTTTCAAGCCGAAGCAATCAAGACC 
tm5032 #2 GGTTTAATTACCCAAGTTTGAGAGAACTCACTGATCTTTCAAGCCGAAGCAATCAAGACC 
 
wild-type TCAAAGCCAATCAACTCTACTCACTTTTCTTCAGAACCTTAACTTTTTGTGTCACTTTCC 
tm5032 #1 TCAAAGCCAATCAACTCTACTCACTTTTCTTCAGAACCTTAACTTTTTGTGTCACTTTCC 
tm5032 #2 TCAAAGCCAATCAACTCTACTCACTTTTCTTCAGAACCTTAACTTTTTGTGTCACTTTCC 
 
wild-type CCAAAAACCGTTCAAGCTGCTGCCTTCACTCTCATCCCCTCCTCTTACTCCTTCTTTCTC 
tm5032 #1 CCAAAAACCGTTCAAGCTGCTGCCTTCACTCTCATCCCCTCCTCTTACTCCTTCTTTCTC 
tm5032 #2 CCAAAAACCGTTCAAGCTGCTGCCTTCACTCTCATCCCCTCCTCTTACTCCTTCTTTCTC 
 
wild-type GTCCGCTACTACTGTATCTTCTGGACATCTACCTGTATACACACCAGTGGCCAGTCATCT 
tm5032 #1 GTCCGCTACTACTGTATCTTCTGGACATCTACCTGTATACACACCAGTGGCCAGTCATCT 
tm5032 #2 GTCCGCTACTACTGTATCTTCTGGACATCTACCTGTATACACACCAGTGGCCAGTCATCT 
 
wild-type GCCATTACAATTTCATCAATTGACACTTCTTCAACAACAACCGCCGTCCTCATTCACTCC 
tm5032 #1 GCCATTACAATTTCATCAATTGACACTTCTTCAACAACAACCGCCGTCCTCATTCACTCC 
tm5032 #2 GCCATTACAATTTCATCAATTGACACTTCTTCAACAACAACCGCCGTCCTCATTCACTCC 
 
wild-type CGATTCTTCCTCATCCTCAACATCGTCGTCTTTGGCTGAAATTCCCGAAGACGTTATGAT 
tm5032 #1 CGATTCTTCCTCATCCTCAACATCGTCGTCTTTGGCTGAAATTCCCGAAGACGTTATGAT 
tm5032 #2 CGATTCTTCCTCATCCTCAACATCGTCGTCTTTGGCTGAAATTCCCGAAGACGTTATGAT 
 
wild-type GGAGATGCTGGTAGATCAGGGAACTGATGCATCGTCATCCGCCTCCACGTCCACCTCATC 
tm5032 #1 GGAGATGCTGGTAGATCAGGGAACTGATGCATCGTCATCCGCCTCCACGTCCACCTCATC 
tm5032 #2 GGAGATGCTGGTAGATCAGGGAACTGATGCATCGTCATCCGCCTCCACGTCCACCTCATC 
 
wild-type TGTTTCGAGATTCGGAGCGGACACGTTCATGAATACACCGGATGATGTGATGATGAATGA 
tm5032 #1 TGTTTCGAGATTCGGAGCGGACACGTTCATGAATACACCGGATGATGTGATGATGAATGA 
tm5032 #2 TGTTTCGAGATTCGGAGCGGACACGTTCATGAATACACCGGATGATGTGATGATGAATGA 
 
wild-type TGATATGGAACCGATTCCTCGTGATCGGTGCAATACGTGGCCAATGCGTAGGCCGCAACT 
tm5032 #1 TGATATGGAACCGATTCCTCGTGATCGGTGCAATACGTGGCC------------------ 
tm5032 #2 TGATATGGAACCGATTCCTCGTGATCGGTGCAATACGTGGCC------------------ 
 
wild-type CGAACCACCACTCAACTCGAGTCCCATTATTCATGAACAAATTCCTGAAGAAGATGCTGA 
tm5032 #1 ------------------------------------------------------------ 
tm5032 #2 ------------------------------------------------------------ 
 
wild-type ------------------------------------------------------------ 
tm5032 #1 ttttgtatttttggagcataa*-------------------------------------- 
tm5032 #2 ttttgtatttttggagcataa*gtaatacgactgatatgaacctgaaaaaccaccaatta        
                            STOP 
 
wild-type ------------------------------------------|CCTATACGGGAGCA... 
tm5032 #1 -------------------------------------------CCTATACGGGAGCA... 





Supplemental Figure 4.5. Predicted DAF-16A proteins encoded by daf-16a mutants 
For wild-type DAF-16A, 162 out of 510 amino acids are shown. Predicted mutant DAF-16A sequences are 
aligned to wild-type. Note that R13H8.1b and R13H8.1c are two nearly identical transcripts that both 
encode DAF-16A. 
Legend 
| = identity with wild-type sequence 
Underline: start of forkhead domain 
Bold: RxRxxT AKT family phosphorylation motif 
↓ = phosphothreonine 
* = early stop 
Blue: amino acids included in the protein products of R13H8.1c but not R13H8.1b due to inclusion of 6 
nucleotides that do not affect the reading frame (see figure S4). In wild-type, the three indicated amino 
acids are present in R13H8.1c, but are replaced by a single glutamic acid residue in R13H8.1b. In daf-
16a(tm5030), the three indicated amino acids are present in R13H8.1c, but are replaced by a single lysine 
residue in R13H8.1b. 
 
A. Predicted DAF-16A protein encoded by daf-16a(tm5030) 
                                                               ↓ 
wild-type MMEMLVDQGTDASSSASTSTSSVSRFGADTFMNTPDDVMMNDDMEPIPRDRCNTW 
 identity |||||| 








   tm5030 ------------------------------------------------------- 
 
 
B. Predicted DAF-16A protein encoded by daf-16a(tm5032) 
                                                               ↓ 
wild-type MMEMLVDQGTDASSSASTSTSSVSRFGADTFMNTPDDVMMNDDMEPIPRDRCNTW 
 identity ||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
   tm5032 MMEMLVDQGTDASSSASTSTSSVSRFGADTFMNTPDDVMMNDDMEPIPRDRCNTW 
 
wild-type PMRRPQLEPPLNSSPIIHEQIPEEDADLYGSNEQCGQLGGASSNGSTAMLHTPDG 
 identity ||| 










Supplemental Figure 4.6. qPCR measurements of daf-16/FoxO transcripts in 
isoform-specific mutants.  
Mean values are presented from three biological replicates, error bars represent standard deviation and 
asterisks indicate samples that display statistically significant changes (p < 0.05 by paired ratio t-test). Data 
and statistics are summarized in Table S1. Note that pan-daf-16 #1 primers anneal within the deletion of 
the daf-16(mu86) null allele, and pan-daf-16 #2 primers anneal outside of the deletion. Likewise, tm5030-











Supplemental Table 4.1. daf-16/FoxO isoform-specific qPCR data and statistics. 
 
 
Mean SD Mean SD Mean SD Mean SD
daf$16a(tm5030'specific)
daf$2(e1370) 0.44 0.26 0.71 0.21 0.68 0.26 0.61 0.15 control control
daf$16(mu86);daf$2 0.00 0.03 0.00 0.14 0.00 0.14 0.00 0.00 0.0762 0.00
daf$16(mg54);daf$2 0.47 0.27 0.52 0.12 0.53 0.26 0.51 0.03 0.0029 0.83
daf$16(tm5030);daf$2 0.25 0.26 0.36 0.24 0.30 0.17 0.30 0.06 0.2873 0.49
daf$16(tm5032);daf$2 0.00 0.08 0.00 0.42 0.00 0.31 0.00 0.00 0.0106 0.00
daf$16(tm6659);daf$2 0.38 0.22 0.69 0.32 0.71 0.16 0.60 0.18 0.0015 0.98
N23wild7type 1.00 0.25 1.00 0.21 1.00 0.21 1.00 0.00 0.5286 1.63
daf$16a(tm5032'specific)
daf$2(e1370) 0.32 0.32 0.85 0.47 0.66 0.44 0.61 0.27 control control
daf$16(mu86);daf$2 0.00 0.27 0.00 0.18 0.00 0.05 0.00 0.00 0.0459 0.00
daf$16(mg54);daf$2 0.34 0.45 0.57 0.50 0.43 0.45 0.45 0.12 0.2537 0.73
daf$16(tm5030);daf$2 0.00 0.49 0.00 0.16 0.00 0.27 0.00 0.00 0.0039 0.00
daf$16(tm5032);daf$2 0.16 0.21 0.40 0.49 0.15 0.55 0.24 0.14 0.0586 0.39
daf$16(tm6659);daf$2 0.26 0.13 0.77 0.44 0.45 0.44 0.50 0.25 0.1107 0.81
N23wild7type 1.00 0.27 1.00 0.45 1.00 0.45 1.00 0.00 0.1926 1.63
daf$16b
daf$2(e1370) 0.81 0.32 0.88 0.08 0.82 0.11 0.84 0.04 control control
daf$16(mu86);daf$2 0.00 0.27 0.00 1.24 0.00 0.19 0.00 0.00 0.0017 0.00
daf$16(mg54);daf$2 1.15 0.26 0.86 0.13 0.93 0.11 0.98 0.15 0.3017 1.17
daf$16(tm5030);daf$2 1.06 0.14 0.99 0.11 0.63 0.28 0.89 0.23 0.8191 1.07
daf$16(tm5032);daf$2 0.97 0.26 0.92 0.12 0.60 0.32 0.83 0.20 0.8654 0.99
daf$16(tm6659);daf$2 0.67 0.20 0.49 0.06 0.55 0.33 0.57 0.09 0.0790 0.68
N23wild7type 1.00 0.29 1.00 0.07 1.00 0.17 1.00 0.00 0.0233 1.20
daf$16f
daf$2(e1370) 0.80 0.10 1.03 0.09 1.04 0.16 0.96 0.14 control control
daf$16(mu86);daf$2 0.00 0.03 0.00 0.07 0.00 0.14 0.00 0.00 0.0036 0.00
daf$16(mg54);daf$2 0.16 0.09 0.17 0.08 0.13 0.14 0.16 0.02 0.0063 0.16
daf$16(tm5030);daf$2 0.65 0.09 0.92 0.08 0.64 0.13 0.74 0.16 0.1419 0.77
daf$16(tm5032);daf$2 0.73 0.09 0.79 0.11 0.63 0.19 0.72 0.08 0.1386 0.75
daf$16(tm6659);daf$2 0.00 0.15 0.00 0.14 0.00 0.02 0.00 0.00 <0.0001 0.00
N23wild7type 1.00 0.25 1.00 0.12 1.00 0.23 1.00 0.00 0.6128 1.04
pan$daf$161#1
daf$2(e1370) 0.72 0.06 0.95 0.07 0.96 0.10 0.88 0.14 control control
daf$16(mu86);daf$2 0.00 0.03 0.00 0.07 0.00 0.14 0.00 0.00 0.0159 0.00
daf$16(mg54);daf$2 0.31 0.09 0.33 0.07 0.28 0.11 0.31 0.03 0.0120 0.35
daf$16(tm5030);daf$2 0.68 0.08 0.88 0.06 0.62 0.09 0.72 0.13 0.2511 0.83
daf$16(tm5032);daf$2 0.78 0.08 0.89 0.11 0.68 0.14 0.78 0.11 0.4710 0.89
daf$16(tm6659);daf$2 0.23 0.15 0.23 0.15 0.31 0.03 0.26 0.04 0.0054 0.29
N23wild7type 1.00 0.16 1.00 0.26 1.00 0.15 1.00 0.00 0.2767 1.14
pan$daf$16.#2
daf$2(e1370) 0.63 0.20 0.99 0.04 1.05 0.06 0.89 0.22 control control
daf$16(mu86);daf$2 0.76 0.13 0.54 0.08 0.78 0.08 0.69 0.13 0.0377 0.78
daf$16(mg54);daf$2 0.30 0.14 0.33 0.05 0.30 0.09 0.31 0.01 0.0014 0.35
daf$16(tm5030);daf$2 0.62 0.23 0.90 0.07 0.57 0.27 0.70 0.18 0.2679 0.79
daf$16(tm5032);daf$2 0.66 0.21 0.86 0.12 0.56 0.35 0.69 0.15 0.2132 0.78
daf$16(tm6659);daf$2 0.22 0.20 0.24 0.07 0.30 0.32 0.26 0.04 0.0012 0.29










Supplemental Table 4.2. Summary of dauer data and statistics 
Column statistics are calculated from multiple replicates. 
 
*** p-value cannot be calculated because SD = 0, but effectively p < 0.0001 
^ p-value cannot be calculated because SD = 0, but effectively p = 1 
# daf-16(tm5030);daf-2(e1370) and daf-2(tm5032);daf-2(e1370) non-dauer larvae developed into sterile 














significant mean SD mean SD mean SD N
3 daf$2(e1368) control control 92.8 3.1 0.8 1.4 6.4 3.7 807
3 daf$16(mu86);daf$2 0.0004 yes 0.0 0.0 100.0 0.0 0.0 0.0 965
6 daf$16(mg54);daf$2 0.0004 yes 0.0 0.0 100.0 0.0 0.0 0.0 2318
3 daf$16(tm5030);daf$2 0.0004 yes 0.0 0.0 100.0 0.0 0.0 0.0 1280
3 daf$16(tm5032);daf$2 0.0004 yes 0.0 0.0 100.0 0.0 0.0 0.0 1338
5 daf$16(tm6659);daf$2 0.4342 no 95.3 5.6 1.5 2.6 3.2 3.5 1403
4 N2!wildBtype 0.0004 yes 0.0 0.0 100.0 0.0 0.0 0.0 950
2 wildBtype!sib!of!daf$16(tm6659);daf$2 0.0004 yes 0.0 0.0 100.0 0.0 0.0 0.0 793
2 daf$16(tm6659)!sib!of!daf$16(tm6659);daf$2 0.0004 yes 0.0 0.0 100.0 0.0 0.0 0.0 448







significant mean SD mean SD mean SD N
6 daf$2(e1370) control control 100.0 0.0 0.0 0.0 0.0 0.0 1584
5 daf$16(mu86);daf$2 *** yes 0.0 0.0 100.0 0.0 0.0 0.0 1469
6 daf$16(mg54);daf$2 *** yes 0.0 0.0 100.0 0.0 0.0 0.0 1655
6 daf$16(tm5030);daf$29# 0.0204 yes 78.6 15.7 0.1 0.2 21.4 15.7 1339
5 daf$16(tm5032);daf$29# 0.0408 yes 76.5 17.6 0.0 0.0 23.5 17.6 1047
3 daf$16(tm6659);daf$2 0.4226 no 99.7 0.5 0.0 0.0 0.3 0.5 648
3 N2!wildBtype *** yes 0.0 0.0 100.0 0.0 0.0 0.0 752
2 wildBtype!sib!of!daf$16(tm6659);daf$2 *** yes 0.0 0.0 100.0 0.0 0.0 0.0 699
1 daf$16(tm6659)!sib!of!daf$16(tm6659);daf$2 *** yes 0.0 0.0 100.0 0.0 0.0 0.0 289






Supplemental Table 4.3. daf-2(e1368) dauer arrest raw data.  
Column statistics are calculated from measurements from three plates per genotype for each replicate. 
 









mean SD mean SD mean SD N
Replicate+1 daf"2(e1368) control 95.1 2.5 0.0 0.0 4.9 2.5 175
*shown0figure daf"16(mu86);daf"2 0.0002 0.0 0.0 100.0 0.0 0.0 0.0 244
Both+A+and+F daf"16(mg54);daf"2 0.0002 0.0 0.0 100.0 0.0 0.0 0.0 450
daf"16(tm5030);daf"2 0.0002 0.0 0.0 100.0 0.0 0.0 0.0 314
daf"16(tm5032);daf"2 0.0002 0.0 0.0 100.0 0.0 0.0 0.0 370
daf"16(tm6659);daf"2 0.3347 97.4 2.7 0.0 0.0 2.6 2.7 184
N2+wild/type 0.0002 0.0 0.0 100.0 0.0 0.0 0.0 391
Replicate+2 daf"2(e1368) control 89.3 4.1 0.0 0.0 10.7 4.1 289
Both+A+and+F daf"16(mu86);daf"2 0.0007 0.0 0.0 100.0 0.0 0.0 0.0 425
daf"16(mg54);daf"2 0.0007 0.0 0.0 100.0 0.0 0.0 0.0 397
daf"16(tm5030);daf"2 0.0007 0.0 0.0 100.0 0.0 0.0 0.0 318
daf"16(tm5032);daf"2 0.0007 0.0 0.0 100.0 0.0 0.0 0.0 350
daf"16(tm6659);daf"2 0.1255 95.0 2.2 0.0 0.0 5.0 2.2 287
N2+wild/type 0.0007 0.0 0.0 100.0 0.0 0.0 0.0 372
Replicate+3 daf"2(e1368) control 93.9 1.7 2.5 0.9 3.7 2.4 343
A+only daf"16(mu86);daf"2 0.0001 0.0 0.0 100.0 0.0 0.0 0.0 296
daf"16(mg54);daf"2 0.0001 0.0 0.0 100.0 0.0 0.0 0.0 464
daf"16(tm5030);daf"2 0.0001 0.0 0.0 100.0 0.0 0.0 0.0 648
daf"16(tm5032);daf"2 0.0001 0.0 0.0 100.0 0.0 0.0 0.0 618
Replicate+4 daf"2(e1368)6sib+of+daf"16(tm6659);daf"2 control 100.0 0.0 0.0 0.0 0.0 0.0 207
F+only daf"16(mg54);daf"2 *** 0.0 0.0 100.0 0.0 0.0 0.0 282
daf"16(tm6659);daf"2 0.4226 99.6 0.8 0.4 0.8 0.0 0.0 252
daf"16(tm6659)6sib+of+daf"16(tm6659);daf"2 *** 0.0 0.0 100.0 0.0 0.0 0.0 300
N2+wild/type *** 0.0 0.0 100.0 0.0 0.0 0.0 98
Replicate+5 daf"2(e1368)6sib+of+daf"16(tm6659);daf"2 control 97.8 2.9 2.2 2.9 0.0 0.0 224
F+only daf"16(mg54);daf"2 0.0003 0.0 0.0 100.0 0.0 0.0 0.0 229
daf"16(tm6659);daf"2 0.5633 98.9 0.9 1.1 0.9 0.0 0.0 222
wild/type+sib+of+daf"16(tm6659);daf"2 0.0003 0.0 0.0 100.0 0.0 0.0 0.0 354
N2+wild/type 0.0003 0.0 0.0 100.0 0.0 0.0 0.0 89
Replicate+6 daf"2(e1368)6sib+of+daf"16(tm6659);daf"2 control 87.4 2.8 11.6 3.2 1.0 0.5 413
F+only daf"16(mg54);daf"2 0.0003 0.0 0.0 100.0 0.0 0.0 0.0 496
daf"16(tm6659);daf"2 0.5099 85.8 2.7 6.0 1.5 8.2 3.9 458
wild/type+sib+of+daf"16(tm6659);daf"2 0.0003 0.0 0.0 100.0 0.0 0.0 0.0 439





Supplemental Table 4.4. daf-2(e1370) dauer arrest raw data.  
Column statistics are calculated from measurements from three plates per genotype for each replicate. 
 
*** p-value cannot be calculated because SD = 0, but effectively p < 0.0001 
^ p-value cannot be calculated because SD = 0, but effectively p = 1 
# daf-16(tm5030);daf-2(e1370) and daf-2(tm5032);daf-2(e1370) non-dauer larvae developed into sterile 







mean SD mean SD mean SD N
Replicate!1 daf$2(e1370) control 100.0 0.0 0.0 0.0 0.0 0.0 321
Both!A!and!F daf$16(mu86);daf$2 *** 0.0 0.0 100.0 0.0 0.0 0.0 419
daf$16(mg54);daf$2 *** 0.0 0.0 100.0 0.0 0.0 0.0 465
daf$16(tm5030);daf$28# 0.0102 65.4 6.1 0.0 0.0 34.6 6.1 446
daf$16(tm5032);daf$28# 0.0032 46.5 5.3 0.0 0.0 53.5 5.3 270
daf$16(tm6659);daf$2 ^ 100.0 0.0 0.0 0.0 0.0 0.0 265
N2!wild*type *** 0.0 0.0 100.0 0.0 0.0 0.0 527
Replicate!2 daf$2(e1370) control 100.0 0.0 0.0 0.0 0.0 0.0 176
Both!A!and!F daf$16(mu86);daf$2 *** 0.0 0.0 100.0 0.0 0.0 0.0 173
daf$16(mg54);daf$2 *** 0.0 0.0 100.0 0.0 0.0 0.0 133
daf$16(tm5030);daf$28# 0.1884 94.3 5.0 0.0 0.0 5.7 5.0 194
daf$16(tm5032);daf$28# 0.1441 93.2 5.1 0.0 0.0 6.8 5.1 186
daf$16(tm6659);daf$2 ^ 100.0 0.0 0.0 0.0 0.0 0.0 150
N2!wild*type *** 0.0 0.0 100.0 0.0 0.0 0.0 120
wild*type!sib!of!daf$16(tm6659);daf$2 *** 0.0 0.0 100.0 0.0 0.0 0.0 351
daf$28sib!of!daf$16(tm6659);daf$2 ^ 100.0 0.0 0.0 0.0 0.0 0.0 160
Replicate!3 daf$2(e1370) control 100.0 0.0 0.0 0.0 0.0 0.0 267
Both!A!and!F daf$16(mg54);daf$2 *** 0.0 0.0 100.0 0.0 0.0 0.0 171
daf$16(tm5030);daf$28# 0.2697 97.3 3.1 0.0 0.0 2.7 3.1 135
daf$16(tm6659);daf$2 0.1840 99.1 0.8 0.0 0.0 0.9 0.8 233
N2!wild*type *** 0.0 0.0 100.0 0.0 0.0 0.0 105
wild*type!sib!of!daf$16(tm6659);daf$2 *** 0.0 0.0 100.0 0.0 0.0 0.0 348
daf$16(tm6659)!sib!of!daf$16(tm6659);daf$2 *** 0.0 0.0 100.0 0.0 0.0 0.0 289
daf$28sib!of!daf$16(tm6659);daf$2 ^ 100.0 0.0 0.0 0.0 0.0 0.0 236
Replicate!4 daf$2(e1370) 100.0 0.0 0.0 0.0 0.0 0.0 209
A!only daf$16(mu86);daf$2 *** 0.0 0.0 100.0 0.0 0.0 0.0 168
daf$16(mg54);daf$2 *** 0.0 0.0 100.0 0.0 0.0 0.0 137
daf$16(tm5030);daf$28# 0.0240 59.3 11.1 0.0 0.0 40.7 11.1 87
daf$16(tm5032);daf$28# 0.0375 79.5 7.0 0.0 0.0 20.5 7.0 97
Replicate!5 daf$2(e1370) control 100.0 0.0 0.0 0.0 0.0 0.0 286
A!ony daf$16(mu86);daf$2 *** 0.0 0.0 100.0 0.0 0.0 0.0 264
daf$16(mg54);daf$2 *** 0.0 0.0 100.0 0.0 0.0 0.0 297
daf$16(tm5030);daf$28# 0.0130 71.2 5.7 0.0 0.0 28.8 5.7 167
daf$16(tm5032);daf$28# 0.0202 82.2 4.4 0.0 0.0 17.8 4.4 185
Replicate!6 daf$2(e1370) control 100.0 0.0 0.0 0.0 0.0 0.0 325
A!ony daf$16(mu86);daf$2 *** 0.0 0.0 100.0 0.0 0.0 0.0 445
daf$16(mg54);daf$2 *** 0.0 0.0 100.0 0.0 0.0 0.0 488
daf$16(tm5030);daf$28# 0.0556 84.0 6.8 0.4 0.6 15.7 6.3 310






























Figure(2C daf$2(e1368) 94'(6) 22.0 4.6 22 26
Replicate'1 daf$16(mu86);daf$2 54'(50) 13.1 1.9 13 14 <0.0001 daf$2(e1368) +40 +46
*shown(figure daf$16(mg54);daf$2 84'(15) 14.6 1.6 14 15 <0.0001 daf$2(e1368) +34 +42
daf$16(tm5030);daf$2 91'(9) 17.7 3.4 17 20 <0.0001 daf$2(e1368) +20 +23
daf$16(tm5032);daf$2 89'(11) 18.8 3.4 18 21 <0.0001 daf$2(e1368) +15 +19
Figure(2C daf$2(e1368) 44'(48) 26.5 4.9 27 31
Replicate'2 daf$16(mg54);daf$2 59'(46) 16.4 3.4 17 19 <0.0001 daf$2(e1368) +38 +39
daf$16(tm5030);daf$2 58'(48) 20.8 3.9 21 23 <0.0001 daf$2(e1368) +22 +26
daf$16(tm5032);daf$2 80'(25) 19.9 4.1 21 23 <0.0001 daf$2(e1368) +25 +26
N2'wild+type 22'(28) 18.5 2.7 19 21 <0.0001 daf$2(e1368) +30 +32
Figure(2C daf$2(e1368) 90'(10) 20.9 4.1 21 24
Replicate'3 daf$16(mu86);daf$2 88'(12) 13.1 2.0 13 14 <0.0001 daf$2(e1368) +37 +42
daf$16(mg54);daf$2 75'(25) 12.8 1.7 12 14 <0.0001 daf$2(e1368) +39 +42
daf$16(tm5030);daf$2 98'(2) 17.5 3.2 18 20 <0.0001 daf$2(e1368) +16 +17
daf$16(tm5032);daf$2 90'(10) 18.3 2.7 18 20 <0.0001 daf$2(e1368) +12 +17
Figure(2D daf$2(e1368)5$5sib'of'daf$16(tm6659);daf$2 94'(10) 26.0 6.7 27 32
Replicate'1 daf$16(mg54);daf$2 46'(4) 16.7 3.8 13 15 <0.0001 daf$2(e1368) +36 +53
daf$16(tm6659);daf$2 100'(7) 24.8 5.7 25 29 0.0356 daf$2(e1368) +5 +9
daf$16(tm6659)'sib'of'daf$16(tm6659);daf$2 51'(0) 16.9 5.0 18 20 <0.0001 daf$2(e1368) +35 +38
wild+type'sib'of'daf$16(tm6659);daf$2 48'(3) 17.0 5.2 18 21 <0.0001 daf$2(e1368) +35 +34
N2'wild+type 49'(0) 16.5 5.3 18 20 <0.0001 daf$2(e1368) +37 +38
Figure(2D daf$2(e1368)5$5sib'of'daf$16(tm6659);daf$2 86'(16) 24.8 3.7 25 27
Replicate'2 daf$16(mg54);daf$2 35'(25) 14.5 1.7 15 15 <0.0001 daf$2(e1368) +42 +44
daf$16(tm6659);daf$2 88'(13) 22.6 4.0 23 25 0.0013 daf$2(e1368) +9 +7
wild+type'sib'of'daf$16(tm6659);daf$2 44'(16) 16.4 2.5 17 19 <0.0001 daf$2(e1368) +34 +30
N2'wild+type 52'(8) 17.9 2.9 19 19 <0.0001 daf$2(e1368) +28 +30
Figure(2D daf$2(e1368)5$5sib'of'daf$16(tm6659);daf$2 70'(35) 23.1 7.5 21 28
Replicate'3 daf$16(mg54);daf$2 45'(59) 12.1 2.4 12 14 <0.0001 daf$2(e1368) +48 +50
*shown(figure daf$16(tm6659);daf$2 70'(35) 23.7 5.8 23 28 0.8216 daf$2(e1368) NS NS
wild+type'sib'of'daf$16(tm6659);daf$2 63'(43) 16.8 3.1 18 19 <0.0001 daf$2(e1368) +27 +32
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Figure(2A daf$2(e1370) 100'(0) 43.7 10.6 43.5 53
Replicate'1 daf$16(tm5030);daf$2 97'(2) 32.4 8.3 35 38 <0.0001 daf$2(e1370) +26 +28
*shown(figure daf$16(tm5032);daf$2 94'(6) 31.8 6.7 33 36 <0.0001 daf$2(e1370) +27 +32
daf$16(mu86);daf$2 79'(22) 13.9 2.1 14 15 <0.0001 daf$2(e1370) +68 +72
daf$16(mg54);daf$2 75'(23) 15.0 3.6 14 16 <0.0001 daf$2(e1370) +66 +70
Figure(2A daf$2(e1370) 98'(0) 46.5 8.6 47 52
Replicate'2 daf$16(tm5030);daf$2 91'(7) 26.5 5.9 27 31 <0.0001 daf$2(e1370) +43 +40
daf$16(tm5032);daf$2 91'(7) 31.6 7.5 31 36 <0.0001 daf$2(e1370) +32 +31
daf$16(mu86);daf$2 60'(32) 19.4 5.1 18 24 <0.0001 daf$2(e1370) +58 +54
daf$16(mg54);daf$2 84'(10) 16.0 2.0 16 18 <0.0001 daf$2(e1370) +66 +65
Figure(2A daf$2(e1370) 200'(0) 48.5 10.8 51 56
Replicate'3 daf$16(tm5030);daf$2 96'(4) 29.3 11.0 30.5 38 <0.0001 daf$2(e1370) +40 +32
daf$16(tm5032);daf$2 99'(1) 31.1 8.6 31 38 <0.0001 daf$2(e1370) +39 +32
Figure(2A **daf$2(e1370) 48'(0) 41.6 6.7 43 48
Replicate'4 **daf$16(mu86);daf$2 44'(6) 14.0 1.9 14 15 <0.0001 daf$2(e1370) +66 +69
Figure(2B **daf$16(mg54);daf$2 35'(14) 14.5 3.1 15 16 <0.0001 daf$2(e1370) +65 +67
Replicate'1 **daf$16(tm5030);daf$2 43'(7) 34.2 6.8 36 38 <0.0001 daf$2(e1370) +18 +21
**RNAEseq **daf$16(tm5032);daf$2 45'(3) 34.6 5.6 36 38 <0.0001 daf$2(e1370) +17 +21
Replicate'1 **daf$16(tm6659);daf$2 105'(0) 40.5 7.5 43 45 0.4489 daf$2(e1370) NS NS
daf$28sib'of'daf$16(tm6659);daf$2 45'(0) 38.9 9.1 42 45 0.1648 daf$2(e1370) NS NS
wild+type8sib'of'daf$16(tm6659);daf$2 37'(5) 16.3 3.0 16 18 <0.0001 daf$2(e1370) +61 +63
N2'wild+type 40'(5) 16.1 2.1 16 17 <0.0001 daf$2(e1370) +61 +65
Figure(2A **daf$2(e1370) 60'(0) 46.2 9.7 48 53
Replicate'5 **daf$16(mu86);daf$2 40'(10) 14.7 2.6 15 17 <0.0001 daf$2(e1370) +68 +68
Figure(2B **daf$16(mg54);daf$2 41'(9) 15.3 3.2 17 17 <0.0001 daf$2(e1370) +67 +68
Replicate'2 **daf$16(tm5030);daf$2 40'(10) 38.2 6.3 38 43 <0.0001 daf$2(e1370) +17 +19
*shown(figure **daf$16(tm5032);daf$2 47'(3) 36.1 7.4 37 43 <0.0001 daf$2(e1370) +22 +19
**RNAEseq **daf$16(tm6659);daf$2 104'(1) 46.2 7.6 51 55 0.2284 daf$2(e1370) NS NS
Replicate'2 daf$28sib'of'daf$16(tm6659);daf$2 51'(1) 47.1 10.4 51 53 0.2618 daf$2(e1370) NS NS
wild+type8sib'of'daf$16(tm6659);daf$2 37'(13) 16.5 2.8 17 17 <0.0001 daf$2(e1370) +64 +68
N2'wild+type 32'(18) 17.0 2.0 17 17 <0.0001 daf$2(e1370) +63 +68
Figure(2A **daf$2(e1370) 50'(0) 46.0 8.9 47.5 54
Replicate'6 **daf$16(mu86);daf$2 39'(9) 15.2 2.2 16 17 <0.0001 daf$2(e1370) +67 +69
Figure(2B **daf$16(mg54);daf$2 37'(12) 16.7 2.8 16 19 <0.0001 daf$2(e1370) +64 +65
Replicate'3 **daf$16(tm5030);daf$2 47'(3) 39.6 7.9 41 45 <0.0001 daf$2(e1370) +14 +17
**RNAEseq **daf$16(tm5032);daf$2 50'(2) 35.6 7.9 37 41 <0.0001 daf$2(e1370) +23 +24
Replicate'3 **daf$16(tm6659);daf$2 98'(3) 46.9 7.8 51 54 0.0503 daf$2(e1370) NS NS
daf$28sib'of'daf$16(tm6659);daf$2 47'(3) 46.0 7.9 47 52 0.7780 daf$2(e1370) NS NS
wild+type8sib'of'daf$16(tm6659);daf$2 32'(19) 19.0 3.2 18 20 <0.0001 daf$2(e1370) +59 +63
N2'wild+type 37'(13) 17.6 2.3 17 19 <0.0001 daf+2(e1370) +62 +65
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Replicate-1 daf$2(e1370);control(RNAi control(RNAi 99((5) 46.0 11.2
Figure(4A daf$2(e1370);daf$16a(RNAi A(RNAi 104((1) 33.0 6.0 <0.0001 control(RNAi 428
Figure(4B daf$2(e1370);daf$16f(RNAi F(RNAi 102((1) 40.9 7.8 <0.0001 control(RNAi 411
Figure(4C daf$2(e1370);pan$daf$16(RNAi A/F/B(RNAi 59((0) 20.6 3.1 <0.0001 control(RNAi 455
daf$16(tm5032);daf$2(e1370);control(RNAi A(mutant(+(control(RNAi 98((6) 32.0 5.4 <0.0001 control(RNAi 430
daf$16(tm5032);daf$2(e1370);daf$16a(RNAi A(mutant(+(A(RNAi 84((19) 28.0 3.4 <0.0001 A(mutant(+(control(RNAi 413
daf$16(tm5032);daf$2(e1370);daf$16f(RNAi A(mutant(+(F(RNAi 81((24) 18.3 2.2 <0.0001 A(mutant(+(control(RNAi 443
daf$16(tm5032);daf$2(e1370);pan$daf$16(RNAi A(mutant(+(A/F/B(RNAi 50((10) 17.5 1.3 <0.0001 A(mutant(+(control(RNAi 445
daf$16(tm6659);daf$2(e1370);control(RNAi F(mutant(+(control(RNAi 99((7) 48.2 11.7 0.2284 control(RNAi NS
daf$16(tm6659);daf$16a(RNAi F(mutant(+(A(RNAi 97((7) 22.9 4.1 <0.0001 F(mutant(+(control(RNAi 452
daf$16(tm6659);daf$2(e1370);daf$16f(RNAi F(mutant(+(F(RNAi 99((6) 47.1 9.4 0.7294 F(mutant(+(control(RNAi NS
daf$16(tm6659);daf$2(e1370);pan$daf$16(RNAi F(mutant(+(A/F/B(RNAi 57((3) 19.9 2.7 <0.0001 F(mutant(+(control(RNAi 459
Replicate-2 daf$2(e1370);control(RNAi control(RNAi 106((1) 50.9 10.5
Figure(4A daf$2(e1370);daf$16a(RNAi A(RNAi 101((4) 36.8 4.9 <0.0001 control(RNAi 428
Figure(4B daf$2(e1370);daf$16f(RNAi F(RNAi 104((2) 39.2 4.6 <0.0001 control(RNAi 423
Figure(4C daf$2(e1370);pan$daf$16(RNAi A/F/B(RNAi 57((3) 22.1 2.2 <0.0001 control(RNAi 457
daf$16(tm5032);daf$2(e1370);control(RNAi A(mutant(+(control(RNAi 88((21) 34.5 5.9 <0.0001 control(RNAi 432
daf$16(tm5032);daf$2(e1370);daf$16a(RNAi A(mutant(+(A(RNAi 65((41) 32.1 1.8 0.0015 A(mutant(+(control(RNAi 47
daf$16(tm5032);daf$2(e1370);daf$16f(RNAi A(mutant(+(F(RNAi 60((46) 18.7 2.0 <0.0001 A(mutant(+(control(RNAi 446
daf$16(tm5032);daf$2(e1370);pan$daf$16(RNAi A(mutant(+(A/F/B(RNAi 42((18) 17.7 1.5 <0.0001 A(mutant(+(control(RNAi 449
daf$16(tm6659);daf$2(e1370);control(RNAi F(mutant(+(control(RNAi 92((4) 55.4 10.1 0.0094 control(RNAi +9
daf$16(tm6659);daf$16a(RNAi F(mutant(+(A(RNAi 94((11) 23.6 2.9 <0.0001 F(mutant(+(control(RNAi 455
daf$16(tm6659);daf$2(e1370);daf$16f(RNAi F(mutant(+(F(RNAi 99((6) 58.3 9.9 0.0922 F(mutant(+(control(RNAi NS
daf$16(tm6659);daf$2(e1370);pan$daf$16(RNAi F(mutant(+(A/F/B(RNAi 59((1) 21.2 2.1 <0.0001 F(mutant(+(control(RNAi 462
Replicate-3 daf$2(e1370);control(RNAi control(RNAi 88((2) 54.0 7.7
Figure(4A daf$2(e1370);daf$16a(RNAi A(RNAi 74((1) 43.9 7.1 <0.0001 control(RNAi 419
Figure(4B daf$2(e1370);daf$16f(RNAi F(RNAi 75((0) 45.4 5.6 <0.0001 control(RNAi 416
Figure(4C daf$2(e1370);pan$daf$16(RNAi A/F/B(RNAi 56((5) 23.2 3.9 <0.0001 control(RNAi 457
daf$2(e1370);daf$16a/f(RNAi A/F(RNAi 73((2) 23.9 4.4 <0.0001 control(RNAi 456
daf$16(tm5030);daf$2(e1370);control(RNAi A(mutant(+(control(RNAi 72((17) 41.0 4.8 <0.0001 control(RNAi 424
daf$16(tm5030);daf$2(e1370);daf$16a(RNAi A(mutant(+(A(RNAi 55((21) 39.5 6.7 0.9948 A(mutant(+(control(RNAi NS
daf$16(tm5030);daf$2(e1370);daf$16f(RNAi A(mutant(+(F(RNAi 50((25) 20.4 2.4 <0.0001 A(mutant(+(control(RNAi 450
daf$16(tm5030);daf$2(e1370);pan$daf$16(RNAi A(mutant(+(A/F/B(RNAi 40((20) 18.7 2.0 <0.0001 A(mutant(+(control(RNAi 454
daf$16(tm5030);daf$2(e1370);daf$16a/f(RNAi A(mutant(+(A/F(RNAi 41((36) 20.0 1.8 <0.0001 A(mutant(+(control(RNAi 451
daf$16(tm6659);daf$2(e1370);control(RNAi F(mutant(+(control(RNAi 86((3) 55.7 5.5 0.4591 control(RNAi NS
daf$16(tm6659);daf$16a(RNAi F(mutant(+(A(RNAi 75((1) 25.8 4.4 <0.0001 F(mutant(+(control(RNAi 454
daf$16(tm6659);daf$2(e1370);daf$16f(RNAi F(mutant(+(F(RNAi 73((2) 56.0 7.4 0.3320 F(mutant(+(control(RNAi NS
daf$16(tm6659);daf$2(e1370);pan$daf$16(RNAi F(mutant(+(A/F(RNAi 58((3) 22.6 3.7 <0.0001 F(mutant(+(control(RNAi 459
daf$16(tm6659);daf$2(e1370);daf$16a/f(RNAi F(mutant(+(A/F/B(RNAi 73((1) 25.3 4.1 <0.0001 F(mutant(+(control(RNAi 455
Replicate-4 daf$16(tm5030);daf$2(e1370);control(RNAi A(mutant(+(control(RNAi 98((2) 34.2 5.8
Figure(4B daf$16(tm5030);daf$2(e1370);daf$16a(RNAi A(mutant(+(A(RNAi 96((4) 27.8 5.3 <0.0001 A(mutant(+(control(RNAi 419
daf$16(tm5030);daf$2(e1370);daf$16f(RNAi A(mutant(+(F(RNAi 88((12) 18.8 3.2 <0.0001 A(mutant(+(control(RNAi 445
daf$16(tm5030);daf$2(e1370);pan$daf$16(RNAi A(mutant(+(A/F/B(RNAi 94((6) 17.0 2.2 <0.0001 A(mutant(+(control(RNAi 450
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Supplemental Table 4.8. glp-1(e2141) life span data and statistics.
 

























Figure(2E glp$1(e2141) 98'(1) 24.8 8.4 26 32
Replicate'1 daf$16(mu86);glp$1 89'(5) 13.0 2.0 13 14 <0.0001 glp$1(e2141) +48 +56
*shown(figure daf$16(mg54);glp$1 95'(1) 12.7 1.9 13 14 <0.0001 glp$1(e2141) 49 +56
daf$16(tm5030);glp$1 91'(6) 19.3 6.6 18 24 <0.0001 glp$1(e2141) +22 +25
daf$16(tm5032);glp$1 102'(0) 20.5 7.0 21 25 <0.0001 glp$1(e2141) +17 +22
Figure(2E glp$1(e2141) 96'(2) 22.1 8.1 21 28
Replicate'2 daf$16(mu86);glp$1 91'(9) 13.0 2.9 12 16 <0.0001 glp$1(e2141) +41 +43
daf$16(mg54);glp$1 98'(1) 13.0 3.0 12 16 <0.0001 glp$1(e2141) +41 +43
daf$16(tm5030);glp$1 103'(2) 18.4 6.0 18 23 <0.0001 glp$1(e2141) +17 +18
daf$16(tm5032);glp$1 97'(1) 17.8 6.4 18 23 <0.0001 glp$1(e2141) +19 +18
Figure(2E glp$1(e2141) 84'(10) 22.8 10.0 25 33
Replicate'3 daf$16(mu86);glp$1 73'(22) 11.8 2.5 12 13 <0.0001 glp$1(e2141) +48 +61
daf$16(mg54);glp$1 91'(0) 10.7 2.1 11 13 <0.0001 glp$1(e2141) +53 +61
daf$16(tm5030);glp$1 96'(4) 19.4 7.4 22 25 <0.0001 glp$1(e2141) +15 +24
daf$16(tm5032);glp$1 94'(4) 18.0 7.3 20 25 <0.0001 glp$1(e2141) +21 +24
Figure(2E glp$1(e2141) 58'(1) 26.3 4.0 27 28
Replicate'4 daf$16(mu86);glp$1 56'(4) 16.0 2.4 16 18 <0.0001 glp$1(e2141) +39 +36
daf$16(mg54);glp$1 49'(1) 16.4 1.6 16 17 <0.0001 glp$1(e2141) +38 +39
daf$16(tm5030);glp$1 60'(0) 22.2 2.9 22 24 <0.0001 glp$1(e2141) +16 +14
daf$16(tm5032);glp$1 60'(0) 22.2 3.4 22 24 <0.0001 glp$1(e2141) +16 +14
Figure(2F glp$1(e2141)7sib'of'daf$16(tm6659);glp$1 99'(6) 22.1 12.5 19 35
Replicate'1 daf$16(mu86);glp$1 102'(3) 12.9 3.6 13 16 <0.0001 glp$1(e2141) +42 +54
*shown(figure daf$16(tm6659);glp$1 102'(3) 24.6 14.8 19 37 0.0454 glp$1(e2141) +11 +6
Figure(2F glp$1(e2141)7sib'of'daf$16(tm6659);glp$1 106'(1) 19.3 11.0 13 28
Replicate'2 daf$16(mu86);glp$1 105'(0) 13.6 3.4 13 16 <0.0001 glp$1(e2141) +30 +43
daf$16(tm6659);glp$1 108'(0) 19.8 11.1 14 28 0.9139 glp$1(e2141) NS NS
Figure(2F glp$1(e2141)7sib'of'daf$16(tm6659);glp$1 91'(0) 22.1 11.6 18 33
Replicate'3 daf$16(mu86);glp$1 89'(1) 11.5 3.7 11 15 <0.0001 glp$1(e2141) +48 +55












Replicate-1 daf$2(e1370);control(RNAi control(RNAi 94((11) 25.7 6.4
Figure(4D daf$2(e1370);daf$16a(RNAi A(RNAi 48((57) 23.9 3.4 0.0003 control(RNAi 47
Figure(4E daf$2(e1370);daf$16f(RNAi F(RNAi 81((21) 24.0 4.6 <0.0001 control(RNAi 47
Figure(4F daf$2(e1370);pan$daf$16(RNAi A/F/B(RNAi 26((33) 17.0 2.5 <0.0001 control(RNAi 434
daf$16(tm5030);daf$2(e1370);control(RNAi A(mutant(+(control(RNAi 81((21) 20.7 6.0 <0.0001 control(RNAi 420
daf$16(tm5030);daf$2(e1370);daf$16a(RNAi A(mutant(+(A(RNAi 71((32) 22.1 0.8 0.9582 A(mutant(+(control(RNAi NS
daf$16(tm5030);daf$2(e1370);daf$16f(RNAi A(mutant(+(F(RNAi 82((23) 15.9 2.4 <0.0001 A(mutant(+(control(RNAi 423
daf$16(tm5030);daf$2(e1370);pan$daf$16(RNAi A(mutant(+(A/F/B(RNAi 43((17) 14.7 2.3 <0.0001 A(mutant(+(control(RNAi 429
daf$16(tm6659);daf$2(e1370);control(RNAi F(mutant(+(control(RNAi 100((6) 23.9 6.8 0.0293 control(RNAi 47
daf$16(tm6659);daf$16a(RNAi F(mutant(+(A(RNAi 61(((43) 18.9 2.3 <0.0001 F(mutant(+(control(RNAi 421
daf$16(tm6659);daf$2(e1370);daf$16f(RNAi F(mutant(+(F(RNAi 96((9) 26.2 5.4 0.3143 F(mutant(+(control(RNAi NS
daf$16(tm6659);daf$2(e1370);pan$daf$16(RNAi F(mutant(+(A/F/B(RNAi 38((22) 16.8 2.0 <0.0001 F(mutant(+(control(RNAi 430
Replicate-2 daf$2(e1370);control(RNAi control(RNAi 78((11) 27.3 6.5
Figure(4D daf$2(e1370);daf$16a(RNAi A(RNAi 30((44) 21.7 3.7 <0.0001 control(RNAi 420
Figure(4E daf$2(e1370);daf$16f(RNAi F(RNAi 63((11) 26.5 3.3 0.0003 control(RNAi 43
Figure(4F daf$2(e1370);pan$daf$16(RNAi A/F/B(RNAi 27((32) 17.6 2.2 <0.0001 control(RNAi 436
daf$2(e1370);daf$16a/f(RNAi A/F(RNAi 23((51) 19.3 2.1 <0.0001 control(RNAi 430
daf$16(tm5032);daf$2(e1370);control(RNAi A(mutant(+(control(RNAi 75((15) 20.1 5.4 <0.0001 control(RNAi 426
daf$16(tm5032);daf$2(e1370);daf$16a(RNAi A(mutant(+(A(RNAi 60((15) 22.0 4.5 0.3603 A(mutant(+(control(RNAi NS
daf$16(tm5032);daf$2(e1370);daf$16f(RNAi A(mutant(+(F(RNAi 53((22) 16.0 2.1 <0.0001 A(mutant(+(control(RNAi 420
daf$16(tm5032);daf$2(e1370);pan$daf$16(RNAi A(mutant(+(A/F/B(RNAi 46((14) 15.5 2.0 <0.0001 A(mutant(+(control(RNAi 423
daf$16(tm5032);daf$2(e1370);daf$16a/f(RNAi A(mutant(+(A/F(RNAi 53((20) 17.1 1.9 <0.0001 A(mutant(+(control(RNAi 415
daf$16(tm6659);daf$2(e1370);control(RNAi F(mutant(+(control(RNAi 83((7) 26.3 7.1 0.5149 control(RNAi NS
daf$16(tm6659);daf$16a(RNAi F(mutant(+(A(RNAi 30((45) 18.5 2.7 <0.0001 F(mutant(+(control(RNAi 430
daf$16(tm6659);daf$2(e1370);daf$16f(RNAi F(mutant(+(F(RNAi 68((7) 30.8 4.6 0.0004 F(mutant(+(control(RNAi +17
daf$16(tm6659);daf$2(e1370);pan$daf$16(RNAi F(mutant(+(A/F/B(RNAi 30((30) 18.0 2.0 <0.0001 F(mutant(+(control(RNAi 432
daf$16(tm6659);daf$2(e1370);daf$16a/f(RNAi F(mutant(+(A/F(RNAi 34((42) 18.3 2.7 <0.0001 F(mutant(+(control(RNAi 430
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Supplemental Figure 4.7. Thermotolerance, oxidative stress resistance, and UV 
stress resistance of daf-16 isoform-specific mutants in the daf-2(e1370) background.  
Survival data for animals exposed to 33°C heat, 7.5mM t-BOOH, or 1200 J/m2 UV are shown. See 
Methods for more detail. For thermotolerance and oxidative stress assays, patterns and absolute values of 
survival were very similar for all 3 replicates, and therefore combined data for all replicates are presented. 
For UV stress resistance, one representative trial is shown, but note that daf-16f mutation reduced UV 






































daf$2(e1370) 40!(22) 30.1 6.3 35.5
daf$16(mg54);daf$2 57!(3) 19.5 4.4 19 <0.0001 daf$2(e1370) +35 +46 0.0721 N2!wild+type NS NS
daf$16(tm5030);daf$2 58!(3) 24.4 3.1 24 <0.0001 daf$2(e1370) +19 +32 0.5459 daf$16(tm5032);daf$2 NS NS
daf$16(tm5032);daf$2 60!(1) 24.8 4.1 24 <0.0001 daf$2(e1370) +18 +32
daf$16(tm6659);daf$2 49!(8) 31.2 6.2 35.5 0.9993 daf$2(e1370) NS NS
N2!wild+type 57!(3) 18.5 3.4 19 <0.0001 daf$2(e1370) +39 +46
Replicate#2
daf$2(e1370) 55!(6) 34.0 5.4 34.5
daf$16(mg54);daf$2 60!(0) 20.7 2.8 22 <0.0001 daf$2(e1370) +39 +36 0.8421 N2!wild+type
daf$16(tm5030);daf$2 58!(1) 24.6 5.6 22 <0.0001 daf$2(e1370) +28 +36 0.0001 daf$16(tm5032);daf$2 +15 +15
daf$16(tm5032);daf$2 58!(2) 28.9 5.6 26 <0.0001 daf$2(e1370) +15 +25
daf$16(tm6659);daf$2 50!(1) 35.1 4.6 34.5 0.4300 daf$2(e1370) NS NS
N2!wild+type 54!(2) 20.5 2.4 22 <0.0001 daf$2(e1370) +40 +36
Replicate#3
daf$2(e1370) 44!(1) 30.2 4.6 33.5
daf$16(mg54);daf$2 44!(0) 18.0 2.4 19 <0.0001 daf$2(e1370) +40 +43 0.0118 N2!wild+type +9 0
daf$16(tm5030);daf$2 52!(1) 24.1 3.5 25 <0.0001 daf$2(e1370) +20 +25
daf$16(tm6659);daf$2 41!(2) 31.5 6.1 33.5 0.1278 daf$2(e1370) NS NS
































daf$2(e1370) 58!(1) 53.7 8.2 54
daf$16(mg54);daf$2 60!(0) 23.3 5.5 27 <0.0001 daf$2(e1370) +57 +50 0.0163 N2!wild+type +14 +64
daf$16(tm5030);daf$2 59!(1) 41.9 12.2 41 <0.0001 daf$2(e1370) +22 +24 <0.0001 daf$16(tm5032);daf$2 +21 +24
daf$16(tm5032);daf$2 60!(0) 34.6 11.3 33 <0.0001 daf$2(e1370) +36 +39
daf$16(tm6659);daf$2 54!(3) 54.1 7.5 54 0.9578 daf$2(e1370) NS NS
N2!wild+type 60!(0) 20.4 6.7 16.5 <0.0001 daf$2(e1370) +62 +69
Replicate#2
daf$2(e1370) 59!(0) 49.8 4.9 47
daf$16(mg54);daf$2 56!(2) 15.8 6.7 12.5 <0.0001 daf$2(e1370) +68 +73 0.0705 N2!wild+type NS NS
daf$16(tm5030);daf$2 57!(1) 36.1 9.9 38 <0.0001 daf$2(e1370) +28 +19 0.0001 daf$16(tm5032);daf$2 +19 +25
daf$16(tm5032);daf$2 60!(0) 30.3 7.9 30.5 <0.0001 daf$2(e1370) +39 +35
daf$16(tm6659);daf$2 59!(0) 55.2 7.8 59 <0.0001 daf$2(e1370) +11 +26
N2!wild+type 57!(2) 18.0 6.7 22.5 <0.0001 daf$2(e1370) +64 +52
Replicate#3
daf$2(e1370) 48!(11) 49.9 13.9 48
daf$16(mg54);daf$2 60!(0) 16.9 5.2 12.5 <0.0001 daf$2(e1370) +66 +74 0.0289 N2!wild+type +7 +46
daf$16(tm5030);daf$2 46!(10) 35.9 12.0 32 <0.0001 daf$2(e1370) +28 +33
daf$16(tm6659);daf$2 57!(3) 46.5 16.3 48 0.4865 daf$2(e1370) NS NS
































daf$2(e1370) 55!(2) 197.1 68.4 202
daf$16(mg54);daf$2 60!(0) 116.2 39.3 105 <0.0001 daf$2(e1370) +41 +48 <0.0001 N2!wild+type +23 +28
daf$16(tm5030);daf$2 59!(0) 165.8 60.6 156 0.0069 daf$2(e1370) +16 +23 0.0600 daf$16(tm5032);daf$2 NS NS
daf$16(tm5032);daf$2 55!(1) 158.1 39.6 156 <0.0001 daf$2(e1370) +20 +23
daf$16(tm6659);daf$2 58!(0) 188.5 70.1 175 0.6215 daf$2(e1370) NS NS
N2!wild+type 57!(0) 94.6 21.5 82 <0.0001 daf$2(e1370) +52 +59
Replicate#2
daf$2(e1370) 55!(4) 196.7 57.5 179
daf$16(mg54);daf$2 52!(1) 119.3 32.6 126 <0.0001 daf$2(e1370) +39 +30 <0.0001 N2!wild+type +31 +42
daf$16(tm5030);daf$2 53!(2) 167.4 44.9 155 0.0010 daf$2(e1370) +15 +13 0.0620 daf$16(tm5032);daf$2 NS NS
daf$16(tm5032);daf$2 57!(1) 150.2 44.0 155 <0.0001 daf$2(e1370) +24 +13
daf$16(tm6659);daf$2 56!(1) 190.3 58.9 179 0.5871 daf$2(e1370) NS NS
N2!wild+type 54!(2) 91.3 20.9 89 <0.0001 daf$2(e1370) +54 +50
Replicate#3
daf$2(e1370) 61!(0) 250.2 76.4 248
daf$16(mg54);daf$2 59!(0) 126.9 36.6 128 <0.0001 daf$2(e1370) +49 +48 <0.0001 N2!wild+type +46 +38
daf$16(tm5030);daf$2 62!(0) 194.0 74.7 200 <0.0001 daf$2(e1370) +22 +19
daf$16(tm6659);daf$2 60!(0) 171.0 62.6 175 <0.0001 daf$2(e1370) +32 +29
N2!wild+type 58!(0) 86.9 36.6 93 <0.0001 daf$2(e1370) +65 +63
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Supplemental Figure 4.8. qPCR validation of additional DAF-16A/F target genes 
Mean and standard deviation are plotted for three biological replicates of young adults. Asterisks denote 










Supplemental Figure 4.9. Expanded scatterplot showing more DAF-16A/F targets.  
Central box demarcated by intersection of dashed lines represents the scatterplot shown in Figure 5F. Three 










Supplemental Table 4.11. qPCR data and statistics for DAF-16A/F targets 
Mean and standard deviation for each cohort is calculated based on triplicate measurements. Mean and 
standard deviation overall is calculated based on means of three biological replicates. 
 
 
Mean SD Mean SD Mean SD Mean SD
dod#17
daf$2(e1370) 0.40 0.57 0.31 0.23 0.28 0.18 0.33 0.06 control control
daf$16(mu86);daf$2 2.01 0.44 3.36 0.20 5.17 0.17 3.52 1.58 0.0200 10.660
daf$16(mg54);daf$2 2.91 0.43 2.22 0.28 4.47 0.17 3.20 1.15 0.0092 9.699
daf$16(tm5030);daf$2 0.62 0.34 0.67 0.25 0.77 0.12 0.69 0.07 0.9712 2.084
daf$16(tm5032);daf$2 0.42 0.23 0.44 0.31 0.58 0.19 0.48 0.09 0.5286 1.453
daf$16(tm6659);daf$2 0.33 0.27 0.57 0.36 0.32 0.20 0.41 0.14 0.9818 1.232
N23wild7type 1.00 0.51 1.00 0.19 1.00 0.23 1.00 0.00 0.0053 3.032
far#3
daf$2(e1370) 2.16 0.13 5.28 0.23 4.20 0.21 3.88 1.58 control control
daf$16(mu86);daf$2 0.44 0.15 0.35 0.18 0.41 0.23 0.40 0.05 0.0215 0.104
daf$16(mg54);daf$2 0.43 0.20 0.76 0.08 0.54 0.19 0.57 0.17 0.0050 0.148
daf$16(tm5030);daf$2 0.38 0.16 0.82 0.15 0.46 0.01 0.55 0.23 0.0055 0.143
daf$16(tm5032);daf$2 0.59 0.37 1.07 0.12 0.78 0.19 0.81 0.24 0.0056 0.209
daf$16(tm6659);daf$2 2.35 0.16 5.58 0.13 3.68 0.15 3.87 1.62 0.9758 0.997
N23wild7type 1.00 0.22 1.00 0.24 1.00 0.28 1.00 0.00 0.0407 0.258
fat#7
daf$2(e1370) 0.13 0.40 0.15 0.13 0.15 0.04 0.14 0.01 control control
daf$16(mu86);daf$2 0.82 0.34 0.81 0.03 0.73 0.05 0.79 0.05 0.0023 5.597
daf$16(mg54);daf$2 0.63 0.38 0.69 0.03 0.49 0.07 0.60 0.10 0.0075 4.289
daf$16(tm5030);daf$2 0.23 0.37 0.29 0.23 0.40 0.01 0.31 0.09 0.0258 2.174
daf$16(tm5032);daf$2 0.26 0.38 0.26 0.10 0.44 0.09 0.32 0.10 0.0377 2.260
daf$16(tm6659);daf$2 0.09 0.27 0.17 0.13 0.14 0.11 0.13 0.04 0.6365 0.955
N23wild7type 1.00 0.41 1.00 0.07 1.00 0.09 1.00 0.00 0.0008 7.107
hen#1
daf$2(e1370) 14.72 0.28 23.26 0.17 32.22 0.30 23.40 8.75 control control
daf$16(mu86);daf$2 1.06 0.27 0.43 0.18 2.22 0.27 1.24 0.91 0.0200 0.053
daf$16(mg54);daf$2 0.72 0.32 0.58 0.12 2.25 0.46 1.18 0.93 0.0092 0.051
daf$16(tm5030);daf$2 17.39 0.18 43.11 0.25 15.45 0.43 25.32 15.44 0.9712 1.082
daf$16(tm5032);daf$2 19.97 0.22 42.81 0.11 23.75 0.16 28.85 12.24 0.5286 1.233
daf$16(tm6659);daf$2 14.22 0.16 32.45 0.14 24.25 0.15 23.64 9.13 0.9818 1.010
N23wild7type 1.00 0.20 1.00 0.24 1.00 0.43 1.00 0.00 0.0053 0.043
lea#1
daf$2(e1370) 6.77 0.12 8.51 0.24 8.46 0.33 7.92 0.99 control control
daf$16(mu86);daf$2 0.57 0.11 0.43 0.37 0.55 0.15 0.52 0.08 0.0029 0.066
daf$16(mg54);daf$2 0.54 0.11 0.54 0.30 0.56 0.23 0.54 0.02 0.0006 0.069
daf$16(tm5030);daf$2 6.50 0.09 10.34 0.33 6.02 0.09 7.62 2.37 0.7266 0.963
daf$16(tm5032);daf$2 7.01 0.13 8.88 0.28 6.96 0.15 7.62 1.09 0.6655 0.962
daf$16(tm6659);daf$2 0.68 0.11 0.70 0.40 0.87 0.28 0.75 0.11 0.0009 0.095
N23wild7type 1.00 0.06 1.00 0.28 1.00 0.31 1.00 0.00 0.0013 0.126
Statistical,AnalysisIndependent,cohorts






Supplemental Table 11 (continued) 
 
  
Mean SD Mean SD Mean SD Mean SD
lipl$2
daf$2(e1370) 58.49 0.16 38.59 0.28 25.99 0.50 41.02 16.38 control control
daf$16(mu86);daf$2 3.53 0.24 1.69 0.29 1.55 0.18 2.26 1.11 0.0013 0.055
daf$16(mg54);daf$2 2.57 0.17 1.12 0.32 1.83 0.37 1.84 0.72 0.0067 0.045
daf$16(tm5030);daf$2 17.75 0.09 15.89 0.25 13.27 0.17 15.64 2.25 0.0260 0.381
daf$16(tm5032);daf$2 18.38 0.13 16.11 0.20 10.85 0.36 15.11 3.86 0.0094 0.368
daf$16(tm6659);daf$2 50.21 0.17 41.50 0.31 27.67 0.36 39.79 11.37 0.9442 0.970
N23wild7type 1.00 0.12 1.00 0.53 1.00 0.28 1.00 0.00 0.0041 0.024
lys$7
daf$2(e1370) 8.28 0.14 3.27 0.31 11.63 0.13 7.73 4.21 control control
daf$16(mu86);daf$2 0.60 0.05 0.76 0.13 1.09 0.16 0.82 0.25 0.0262 0.106
daf$16(mg54);daf$2 0.50 0.15 0.63 0.36 1.03 0.23 0.72 0.27 0.0213 0.093
daf$16(tm5030);daf$2 3.89 0.04 8.69 0.26 7.78 0.17 6.79 2.55 0.9199 0.878
daf$16(tm5032);daf$2 4.03 0.13 7.11 0.22 8.63 0.14 6.59 2.35 0.8731 0.853
daf$16(tm6659);daf$2 4.26 0.17 11.63 0.43 7.36 0.18 7.75 3.70 0.9438 1.003
N23wild7type 1.00 0.06 1.00 0.17 1.00 0.18 1.00 0.00 0.0369 0.129
mtl$1
daf$2(e1370) 23.59 0.34 28.25 0.18 28.64 0.08 26.83 2.81 control control
daf$16(mu86);daf$2 0.35 0.36 0.31 0.28 0.09 0.14 0.25 0.14 0.0092 0.009
daf$16(mg54);daf$2 0.28 0.34 0.68 0.25 0.14 0.16 0.37 0.28 0.0104 0.014
daf$16(tm5030);daf$2 4.89 0.26 15.03 0.23 5.62 0.11 8.51 5.66 0.0587 0.317
daf$16(tm5032);daf$2 5.31 0.28 12.64 0.18 5.86 0.13 7.94 4.08 0.0344 0.296
daf$16(tm6659);daf$2 12.73 0.24 27.28 0.10 13.83 0.13 17.95 8.10 0.1658 0.669
N23wild7type 1.00 0.37 1.00 0.29 1.00 0.11 1.00 0.00 0.0004 0.037
sod$3
daf$2(e1370) 22.94 0.25 14.52 0.50 24.08 0.14 20.51 5.22 control control
daf$16(mu86);daf$2 0.47 0.24 0.55 0.26 0.65 0.15 0.56 0.09 0.0024 0.027
daf$16(mg54);daf$2 1.25 0.23 1.60 0.40 1.92 0.16 1.59 0.33 0.0064 0.078
daf$16(tm5030);daf$2 4.86 0.21 5.03 0.33 7.89 0.20 5.93 1.70 0.0153 0.289
daf$16(tm5032);daf$2 4.47 0.25 3.51 0.25 6.23 0.18 4.74 1.38 0.0034 0.231
daf$16(tm6659);daf$2 19.70 0.17 26.35 0.38 23.10 0.24 23.05 3.33 0.6236 1.124
N23wild7type 1.00 0.26 1.00 0.57 1.00 0.18 1.00 0.00 0.0029 0.049
sams$5
daf$2(e1370) 14.03 0.23 5.58 0.13 5.66 0.11 8.42 4.86 control control
daf$16(mu86);daf$2 1.91 0.27 4.23 0.14 2.30 0.08 2.81 1.24 0.1698 0.334
daf$16(mg54);daf$2 2.62 0.25 2.38 0.19 2.27 0.10 2.42 0.18 0.0494 0.288
daf$16(tm5030);daf$2 6.28 0.21 3.36 0.27 7.84 0.08 5.83 2.27 0.4342 0.692
daf$16(tm5032);daf$2 5.90 0.27 1.64 0.14 6.06 0.11 4.53 2.51 0.2228 0.538
daf$16(tm6659);daf$2 2.14 0.20 2.55 0.19 1.38 0.26 2.02 0.60 0.0505 0.240
N23wild7type 1.00 0.14 1.00 0.18 1.00 0.13 1.00 0.00 0.0218 0.119
Independent+cohorts Statistical+Analysis






Supplemental Table 11 (continued) 
 
Supplemental Table 4.12. Comparison of A- and F-indices calculated from qPCR 
and RNA-seq data.  
Indices are calculated from mean gene expression values (qPCR) or from FPKM gene expression values 
(RNA-seq) as described in Methods. 
 
	  	   A-­‐Index	   F-­‐Index	   	  	  
gene	   qPCR	   RNA-­‐seq	   qPCR	   RNA-­‐seq	   Class	  
far-­‐3	   0.97	   0.94	   0.00	   -­‐0.14	   A-­‐specific	  
scl-­‐20	   1.00	   0.99	   0.22	   -­‐0.10	   A-­‐specific	  
lea-­‐1	   0.04	   -­‐0.18	   0.97	   1.00	   F-­‐specific	  
dod-­‐17	   0.09	   0.13	   0.03	   0.05	   Redundant	  
hen-­‐1	   -­‐0.17	   -­‐0.21	   -­‐0.01	   0.10	   Redundant	  
lys-­‐7	   0.15	   -­‐0.03	   0.00	   -­‐0.12	   Redundant	  
mtl-­‐1	   0.70	   0.61	   0.34	   0.23	   Redundant	  
fat-­‐7	   0.37	   0.36	   -­‐0.01	   0.03	   Shared	  A>F	  
lipl-­‐2	   0.65	   0.58	   0.03	   -­‐0.05	   Shared	  A>F	  
sod-­‐3	   0.80	   0.79	   -­‐0.13	   -­‐0.21	   Shared	  A>F	  
sams-­‐5	   0.54	   0.22	   1.07	   1.10	   Shared	  F>A	  
ttr-­‐23	   0.60	   0.49	   0.33	   0.36	   Shared	  A=F	  
 
Mean SD Mean SD Mean SD Mean SD
scl$20
daf$2(e1370) 512.00 0.25 229.13 0.17 198.09 0.16 313.07 172.97 control control
daf$16(mu86);daf$2 0.85 0.21 0.17 1.64 0.28 0.06 0.43 0.36 0.0013 0.001
daf$16(mg54);daf$2 0.59 0.21 0.35 0.12 0.43 0.05 0.46 0.12 0.0008 0.001
daf$16(tm5030);daf$2 1.38 0.54 0.71 1.01 0.66 0.68 0.91 0.40 0.0001 0.003
daf$16(tm5032);daf$2 1.48 0.69 0.81 0.45 1.35 0.35 1.21 0.36 0.0022 0.004
daf$16(tm6659);daf$2 240.52 0.44 340.14 0.20 151.17 0.22 243.94 94.53 0.5928 0.779
N23wild7type 1.00 0.12 1.00 0.35 1.00 0.03 1.00 0.00 0.0027 0.003
ttr$23
daf$2(e1370) 27.28 0.12 11.08 0.22 4.72 0.38 14.36 11.63 control control
daf$16(mu86);daf$2 2.99 0.39 1.49 0.22 1.26 0.24 1.91 0.94 0.0204 0.133
daf$16(mg54);daf$2 3.10 0.10 1.09 0.41 1.72 0.23 1.97 1.02 0.0472 0.137
daf$16(tm5030);daf$2 9.99 0.15 5.94 0.33 4.20 0.21 6.71 2.97 0.1517 0.467
daf$16(tm5032);daf$2 9.65 0.11 8.11 0.34 3.78 0.13 7.18 3.04 0.1801 0.500
daf$16(tm6659);daf$2 12.21 0.15 16.22 0.44 2.41 0.22 10.28 7.10 0.4331 0.716
N23wild7type 1.00 0.62 1.00 0.25 1.00 0.41 1.00 0.00 0.0410 0.070
Independent+cohorts Statistical+Analysis







Supplemental Table 4.13. Strains used and generated in this study.  
Double and triple mutant strains and siblings were constructed using standard genetic techniques. 
 
Strain	   Genotype	   Outcrossed	   Reference	  
N2	  Bristol	   wild-­‐type	   	  	   	  	  
DR1572	   daf-­‐2(e1368)	   6X	   Kimura	  et	  al.	  1997	  
CB1370	   daf-­‐2(e1370)	   6X	   Kimura	  et	  al.	  1997	  
CB4037	   glp-­‐1(e2141)	   6X	   Priess	  et	  al.	  1987	  
CF1038	   daf-­‐16(mu86)	   6X	   Lin	  et	  al.	  1997	  
GR1308	   daf-­‐16(mg54)	   6X	   Ogg	  et	  al.	  1997	  
BQ63	   daf-­‐16(tm5030)	   6X	   This	  study	  
BQ64	   daf-­‐16(tm5032)	   6X	   This	  study	  
BQ65	   daf-­‐16(tm6659)	   6X	   This	  study	  
COP308	   Pdaf-­‐16a::daf-­‐16a	  +	  Cb	  unc-­‐119(+)	   6X	   This	  study	  
COP339	   Pdaf-­‐16f::daf-­‐16f	  +	  Cb	  unc-­‐119(+)	   6X	   This	  study	  
 
Supplemental Table 4.14. RACE, qPCR, and RNAi cloning primer sequences.  
Continued on next page. 
RACE primers 
Target Primer name Primer 1 sequence (5' to 3') Reference 
daf-16a/d/f/h A/F-RACE GCTGTCGACCCGTTTGAAGAT This study 
daf-16a A-RACE AGGTCAGCATCTTCTTCAGGAA This study 
daf-16d/f/h F-RACE TGTTGATGGAGGTCGAGATTGA This study 
daf-16a, daf-






qPCR primers for daf-16/FoxO isoforms 
Target Primer 1 name Primer 1 sequence (5' to 3') Reference 
daf-16 pan-qPCR1_For AAAGAGCTCGTGGTGGGTTA This study 
daf-16 pan-qPCR1_Rev TTCGAGTTGAGCTTTGTAGTCG This study 
daf-16 pan-qPCR2_For AAGCCGATTAAGACGGAACC Bansal et al 2014 
daf-16 pan-qPCR2_Rev GTAGTGGCATTGGCTTGAAG Bansal et al 2014 
daf-16a A30-qPCR_For TGAAGAAGATGCTGACCTA This study 
daf-16a A32-qPCR_For TGAATGATGATATGGAACCG This study 
daf-16d/f/h F-qPCR_For TTGACAGCGGAAGAACTA This study 
daf-16a, daf-
16d/f/h AF-qPCR_Rev ATCTGGAGTATGAAGCATTG This study 
daf-16b B-qPCR_For TCGGATATCATTGCCAAAGC This study 




qPCR primers for daf-16/FoxO target genes 
Target Primer 1 name Primer 1 sequence (5' to 3') Reference 
act-1 act-1_Rev TGGAGAGGGAAGCGAGGATAGA Alam et al. 2010 
act-1 act-1_For CCAGGAATTGCTGATCGTATGCAGAA Alam et al. 2010 
dod-17 dod-17_Rev GTTAGCGACAGTGAGTGTG Gubelmann et al 2011 
dod-17 dod-17_For CAGGAAATCTTATTCGGACTACTC Gubelmann et al 2011 
far-3 far-3_Rev AGCAACTTGGGTTTCAATGAG Gubelmann et al 2011 
far-3 far-3_For ACGTGGTCTTTATGCTCGT Gubelmann et al 2011 
fat-7 fat-7_Rev GGGAAATAGTGCTTTCTCTGG Gubelmann et al 2011 
fat-7 fat-7_For AGTTAAGGAGCATGGAGGC Gubelmann et al 2011 
hen-1 hen-1_Rev AATCAGCCAGTTTGATACATGG Gubelmann et al 2011 
hen-1 hen-1_For GTCATGGCAACAAGTACATACC Gubelmann et al 2011 
lea-1 lea-1_Rev CCTTGTCCTTGGTCTTGTC Gubelmann et al 2011 
lea-1 lea-1_For ATGTAGAGAACAAAGCAGCAG Gubelmann et al 2011 
lipl-2 lipl-2_Rev AAACGAAAGCTGCACTCTG Gubelmann et al 2011 
lipl-2 lipl-2_For GTTACATGGCCAAATGGGA Gubelmann et al 2011 
lys-7 lys-7_Rev TTAATCCGGATTGTCTGGC Gubelmann et al 2011 
lys-7 lys-7_For CAACTAACTGGCCAAATAACG Gubelmann et al 2011 
mtl-1 mtl-1_For ATGGCTTGCAAGTGTGACTG Alam et al. 2010 
mtl-1 mtl-1_Rev CACATTTGTCTCCGCACTTG Alam et al. 2010 
sams-5 sams-5_Rev CTTATCCACATGAACTCCAGC Gubelmann et al 2011 
sams-5 sams-5_For CTCGAAAGGATTTGACTACAAGAC Gubelmann et al 2011 
scl-20 scl-20_Rev ACTCTTGGTTCTTCCATCCG Gubelmann et al 2011 
scl-20 scl-20_For GTTCGCTGGATAAATATGCCC Gubelmann et al 2011 
sod-3 sod-3_Rev CGTGCTCCCAAACGTCAATTCCAA Alam et al. 2010 
sod-3 sod-3_For TATTAAGCGCGACTTCGGTTCCCT  Alam et al. 2010 
ttr-23 ttr-23_For CTGCAATCATTACGGTATGTG Gubelmann et al 2011 
ttr-23 ttr-23_Rev TCGTAGTTGTCTACTCCGA Gubelmann et al 2011 
  
RNAi cloning 
Target Primer 1 name Primer 1 sequence (5' to 3') Reference 
daf-16a 16C RNAi 5 AACTGAAGCTTCTGGACATCTAC Kwon et al 2010 
daf-16a 16C RNAi 3 TATAGGCTAGCATCTTCTTCAG Kwon et al 2010 
daf-16d/f/h 16D RNAi 5 AACTGAAGCTTGATTCGCCGCTACC Kwon et al 2010 
daf-16d/f/h 16D RNAi 3 CCCGTGCTAGCTAGTTCTTCCGC Kwon et al 2010 
daf-16 16ACD RNAi 5 ATCTGAAGCTTCATTCTCGTTTC Kwon et al 2010 




Supplemental Table 4.15. Number of 5’ RACE clones sequenced for each strain.  
A semi-synchronized population of young adults were harvested for RNA. RNA was purified and analyzed 
as described in Methods. The A/F-RACE primer was used for first-strand cDNA synthesis. PCR 
amplification was performed using either the A30-RACE primer (daf-16a RACE primer) or the F-RACE 
primer (daf-16f RACE primer), in combination with the Abridged Anchor Primer from the Invitrogen 
RACE kit. For daf-16(tm5032), a different primer A32-RACE was used, indicated by asterisks. All 
indicated RACE clones were consistent with sequences presented in Supplemental Figure 4.2 and 
Supplemental Figure 4.4. Note that clones without SL1 trans-spliced leaders (w/o SL1) were partial 
fragments of the sequences. 
 
  
daf-16a RACE primer daf-16f RACE primer 
w/ SL1 w/o SL1 empty w/ SL1 w/o SL1 empty 
N2 wild-type 4 9 2 15 1 1 
daf-16(tm5030) 10 3 6 7 0 0 
daf-16(tm5032) 4* 5* 3* 7 3 0 






Supplemental Figure 4.10. Comparison of effects of two daf-16a alleles on 
expression of DAF-16A/F target genes.  
Log2 fold-change (FC) is shown for daf-2(e1370) vs. daf-16a(tm5030);daf-2 on the X-axis, and log2 FC is 







Supplemental Table 4.16. Effect of more stringent cutoffs for selection of DAF-
16A/F targets on downstream analysis of categories.  
We selected DAF-16A/F targets primarily on the basis of fold-change. Genes must meet the appropriate 
fold-change threshold for all three comparisons: (1) daf-2 vs. daf-2;e1370, daf-2 vs. daf-16(mg54);daf-2 
and daf-2 vs. daf-16(mu86);daf-2. 
 
We then required FDR < 0.05 for only one of the three comparisons for several reasons: (1) Nearly all 
genes showed concordance in fold-change for all three comparisons even if they did not satisfy FDR < 0.05 
for all three. (2) Some known DAF-16/FoxO targets only satisfied FDR < 0.05 in one or two comparisons. 
(3) The choice of requiring FDR < 0.05 for one, two, or three comparisons did not affect downstream 
analysis, and therefore we list all genes for completeness. 
 
See Materials and Methods for all criteria. 
 
	  	  
FDR	  >	  0.05	  for	  at	  least	  
one	  comparison	  
FDR	  >	  0.05	  for	  at	  least	  
two	  comparisons	  
FDR	  >	  0.05	  for	  all	  three	  
comparisons	  
Number	   Percent	   Number	   Percent	   Number	   Percent	  
A-­‐specific	   57	   14	   48	   16	   33	   18	  
F-­‐specific	   8	   2	   6	   2	   4	   2	  
Redundant	   35	   9	   28	   9	   15	   8	  
Shared	  A>F	   219	   55	   173	   56	   102	   56	  
Shared	  A=F	   60	   15	   41	   13	   22	   12	  
Shared	  F>A	   20	   5	   13	   4	   6	   3	  






The finding that DAF-16A plays a stronger role in life span control than DAF-16F was 
surprising, as previous experiments with transgenic strains suggested that DAF-16F was 
more important [35,42]. The previous study by Kwon et al. used transgenic strains 
harboring multiple cDNA copies of either daf-16a or daf-16f in a daf-16 null background 
[35]. We identified two major technical differences in the study by Kwon et al.: (1) over-
expression of DAF-16 isoforms and (2) expression from a non-endogenous genomic 
locus, and therefore may be missing native DNA regulatory elements. Thus, we reasoned 
that experiments employing single-copy transgenic strains might reconcile the two 
studies. 
We generated single-copy transgenic lines expressing either daf-16a or daf-16f 
(Supplemental Figure 4.11) using the Mos1-mediated single-copy insertion (MosSCI) 
technique [86] and verified that the full-length sequences were integrated. Crossing the 
daf-16f transgene into daf-16a/f;daf-2(e1370) rescued life span extension and dauer arrest 
(Supplemental Figure 4.12A-B), indicating that the daf-16f transgene is functional. 
Importantly, these animals had the same phenotypes as daf-16a;daf-2, suggesting that 
this daf-16f transgene has the same activity as daf-16f expressed from the genomic locus. 
This equal activity is also illustrated by partial rescue of life span by the daf-16f 
transgene in daf-16a/f;daf-2(e1368), consistent with daf-16a;daf-2(e1368) life span 
(Supplemental Figure 4.12C). However, the daf-16f transgene did not rescue dauer arrest 
(Supplemental Figure 4.12D). This is consistent with the requirement for daf-16a in daf-
2(e1368) arrest (Figure 4.2A). Thus, daf-16f-transgene-rescued daf-16a/f;daf-2 mutants 
exhibited the same phenotypes as daf-16a;daf-2 mutants, providing a second, 
independent line of evidence that daf-16a is required for dauer arrest and life span 
extension. 
Thus, single-copy daf-16f does not rescue life span to the same extent as multi-copy daf-
16f, which can effectively replace the need for any daf-16 expressed from the endogenous 
genomic locus [35,42]. We tested the hypothesis that copy number of daf-16f is the 
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critical difference between our studies. Thus, we doubled the gene dosage of daf-16f in 
the absence of daf-16a by introducing the daf-16f transgene into daf-16a;daf-2(e1370). 
This extended life span compared to the daf-16a;daf-2 and daf-16a/f;daf-2;daf-16f-
transgene strains (Figure 4.3G, Supplemental Figure 4.12A). Over-expression likely 
allowed the additional DAF-16F protein to assume some functions normally performed 
by DAF-16A, consistent with the expression profiling data that indicated partially 
overlapping roles for DAF-16A and DAF-16F (Figure 4.5). Taken together, the data 
strongly suggest that multi-copy expression of daf-16f in previous studies over-stated the 
role of daf-16f [35,42]. 
However, the single-copy daf-16a transgene had a more modest effect on dauer arrest and 
life span of daf-16a/f;daf-2(e1370) compared to single-copy daf-16f (Supplemental 
Figure 4.13A-B). Thus, both we and Kwon et al. [35] found stronger effects of daf-16f 
transgenes compared to daf-16a transgenes. Given that we found daf-16a expressed from 
the endogenous genomic locus to be sufficient for life span extension (Figure 4.3B,D,G), 
this raised the possibility that daf-16a transgenes are not fully functional. To test this 
hypothesis, we crossed our daf-16a single-copy transgene into daf-16a;daf-2(e1368). The 
daf-16a transgene only rescued ~ 50% of the dauer arrest and life span extension of daf-
16(+);daf-2(e1368) compared to daf-16a;daf-2(e1368) (Supplemental Figure 4.13C-D). 
To ensure this incomplete rescue was not specific to one strain, we tested two 
independently isolated lines expressing the daf-16a transgene and found they had the 
same incomplete dauer rescue (Supplemental Figure 4.13E). Therefore, the single-copy 
daf-16a transgenes are not fully functional. Given the similarity of our transgene 
construct compared to that of Kwon et al. [35], this raises the strong possibility that the 
Kwon et al. daf-16a transgene also does not recapitulate endogenous daf-16a function. 
Taken together, these results reconcile the previous study by Kwon et al. [35] and our 
study. Multi-copy daf-16f over-states the role of daf-16f, while single-copy daf-16f 
supports our model (Figure 4.3G, Figure 4.7, Supplemental Figure 4.12A). daf-16a 
transgenes do not recapitulate endogenous functions of daf-16a (Supplemental Figure 
4.13C-D). Further study is needed to identify the precise DNA regulatory elements 
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required for full activity of daf-16a. In contrast, our isoform-specific mutants express 
intact isoforms at endogenous levels (Supplemental Figure 4.6) from the native genomic 
locus. Given that the interpretation of the Kwon et al. over-expression transgenes is 
complicated by overlapping roles for DAF-16A and DAF-16F (Figure 4.5), our isoform-




Supplemental Figure 4.11. Diagram of single-copy daf-16a and daf-16 transgenes. 
These transgenes are both integrated on Chr II at the ttTi5605 locus. Promoter 1 is 3kb while Promoter 2 is 
4kb. The complete 1.7kb 3’UTR was incorporated. Note that a CB-unc-119 sequence is incorporated 5’ 




Supplemental Figure 4.12. The daf-16f transgene is functional and is consistent with 
the daf-16a mutant. 
(A-B) The daf-16f transgene is functional and rescues daf-16a/f;daf-2(e1370) life span and dauer arrest to 
the same levels as daf-16a;daf-2. Furthermore, the daf-16f transgene further extends daf-16a;daf-2, 
demonstrating that over-expression of daf-16f over-states the role of daf-16f. 
(C-D) The daf-16f transgene is functional and rescues daf-16a/f;daf-2(e1368) life span and dauer arrest to 




Supplemental Figure 4.13. The daf-16a transgene is partially functional. 
(A-B) The daf-16a transgene has a very modest effect on daf-16a/f;daf-2(e1370) life span and dauer arrest, 
consistent with observations by Kwon et al. [35] that daf-16f transgenes promote longevity to a greater 
extent than daf-16a transgenes. 
(C-E) The daf-16a transgene does not rescue the dauer arrest and life span phenotypes of daf-16a;daf-
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Chapter 5 Identification of critical DAF-16/FoxO 
target genes required for longevity 
 
Abstract 
FoxO transcription factors (TFs) control life span and aging in invertebrates and may do 
so in humans. The Caenorhabditis elegans FoxO ortholog DAF-16 promotes longevity 
and controls the expression of thousands of genes, but it is unknown if there exist single 
genes controlled by DAF-16/FoxO that are essential for life span extension. We 
previously used isoform-specific daf-16/FoxO alleles to categorize DAF-16/FoxO target 
genes according to their regulation by distinct DAF-16 isoforms. Life span phenotypes of 
isoform-specific mutants suggested that DAF-16A-specific and DAF-16A/F shared 
targets are most likely to influence life span. Here, we screen loss-of-function mutants to 
identify 8 DAF-16A-specific and 10 shared targets that influence longevity. Strikingly, 
the DAF-16A-specific target genes hsp-12.3 and sodh-1 are fully required for life span 
extension in animals with reduced daf-2/IGFR signaling. To our knowledge this is the 
first use of genetic mutants for systematic functional testing of DAF-16/FoxO targets, 
and demonstrates that a small subset of DAF-16/FoxO targets plays a disproportionate 
role in life span control. This offers a framework to prioritize further study of 





FoxO transcription factors (TFs) control aging, development, and metabolism in diverse 
species. FoxO TFs promote longevity in invertebrates and may do so in humans [1–3], 
and mouse models implicate FoxO dysregulation in the pathogenesis of age-related 
diseases such as cancer, Type 2 diabetes, and osteoporosis [4–9]. However, FoxO TFs are 
highly pleiotropic and their transcriptional outputs vary greatly dependent on context 
[10]. While this complexity may underlie FoxO’s influence on aging, it also poses 
significant challenge to understanding mechanisms of FoxO-mediated life span 
extension. Identifying specific protective functions of FoxO is likely necessary to develop 
targeted treatments to ameliorate and prevent age-related disease.  
In Caenorhabditis elegans, the FoxO ortholog DAF-16 promotes longevity in the 
contexts of reduced DAF-2 insulin-like signaling and germline ablation [11,12]. 
Expression profiling studies have identified thousands of genes regulated by DAF-
16/FoxO in these contexts [13–16]. Studies utilizing RNA interference (RNAi) to knock 
down the expression of individual DAF-16/FoxO target genes suggest that many of these 
genes are likely to make minor contributions to life span extension [14,17,18]. This is 
consistent with a model where DAF-16/FoxO upregulates and downregulates numerous 
genes that act in a cumulative fashion to dramatically increase life span [17,19]. 
It is possible that DAF-16/FoxO targets essential for life span extension remain 
unidentified, as an exhaustive analysis of DAF-16/FoxO target gene contributions to 
longevity has not been experimentally feasible. At the present time, less than 10% of 
target genes have been tested by RNAi, and existing RNAi results have not yet been 
validated by genetic null mutations. In this study, we use prior insights from studies of 






Prioritization of genes for systematic mutant testing 
Three DAF-16/FoxO isoforms are encoded by one genomic locus that share C-termini 
but diverge in their N-termini and regulatory DNA sequences [20,21]. We previously 
found in Chapters 3 and 4 that these three isoforms act in a hierarchy to control longevity, 
where DAF-16A is sufficient for full life span extension, DAF-16F is sufficient for 
partial life span extension in the absence of DAF-16A, and DAF-16B does not promote 
longevity. Importantly, the DAF-16/FoxO isoforms control distinct, though overlapping, 
sets of target genes. This allows us to correlate longevity with the expression of particular 
genes, and therefore we prioritized those genes for functional testing.  
daf-16a/f mutation suppresses the longevity of daf-2(e1370) mutants to the same extent 
as daf-16 null mutation, and therefore target genes controlled specifically by DAF-16A/F 
are most likely to influence life span. We further showed that daf-16a mutation partially 
suppresses longevity, while daf-16f mutation alone has no effect (Figure 5.1A-B), and 
used the gene expression profiles of these isoform-specific daf-16 mutants to bin DAF-
16A/F targets into discrete categories (Figure 5.1C).  
Because DAF-16A-specific targets are the major difference between daf-2(e1370) and 
daf-16a;daf-2, we reasoned that some subset of this category is likely responsible for the 
partially reduced life span of daf-16a;daf-2 animals. Therefore, we sought to test strains 
that harbor loss-of-function mutations in A-specific targets. 
Conversely, because the expression of shared genes is largely maintained after individual 
daf-16a and daf-16f mutation, we reasoned that some subset of this category is 
responsible for the residual life span extension of daf-16a;daf-2 mutants compared to daf-
16a/f;daf-2 mutants. However, the vast majority of genes (334/399) are shared DAF-
16A/F targets, and this list is experimentally intractable. Therefore, we first selected 
those genes that are redundantly regulated, i.e. they show minimal change with either daf-
16a or daf-16f mutation alone. These genes are the most likely to continue to play the 
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same roles they do in daf-2(e1370) mutants, following daf-16a or daf-16f mutation. 
Furthermore, in Chapter 3 we identified DAF-16A/F targets whose expression levels are 
altered in daf-2(e1368) mutants and germline-ablated animals. Therefore, we prioritized 
those genes that are jointly regulated by DAF-16A and DAF-16F in all three contexts, 
because these are highly associated with longevity.  
This prioritization totals 134 genes that are likely to influence life span. We considered 
this a small enough set to proceed with functional analysis.  
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Figure 5.1. Rationale for prioritizing genes for functional testing by genetic 
mutation. 
(A-B) Survival curves of (A) daf-16a;daf-2 and (B) daf-16f;daf-2 mutants. A and AF indicate the suspected 
roles of A-specific and A/F shared targets respectively.  
(C) Flowchart indicating prioritization of DAF-16A/F targets for testing. For definitions of A-specific 
genes and redundantly regulated genes, see text and Chapter 4. The “multiple contexts” category 
encompasses DAF-16A/F targets that we identified in daf-2(e1370), daf-2(e1368), and germline-ablated 
animals (see text and Chapter 3). Note that 4 of the 46 “multiple context” genes from Chapter 3 were 
identified as A-specific or redundantly regulated in Chapter 4. (X/Y) indicates X healthy, available mutants 





Poor correlation between RNAi and mutation screening 
During the course of developing our overall strategy to identify longevity assurance 
mechanisms downstream of DAF-16/FoxO, we also employed RNA interference (RNAi) 
which has previously been used to test DAF-16/FoxO targets for contributions to life 
span extension [13,18]. However, we did not observe significant life span effects using 
RNAi (Figure 5.2A). In particular, RNAi treatments previously reported to reduce life 
span of daf-2 mutants did not do so in our hands (Figure 5.2B), despite daf-16 RNAi 
reducing life span robustly in the same experiment.  
Interpretation of results based on RNAi is often complicated by off-target effects and 
incomplete knockdown, which could vary by laboratory conditions. Furthermore, when 
we compared treating daf-2 mutants with target gene RNAi with the converse experiment 
of treating target gene mutants with daf-2 RNAi, we did not observe any correlation 
(Figure 5.2C). This surprising result indicates that conclusions about the contributions of 
single target genes cannot be drawn from RNAi knockdown of those genes, without 




Figure 5.2. Poor correlation between RNAi and mutation screening 
(A) Testing prioritized DAF-16A/F shared targets by RNAi did not result in substantial life span changes. 
Note that all except F35E12.5 are Class 1 genes (i.e. upregulated by DAF-16/FoxO). 
(B) dod-3, mtl-1, lys-7, and icl-1 RNAi do not reduce daf-2(e1368) longevity in our hands. These were 
previously reported by Murphy et al. [17] reduce daf-2 longevity (dod-3 0-22%, mtl-1 10-25%, lys-7 8-
30%, icl-1 23%). 
(C) RNAi and mutation loss-of-function of individual target genes do not correlate. daf-16 (red) is shown 




Mutant screening strategy 
We developed the following strategy to test these genes: We first obtained mutants that 
were readily available and selected ones that were not obviously sick. This totaled 42 
mutant strains, about one-third of the 134 prioritized genes (57 A-specific, 35 redundant, 
and 42 multi-context targets; Figure 5.1C). Furthermore, we also tested four DAF-16A/F 
target genes that would not be predicted to influence life span based on their pattern of 
regulation by DAF-16 isoforms. 
For Class 1 genes, i.e. those upregulated by DAF-16/FoxO, we screened these strains for 
reduced daf-2-RNAi-mediated life span extension. We performed an initial screen at low 
numbers (~30 animals per strain per RNAi treatment), and then repeated this experiment 
with a larger number of animals for those mutations that had significant effects in the first 
experiment. To determine the effect of each mutation and correct for any changes in 
baseline mutant life span, we calculated the life span extension of each strain on daf-2 
RNAi relative to control RNAi treatment, and compared this to life span extension of N2 
wild-type on daf-2 RNAi relative to control RNAi in the same experimental replicate. 
Thus, as daf-16 mutants do not show any life span extension by daf-2 RNAi, daf-16 
mutation suppressed 100% of the daf-2-RNAi-mediated life span extension. In contrast, a 
lipl-4 mutant shows the same percent life span extension on daf-2 RNAi as wild-type, 
and thus lipl-4 mutation suppresses 0% of the daf-2-RNAi-mediated life span extension. 
For Class 2 genes, i.e. those downregulated by DAF-16/FoxO, we screened these strains 
for increased life span under control conditions. We also screened them for increased life 










Figure 5.3. Results of screening mutations in DAF-16A/F targets  
(A) Effect of Class 1 targets (upregulated by DAF-16/FoxO) on daf-2 RNAi-mediated longevity. (B) Effect 
of Class 2 targets (downregulated by DAF-16/FoxO) on life span compared to wild-type. * indicates 





Genes regulated primarily by DAF-16A are major determinants of life span 
Of all the genes we tested, the two genes with the greatest effects were the A-specific 
targets hsp-12.3 and sodh-1 (Figure 5.3A). Strikingly, hsp-12.3 and sodh-1 mutation 
caused 94% and 81% suppression of daf-2-RNAi mediated life span extension, 
respectively (Figure 5.4A-B). This was nearly the same effect as daf-16 null mutation 
(100%; Figure 5.3A and Figure 5.5E). sodh-1 encodes an enzyme similar to human 
alcohol dehydrogenases and sorbitol dehydrogenases (BLAST, WormBase). sodh-1 
mutants are reported to have reduced alcohol metabolism in vivo [22]. hsp-12.3 encodes a 
heat shock protein similar to human alpha-crystallin, but lacks activity in classic 
chaperone assays [23]. Importantly, these genes suppressed longevity of daf-2-RNAi 
longevity without significantly reducing life span on control RNAi. The sodh-1 mutant 
was 13% shorter lived than wild-type on control RNAi; by comparison, daf-16 is 26% 
shorter-lived. The hsp-12.3 mutant was 13% longer-lived on control RNAi. Therefore, it 
is likely that the animals are not sick, and hsp-12.3 and sodh-1 are major determinants of 
daf-2/IGFR longevity. 
Mutations in another five upregulated DAF-16A-specific targets also significantly 
suppressed longevity: C08E8.10, srp-3, F26A1.8, gst-20, and glt-5 (Figure 5.3A and 
Figure 5.4). C08E8.10 encodes a short 93 amino acid protein of unknown function 
(WormBase). srp-3 encodes a conserved, functional member of the serpin family, acting 
to inhibit the serine peptidases cathepsin G and chymotrypsin in vitro [24]. Translational 
fusion reporters indicate srp-3 is found intracellularly in C. elegans muscle [24]. F26A1.8 
is similar to the TauE family of integral membrane proteins that are involved in anion 
transport during taurine metabolism (BLAST, WormBase). gst-20 is a glutathione-S-
transferase family member that is most similar to human hematopoietic prostaglandin D 
synthase (WormBase). glt-5 is one of six conserved glutamate transporters in C. elegans, 
where it may function to prevent neurotoxic accumulation of glutamate [25].  
For comparison to A-specific targets, we tested two upregulated F-specific targets (out of 
8) for which loss-of-function mutations were available (Figure 5.3A). Interestingly, these 
did reduce life span extension slightly. However, they had far less significant effects than 
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DAF-16A targets, and their pattern of regulation suggests that their upregulation is not 
important for life span extension. 
srr-4, an A-specific target, was the only Class 2 gene that extended life span compared to 
wild-type when mutated (30% extension; Figure 5.3B and Figure 5.4H). srr-4 is 
downregulated 3-fold in daf-2 mutants dependent on daf-16a, and it was not previously 
identified by any microarray studies. srr-4 is a 7 transmembrane-pass G-protein coupled 
receptor of unknown function (www.wormbase.org). Interestingly, srr-4 mutants treated 
with daf-2 RNAi are shorter-lived than wild-type animals treated with daf-2 RNAi (data 
not shown), suggesting srr-4 may have context-specific effects. 
In sum, out of 14 DAF-16A-specific targets functionally tested, we identified 8 that 
influence longevity (Figure 5.3). Remarkably, two of them suppress longevity when 
mutated to almost the same extent as daf-16 mutation itself. This is consistent with 





Figure 5.4. Survival curves of A-specific genes with the largest effects on life span. 
(A-F) Life span curves for six DAF-16A-specific upregulated genes with major effects on daf-2-RNAi-
mediated life span extension are shown. (G) daf-16a(tm5030) mutant treated with daf-2 RNAi or vector is 








Genes regulated jointly by DAF-16A/F are major determinants of life span 
After the three DAF-16A targets, the Class 1 genes with the next strongest, statistically 
significant effects were three genes that we identified as DAF-16A/F targets in multiple 
contexts (Figure 5.3A). These were all more strongly affected by daf-16a mutation than 
daf-16f mutation. The first one is dod-3 (Figure 5.5A), a short 106 amino acid protein 
with unknown function that has been validated in numerous studies of DAF-16 targets 
[13]. 
lipl-2 is a shared DAF-16A/F target in multiple contexts, is upregulated 32-fold in daf-
2(e1370) compared to wild-type, and reduces life span extension by 50% when mutated 
(p < 0.0001; Figure 5.5B). lipl-2 is one of five triglyceride lipases induced by fasting in 
C. elegans that are similar to human lysosomal lipase [26]. Intriguingly, of these five 
lipases, lipl-1, lipl-3, and lipl-4 are also upregulated in daf-2(e1370) mutants according to 
our profiling. lipl-1 is an A-specific target upregulated 100-fold in daf-2(e1370), but lipl-
1 mutation did not have any effect on longevity. For comparison to lipl-2, we noted that 
lipl-3 and lipl-4 are shared DAF-16A/F targets, and thus we tested lipl-3 and lipl-4 but 
found no effect. The lipases lipl-3 and lipl-4 are only DAF-16A/F targets in two contexts, 
and are shared more equally between DAF-16A and DAF-16F compared to lipl-2, both of 
which we had reasoned would make them less likely to influence longevity. lipl-2’s 
stronger influence on longevity supports the notion that our two strategies helped to 
identify the specific lipase that promotes longevity in animals with reduced IIS. 
T02B5.1, another shared DAF-16A/F target that reduces life span extension by 49% when 
mutated (p < 0.0001; Figure 5.5C), is most similar to human cocaine esterase and 
acetylcholinesterase. T02B5.1 possesses a carboxylesterase domain that is 24% identical 
to the acetylcholinesterase of Pacific electric ray Torpedo californica, including 
conserved catalytic residues [27]. We also utilized a second allele of T02B5.1 that 
truncates the C-terminus and likely causes weaker loss-of-function, and this reduced life 
span extension 16%, adding further evidence that T02B5.1 promotes longevity. While it 
is a shared target of DAF-16A/F, daf-16a mutation has a significantly stronger effect on 
its expression, and daf-16f;daf-2 still expresses T02B5.1 at nearly 100-fold greater levels 
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than wild-type (Figure 5.5D). Therefore, T02B5.1’s effect on longevity is consistent with 
the pattern that stronger regulation by DAF-16A is a predictor of a gene’s role in life span 
control. 
Some DAF-16A/F shared target genes such as sod-3, mtl-1, icl-1, and glb-1 previously 
identified as having a role in life span control [17] had minor effects in our experiments 
(Figure 5.3A). Another three shared genes, Y6G8.2, cyp-34A10, and C07A4.2 also had 
minor effects (Figure 5.3A). Their effects were much less significant than those of A-
specific target genes and other A/F shared targets identified by our strategy based on 
hierarchical DAF-16 isoform action. 
In sum, we identified 10 shared DAF-16A/F targets (out of 28 tested) that influence life 
span, including two novel longevity genes lipl-2 and T02B5.1 with major effects. Taken 
together with our A-specific targets (Figure 5.4), many genes are likely to contribute to 





Figure 5.5. Survival curves of shared DAF-16A/F target genes with the largest 
effects on life span. 
(A-C) Effects of the three DAF-16A/F shared targets with the largest influences on life span. (D) qPCR 





In this study, we employed a logical strategy to prioritize specific DAF-16/FoxO target 
genes for functional analysis. The results broadly suggest that regulation by DAF-16A is 
a major predictor of a gene’s role in life span extension, and shared regulation by DAF-
16A and DAF-16F is a secondary predictor (Figure 5.3, Figure 5.4, Figure 5.5). This is 
consistent with the life span phenotypes of isoform-specific daf-16/FoxO mutants, where 
DAF-16A is the dominant isoform, but DAF-16F is a secondary isoform that promotes 
longevity in the absence of DAF-16A. In particular, we discovered that the DAF-16A-
specific target genes hsp-12.3 and sodh-1 are fully required for the longevity of daf-2-
RNAi-treated animals (Figure 5.4A-B). 
We also found a surprising lack of correlation between RNAi and mutation under similar 
laboratory conditions (Figure 5.2C). Our result is similar to a study in zebrafish 
concerning morpholinos, analogous to RNAi, that showed that mutation failed to validate 
80% of morpholino-induced phenotypes [28]. This has major implications for 
understanding the contribution of individual DAF-16/FoxO target genes to longevity. 
RNAi is prone to off-target effects that could lead to false positives (i.e.. RNAi alters life 
span but mutation does not). Furthermore, RNAi may result in incomplete knockdown of 
mRNA and protein levels, especially in neurons and pharynx that are refractory to RNAi, 
resulting in false negatives (i.e. mutation alters life span but RNAi does not). Thus, 
critical longevity genes may be missed by RNAi. 
sodh-1, hsp-12.3, and T02B5.1 illustrate the potential advantages of mutation compared 
to RNAi. Previous studies report that sodh-1 RNAi causes a 5-10% reduction in daf-2 
mutant, while hsp-12.3 RNAi does not affect daf-2 longevity [17,18]. We found an ~ 5% 
increase in life span following T02B5.1 RNAi treatment in daf-2 and germlineless 
mutants (Figure 5.2A). However, promoter reporters indicate that sodh-1 is expressed in 
daf-2 neurons [29] which is refractory to RNAi. qPCR indicates that hsp-12.3 is 
upregulated 50-fold [18] and T02B5.1 is upregulated 200-fold in daf-2(e1370) (Figure 
5.5D), but the efficiency of hsp-12.3 and T02B5.1 RNAi is not known. Therefore, our 
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loss-of-function mutations likely reduced function of sodh-1, hsp-12.3, and T02B5.1 far 
more than RNAi is capable of, and therefore had a much stronger effect on life span. 
RNAi may also have led to false positives. lipl-4 RNAi was previously shown to partially 
reduce the life span extension of daf-2 mutants [30], but we did not observe any effect by 
mutation (Figure 5.3A). The lipl family lipases are likely to influence longevity, as lipl-4 
over-expression extends wild-type life span and lipl-4 RNAi eliminates the longevity of 
animals lacking a germline [30,31]. However, we note that there are multiple lipl genes 
upregulated by daf-2. Thus, it is plausible that lipl-4 RNAi actually reduces the levels 
expression of multiple lipl genes, which explains why lipl-4 mutation has no effect on the 
longevity of daf-2-RNAi-treated animals (Figure 5.3A). Given that lipl-2 is a shared 
DAF-16A/F target gene that contributes to daf-2-RNAi-mediated longevity (Figure 
5.5B), previously observed effects of lipl-4 RNAi may instead by attributable to lipl-2. 
One question is why mutations in single upregulated DAF-16A-specific targets, such as 
sodh-1 and hsp-12.3, appear to reduce longevity more than daf-16a mutation itself 
(Figure 5.4A,B,G). First, DAF-16A-specific targets were chosen based on an arbitrary 
cutoff whereby daf-16a mutation has at least 80% of the effect of daf-16a/f combined 
mutation, and daf-16f mutation has less than 20% of the effect (see Chapter 4). Second, 
neither daf-16 null nor daf-16a mutation fully eliminates expression of these genes. 
Therefore, many of the DAF-16A targets are still expressed and may be slightly 
upregulated in daf-16a;daf-2 mutants compared to wild-type. This maintained expression 
is likely sufficient to mediate some life span extension in daf-16a;daf-2 mutants. 
Our results are still consistent with the idea that many gene expression changes exert 
cumulative effects on life span to produce the dramatic longevity of daf-2/IGFR mutants 
[3,17]. In particular, previously identified genes such as sod-3, mtl-1, and icl-1 involved 
in processes such as stress resistance and metabolism do indeed have small effects on life 
span (Figure 5.3A). However, our results indicate that among all DAF-16/FoxO target 
genes with roles in life span control, a small fraction are particularly important. It will be 
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interesting to determine to what extent those few gene expression changes alone can 
promote longevity. 
It is highly likely that critical genes still remain to be identified. We have tested about 
one-third of genes suggested by our DAF-16 isoform analysis, because strong loss-of-
function mutants are not available for the majority of our genes. Nevertheless, our 
analysis indicates that DAF-16/FoxO target genes absolutely required for daf-2/IGFR 
longevity exist, and that further testing and detailed functional analysis of genes that are 
regulated primarily by DAF-16A or jointly by DAF-16A/F should be prioritized. The 
gene regulatory events we have identified constitute protective functions of FoxO 
transcription factors. As many of the genes are conserved and have major effects on life 
span, they may be used as part of a strategy to manipulate FoxO outputs to prevent or 




Materials and Methods 
C. elegans strains and maintenance 
A complete list of strains used is found in Table 5.1. Animals were maintained at 15°C 
on nematode growth media (NGM) plates seeded with Escherichia coli OP50. Mutations 
with effects on life span were confirmed by PCR amplification to detect restriction 
fragment length or PCR polymorphisms. Percival I-36NL incubators (Percival Scientific, 
Inc., Perry, IA) were used for maintenance and life span assays. 
Life span assays 
Life span assays were performed as previously described [79], with minor modifications. 
Animals derived from a synchronized 4 hr egglay were grown at 15°C until the L4 larval 
stage and then shifted to 20°C. Plates harboring any males were discarded. Animals were 
grown for an additional 20-24 hr to day 1 of adulthood and then placed on life span plates 
containing 25µg/mL 5-fluoro-2’-deoxyuridine (FUDR; Sigma-Aldrich, St. Louis, MO) to 
prevent progeny growth. glp-1 mutant animals were raised at the restrictive temperature 
to ablate the germline. Statistical significance was assessed using the standard chi-square-
based log-rank test in GraphPad Prism. 
RNAi 
All RNAi NGM plates contained 5mM IPTG and 25µg/mL carbenicillin. NGM plates 
were seeded with a 5X concentrated overnight culture of E. coli HT115 with either 
control L4440 vector or RNAi plasmid. Plasmids from E. coli clones were sequenced for 




Table 5.1. List of loss-of-function mutants used in Chapter 5. 
gene	   allele	  
	  
gene	   allele	  
daf-2 e1370 
	  



























lys-7  ok1384 
C07A4.2 gk820370 
	  
lys-7  ok1385 
C08E8.10 gk356583 
	  




















dod-3  gk909808 
	  
sprr-2 ok3290 









F35E12.5  ok3418 
	  
T02B5.1  gk854495 
ftn-1  ok3625 
	  
T12D8.5  gk829473 








Y20C6A.1  gk476820 
gst-29  gk500211 
	  
Y6G8.2 gk707403 
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Chapter 6 Conclusions 
 
Overview 
The goal of this dissertation was to understand the mechanisms by which DAF-16/FoxO 
influences the aging process and extends life span in C. elegans. While much is known 
about the numerous upstream pathways that regulate FoxO transcription factors, the 
downstream effects appear to be even more complex, making it difficult to correlate 
FoxO activation with phenotypic outputs. DAF-16/FoxO regulates other phenotypes that 
can be fully or partially uncoupled from longevity [1], implying that many DAF-16/FoxO 
target genes may be unrelated to longevity. Given that DAF-16/FoxO regulates thousands 
of genes, a coherent conceptual framework predicting how these genes relate to life span 
is needed. 
In Chapters 2 through 4 of this dissertation, we employed different strategies to develop 
this conceptual framework and parse DAF-16/FoxO action into distinct transcriptional 
programs. Importantly, some of these programs promote longevity while others do not. In 
Chapter 5, we rigorously tested the genes found in the pro-longevity modules and 
discovered critical targets. 
SGK-1 and AKT-1 act in opposition to control longevity 
Sgk and Akt are similar kinases that both capable of phosphorylating three conserved 
FoxO protein RxRxxS/T motifs that determine FoxO subcellular localization and 
therefore activity. Some observational data in the literature suggested that C. elegans 
SGK-1 and AKT-1 have opposing effects on life span. This offered an opportunity to 
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discover FoxO transcriptional programs that diverge under Sgk and Akt signaling 
regimes in a conserved manner. 
We sought to clarify the relationship between SGK-1, DAF-16/FoxO, and longevity. 
Using mutations in sgk-1 we found that SGK-1 promotes longevity in a DAF-16/FoxO-
dependent manner. Hypothesizing that SGK-1 activates DAF-16/FoxO, we examined 
known indicators of DAF-16/FoxO activation. In contrast to AKT-1 which inhibits DAF-
16/FoxO in a straightforward manner, we found mixed results with SGK-1 and 
discovered important SGK-1 outputs independent of DAF-16/FoxO. Thus, while SGK-1 
promotes longevity, its relationship with DAF-16/FoxO is far more complex. 
Future studies can further clarify SGK-1’s influence on DAF-16/FoxO by focusing on the 
molecular mechanism by which SGK-1 and AKT-1 differentially regulate DAF-16/FoxO 
activity. Potentially, the divergence could be explained by the affinities of SGK-1 and 
AKT-1 for distinct RxRxxS/T motifs on DAF-16/FoxO. This would require refinement of 
the current model where phosphorylation of these sites inhibits DAF-16/FoxO 
transcriptional activity. Alternatively, SGK-1 and AKT-1 could differentially influence 
other transcriptional regulators that collaborate with DAF-16/FoxO.  
For our purposes, the discovery that SGK-1 has DAF-16-independent effects on outputs 
normally attributed to DAF-16/FoxO activation greatly complicates the interpretation of 
DAF-16/FoxO transcriptional activity under AKT-1 and SGK-1 signaling regimes. 
Furthermore, it was later discovered by the Blackwell group that SGK-1 acts in two 
opposing pathways to control longevity, the balance of which depends on temperature 
and other environmental factors [2]. SGK-1 inhibits SKN-1/Nrf, another DAF-2-
responsive transcription factor, at high temperatures to limit longevity [2]. However, at 
lower temperatures SGK-1 activates DAF-16/FoxO to promote longevity [3]. For future 
studies, it is an important goal to elucidate how SGK-1 and DAF-16/FoxO influence 
longevity in different environmental contexts and in collaboration with other transcription 
factors. However, the problem remains that it is still unclear how DAF-16/FoxO itself 
promotes longevity in a single context. 
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These novel insights into SGK-1 unnecessarily complicate efforts to identify DAF-
16/FoxO target genes that influence life span. Therefore, we pursued other lines of 
inquiry that could untangle DAF-16/FoxO’s complex mechanism of action.  
DAF-16/FoxO isoforms control distinct target genes 
In Chapters 3 and 4, we tested the hypothesis that DAF-16/FoxO isoforms control distinct 
sets of target genes and make differential contributions to longevity. After discovering 
that this is true, we used DAF-16/FoxO isoform-specificity as the basis for our strategy to 
prioritize target genes for rigorous functional testing in Chapter 5. 
Isoform-specific alleles: Novel genetic tools to study longevity 
Much of the work in this dissertation relied on our isolation of the first isoform-specific 
alleles of DAF-16/FoxO that specifically eliminate the function of one or more isoforms 
encoded by the daf-16 genomic locus. In theory, these alleles could be used to uncouple 
different outputs of this pleiotropic transcription factor. However, it was initially 
unknown if cross-isoform interactions, genomic locus complexities, isoform redundancy 
or other unforeseen caveats would prevent useful interpretation. 
For example, the mg54 allele of daf-16 was predicted to specifically eliminate DAF-16A 
and DAF-16F function, and DAF-16B does not promote longevity. Therefore, comparing 
mg54 to daf-16 null mutation could theoretically isolate DAF-16B functions that could 
then be ignored in rigorous testing of target genes. 
Chapter 3 provided the required proof-of-principle that different genetic alleles of daf-16 
could be used in a coherent fashion to dissect DAF-16/FoxO actions. When introduced 
into long-lived strains with active DAF-16/FoxO, mg54 alters gene expression in a 
qualitatively distinct manner compared to the null allele mu86. In particular, many Class 
2 (downregulated by DAF-16) and some Class 1 (upregulated by DAF-16) genes were 
affected by mu86 but not mg54 mutation. This result held true in three separate strains, 
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each with unique signaling regimes and genetic backgrounds. Therefore, mg54 serves as 
a robust genetic filter. 
Chapter 4 introduced isoform-specific alleles that specifically eliminated either DAF-16A 
or DAF-16F. We characterized all the alleles in detail. Importantly, transcript levels and 
sequences of intact isoforms remained the same, mitigating concerns that interactions 
between isoforms would complicate life span and gene expression data. Furthermore, two 
separate daf-16a alleles produced identical effects on phenotypic outputs and gene 
expression, demonstrating reproducibility. Finally, a separate analysis of DAF-16A-
specific targets identified in the context of daf-2/IGFR mutation demonstrated that they 
are also depend on DAF-16A in the context of germline ablation. Taken together, these 
isoform-specific alleles are highly valuable tools to understand how DAF-16/FoxO 
promotes longevity. 
We also note that isoform-specific alleles have many advantages, and few disadvantages, 
compared to previous methods to study DAF-16 isoforms. Previous studies primarily 
relied on transgenic animals over-expressing individual DAF-16 isoforms [4,5]. Using 
single-copy transgenes, we found that simply doubling the gene dosage of DAF-16F 
exaggerates its role. Therefore, quantitative assessments of isoform contributions to 
longevity cannot be made using multi-copy transgenic animals. Isoform-specific 
mutations maintain all of the DNA regulatory elements that normally function to control 
synthesis of daf-16 transcripts. We found that daf-16a transgenes do not rescue daf-16a 
isoform-specific mutation, suggesting that those transgenes are missing key regulatory 
elements. Transgenes do have the advantage of fluorescent tags allowing for visualization 
of tissue expression, but if they are over-expressed or missing key regulatory elements 
then the interpretation is limited. These differences likely explain why our results differ 
from the previously published finding that DAF-16F plays a stronger role than DAF-16A 
in life span control. 
In summary, we characterized the first truly isoform-specific alleles of DAF-16/FoxO 
and demonstrated their utility. With the advent of facile CRISPR genome engineering in 
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C. elegans [6], many more useful daf-16 alleles can be created that alter specific 
sequence elements of each isoform or introduce experimentally useful elements such as 
fluorescent tags. We used the isoform-specific alleles to dissect the mechanism of life 
span extension, but these reagents will also be useful for studying other processes 
modulated by DAF-16/FoxO, including development, reproduction, behavior, cell fate 
plasticity, and tumor growth [7–10]. It will be interesting to exploit these alleles to 
prioritize testing of critical targets in these contexts, similar to our strategy for life span 
control. 
Hierarchical action of DAF-16/FoxO isoforms in longevity control 
In Chapters 3 and 4, we employed isoform-specific daf-16 alleles to reveal hierarchical 
action of DAF-16 isoforms in life span control, in this order: DAF-16A > DAF-16F > 
DAF-16B. This pattern was robust across three separate contexts where DAF-16/FoxO 
promotes longevity: daf-2/IGFR ligand-binding domain mutation, daf-2/IGFR tyrosine 
kinase domain mutation, and germline ablation. Our findings are consistent with previous 
work showing that DAF-16A and DAF-16F are both capable of promoting longevity, 
while DAF-16B is not [4,5]. However, the isoform-specific alleles made it possible to 
assess the endogenous contributions of daf-16 isoforms to longevity and determine that 
DAF-16A plays a stronger role than DAF-16F. 
We used whole-transcriptome profiling (RNA-seq) to elucidate the basis for hierarchical 
action of isoforms. We made conventional comparisons between transcriptomes to define 
general DAF-16 targets, and employed the daf-16a/f allele to filter out DAF-16B targets. 
We then categorized the genes using A-indices and F-indices calculated in silico that 
reflect each gene’s relative regulation by DAF-16A and DAF-16F. We discovered that 
there are far more A-specific genes than F-specific genes, and the majority of shared 
genes show stronger regulation by DAF-16A. Importantly, the fact that DAF-16A exerts 
a stronger effect on global transcriptional regulation correlates with the isoforms’ relative 
contributions to longevity. 
 
 180 
It is important to note that our A-specific, shared, and F-specific targets are actually part 
of the same continuous spectrum, and the precise criteria for classifications are 
necessarily arbitrary. We clearly ruled out the possibility that DAF-16A and DAF-16F 
regulate fully distinct sets of genes. More intriguingly, we shed light on overlapping 
functions of DAF-16A and DAF-16F. When expression changes of all target genes are 
plotted according to regulation by DAF-16A or DAF-16F relative to DAF-16A/F 
together, the genes span the full spectrum from 0% to 100% regulation by each isoform. 
There is no straightforward relationship between a given gene’s regulation by DAF-16A 
and its regulation by DAF-16F. This has implications for interpreting experiments in 
mammalian systems where FoxO isoforms are knocked out. It will be necessary to 
compare all possible combinations of single and multiple mammalian FoxO gene 
knockouts to determine which isoforms preferentially regulate which genes. 
Open questions concerning hierarchical action by DAF-16/FoxO isoforms 
Many questions remain concerning the molecular basis for hierarchical daf-16 isoform 
action. Why do target genes vary in their regulation by DAF-16A and DAF-16F? It is 
unlikely that differences in direct DNA binding are responsible, because the DAF-16A 
and DAF-16F forkhead DNA binding domains are identical. Furthermore, DAF-16A, 
FoxO1, FoxO3, and FoxO4 all vary in their forkhead domains, yet bind the same DNA 
motif in vitro [11]. Another factor could be distinct spatial or temporal expression, 
partially explained by distinct promoters. However, RNA-sequencing reads suggest that 
production of some daf-16a transcripts may be controlled by the canonical daf-16f 
promoter, and some daf-16b transcripts by the daf-16a promoter, suggesting the overlap 
in isoform expression may be greater than originally thought. DAF-16A and DAF-16F 
are expressed in nearly all the same tissues [4], especially the neurons, intestine and 
hypodermis which are critical for DAF-16/FoxO-mediated longevity [12,13], thus 
arguing against tissue-specificity as a differentiating factor. 
A promising unexplored hypothesis is that the unique N-termini of DAF-16A and DAF-
16F confer association with distinct binding partners. Numerous transcriptional co-
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regulators work in collaboration with FoxO transcription factors [1,14,15]. One potential 
experiment is to perform an RNAi screen of all transcriptional regulators, and identify 
those genes whose knockdown affects phenotypes only in the daf-16a mutant or only the 
daf-16f mutant. DAF-16A-specific and DAF-16F-specific genes may also be measured, 
and the A-index and F-index can be exploited for investigating any determinant of 
isoform-specific action. Those regulators that influence critical DAF-16A and shared 
DAF-16A/F life span targets should be prioritized for further study. 
Interestingly, there are hints that DAF-16 isoforms compete with or antagonize each 
other, consistent with having both unique and overlapping roles. We have separately 
found that a daf-16b-specific mutant is long-lived compared to wild-type, suggesting that 
DAF-16B may actually oppose life span. In Chapter 3, we noticed that DAF-16B appears 
to downregulate Class 2 genes, raising the possibility that these Class 2 genes normally 
function to promote longevity, which is contrary to the model that Class 2 genes inhibit 
longevity [16]. Alternatively, DAF-16B may inhibit other isoforms, either through direct 
competition or by modulating signaling feedback loops. Transcriptional profiling of the 
daf-16b mutant would be an appropriate starting point for further experiments. Also, a 
life span assay performed at a lower temperature (15°C) revealed that daf-16f mutation 
extends daf-2 longevity under those conditions. In contrast, daf-16a mutation has no 
effect, and daf-16a/f combined mutation fully suppresses longevity. The simplest 
explanation is that DAF-16F acts as a partial agonist that is sufficient for life span 
extension but antagonizes DAF-16A when both isoforms are present. Observing these 
potential interactions was made possible by the isoform-specific alleles. Future studies 
may clarify the nature of cross-isoform interactions and determine whether or not 
mammalian FoxO1, FoxO3, FoxO4, and FoxO6 share these mechanisms. 
In summary, the isoform-specific alleles of daf-16/FoxO have opened up many new lines 
of inquiry. Ultimately, the hierarchical action of DAF-16/FoxO isoforms should be 




Identification of critical DAF-16/FoxO longevity targets 
In Chapters 3 and 4, we identified DAF-16A/F target genes in multiple long-lived strains 
and further dissected those genes into A-specific, shared, and F-specific genes. With this 
information in hand, in Chapter 5 we proceeded to the practical consideration of how to 
prioritize and perform functional testing of these genes. To assess the role for a given 
gene in longevity, we disrupt the gene’s function and determine its effect on life span. 
Method of functional testing: Mutation versus RNAi 
One of the most important reasons why we need rational prioritization of target genes is 
that null mutation, the “gold standard” method of functional analysis in C. elegans, is 
more laborious and less readily available than RNA interference (RNAi) [17]. Less than 
10% of target genes have been tested by RNAi for effects on life span, and only a handful 
have been tested by mutation. 
All published experiments that functionally tested significant numbers (dozens) of targets 
utilized RNAi [16,18–20]. This was a practical necessity, as loss-of-function alleles of 
most genes had not yet been isolated. However, the percentage of RNAi clones altering 
life span by off-target effects is unknown (false positives). In theory, this could be 
mitigated by using multiple RNAi clones, or by directly comparing RNAi clones 
knocking down DAF-16/FoxO targets with random RNAi clones. Furthermore, 
incomplete knockdown of mRNA and protein levels by RNAi, especially in neurons and 
pharynx which are refractory to RNAi, means that critical longevity genes may be missed 
(false negatives).  
We screened a subset of genes by RNAi before all transcriptome profiling was 
completed. When we later compared these results to mutation of the same genes, we 
found very little correlation between RNAi and mutation. This result is reminiscent of a 
study in zebrafish concerning morpholinos, analogous to RNAi, that showed that 80% of 
morpholino-induced phenotypes were not recapitulated by mutation [21]. Previous 
studies have shown discordant results between RNAi and mutation for the superoxide 
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dismutase sod-3 and the fatty acid desaturase fat-7 [18,22,23]. These results suggest that 
the number of false positives by RNAi is very high, and testing many genes may only 
exacerbate the problem of off-target effects.  
At the time of this writing, isolating loss- and gain-of-function mutations is becoming far 
less time-consuming and laborious. Initiatives such as the Million Mutation project, the 
C. elegans Knockout Consortium, and the National Bioresource Project are concerted 
efforts to ultimately generate alleles of every single gene [24–26]. This greatly reduces 
the need for individual research groups to generate alleles. Furthermore, custom 
mutations can now be made using the CRISPR technique [6]. Mutation analysis is still 
more laborious because of the genetic crosses required to reduce background mutations 
and obtain combination mutants, but the advantages relative to RNAi-based analysis are 
worth the effort. 
To test our genes, we circumvented the labor involved in constructing combination 
mutants by subjecting strains with DAF-16 target gene mutations to daf-2 RNAi. daf-2 
RNAi is robust, validated, and used by many research groups, whereas many other RNAi 
clones have only been tested as part of genome-wide screens and have never been 
validated. When possible, we utilized multiple alleles from different genetic backgrounds 
to reduce the chance of false positives due to background mutations. To reduce the 
chances that the animals are short-lived because they are simply sick, we measured 
animal life span on control RNAi and observed the animals for obvious developmental 
effects. At the time of this writing, we are in the process of even more rigorous life span 
experiments utilizing combination mutants with daf-2 loss-of-function alleles. Thus, it is 
feasible to obtain interpretable data on the life spans of large numbers of mutants. 
Now that isolation of C. elegans mutants is commonplace and straightforward, it will be 
interesting to see how many phenotypes attributed to RNAi gene knockdown will be 
confirmed by mutation. Drawing on our work in Chapter 4 using isoform-specific RNAi 
to treat isoform-specific mutants, we note that RNAi and mutation can and should be 
combined as part of a concerted strategy, especially when genes have overlapping roles. 
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However, mutation is the “gold standard” to assess gene function by reverse genetics. 
Given that the current model that DAF-16 controls many genes to influence longevity is 
based on RNAi data, the fact that mutation produces different results for many genes may 
lead to revision of this model. 
Prioritization of target genes according to DAF-16/FoxO isoform regulation 
We developed a rational approach to prioritizing target genes for functional testing based 
on hierarchical action of DAF-16 isoforms in longevity control. Given that daf-16a 
mutation shortens life span while daf-16f mutation does not, it follows that DAF-16A-
specific targets are very likely to influence longevity. Thus, we chose to test all DAF-16A 
targets where reagents were readily available. The life span data also strongly suggests 
that shared targets contribute to longevity, and we prioritized those shared genes that are 
redundantly regulated by DAF-16A and DAF-16F, and those that were also identified as 
DAF-16A/F targets in the multiple contexts (Chapter 3).  
The results of testing individual genes by mutation broadly validated our strategy. A-
specific genes had the greatest effect on life span, while shared genes also contributed. 
This implies that the reason daf-16a is required for maximal life span extension by daf-
2/IGFR is because certain A-specific genes are required (hsp-12.3 and sodh-1; Figure 
6.1). On the other hand, intact daf-16f can still partially extend life span in the absence of 
daf-16a because some shared daf-16a/f targets promote longevity (T02B5.1 and lipl-2; 
Figure 6.1). Given that DAF-16A and DAF-16F may compete, it will be interesting to 
determine if daf-16f-regulated targets become more important for the longevity of daf-
16a mutants, and vice versa.  
However, we do not yet know if we enriched for longevity genes by prioritizing those 
shared genes that are DAF-16A/F targets in three contexts (two separate daf-2 mutations 
and germline ablation). This would require comparing targets regulated by DAF-16A/F in 
only one or two context with those regulated in all three contexts. 
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It does appear that prioritizing genes redundantly regulated by DAF-16A/F did not enrich 
for longevity genes, as we only identified one redundant gene with a minor effect. By 
definition, redundant genes are those do not change with daf-16a and daf-16f mutation, 
but do change significantly with combined daf-16a/f mutation. Indeed, a separate analysis 
of germline-ablated animals showed that expression of these genes do change with daf-
16a mutation alone in that context, suggesting that redundantly regulated genes do not 
necessarily comprise a biologically significant class. In contrast, A-specific genes were 
equally affected by daf-16a and daf-16a/f mutation in germline-ablated animals, as they 
were in daf-2 mutants. This suggests there exists a unique mechanism to regulate A-
specific genes, but not redundant genes. 
The most limiting criteria for our analysis was availability of mutants. We only tested 
loss-of-function mutants that already exist, a criterion that applied to approximately one-
third of the genes we identified. It is almost certain that we have missed critical longevity 
genes. Therefore, the most obvious next experiment is to utilize CRISPR [6] to generate 
loss-of-function mutations for the rest, prioritizing those genes with high degree of 









This dissertation is a step forward in deciphering the mechanism of DAF-16/FoxO-
mediated life span extension. We identified hierarchical action by DAF-16 isoforms as a 
conceptual framework that can predict whether a given target gene is likely to influence 
longevity or not. We discovered that DAF-16/FoxO does regulate a small set of genes 
with disproportionate effects on longevity, including a handful that are almost fully 
required for life span extension. Future studies will shed light on the mechanism of life 
span extension by these genes, as well as the mechanisms of aging itself. 
Future experiments to define the mechanism of DAF-16/FoxO-mediated longevity 
We demonstrated that DAF-16/FoxO isoforms make differential contributions to 
longevity because they regulate distinct target genes. The next major question is: how are 
each of these genes acting? Many C. elegans gene functions have been predicted simply 
by homology to more well-studied genes. This previously proved useful when studying 
broad processes influenced by DAF-16/FoxO, such as metabolism or oxidative stress 
resistance. However, understanding the mechanism of life span extension by individual 
genes will require a more detailed analysis of function.  
Hopefully, elucidating basic characteristics of these genes such as their molecular 
functions and expression patterns will yield novel lines of inquiry into the mechanisms of 
aging. Those experiments are highly gene-dependent and will not be discussed in detail 
here. However, some experiments apply to all the genes. 
First, the role of individual target genes in control of aging and longevity should be 
further defined. Most of the genes we identified are Class 1 genes that upregulated by 
DAF-16/FoxO and are required for full life span extension due to reduced DAF-2/IGFR 
signaling, so this discussion will focus on those genes. It should be determined whether  
artificially increasing the function of these genes is sufficient for life span extension. This 
experiment would also provide additional evidence that mutation does not simply prevent 
life span extension due to general frailty or sickness. Furthermore, the role of the genes in 
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general longevity assurance can be assessed by mutating the genes in other longevity 
models, including altered mitochondrial function, dietary restriction, and reduced TOR 
(target of rapamycin) signaling [27–29]. 
Second, it will be interesting to understand how these individual genes might work 
together to extend life span. Combination mutants could reveal if the genes work in 
common or independent pathways. Ultimately, a set of DAF-16 target genes can be 
artificially manipulated in daf-16 null mutants to match their expression in daf-16 wild-
type animals. If those animals are long-lived as if DAF-16 were activated, then that set of 
genes may be the most important for DAF-16/FoxO-mediated life span extension. 
Third, the effect of these genes on markers of age-related decline should be assessed, as 
we have only measured life span in our studies. Analysis of aged C. elegans has revealed 
numerous changes that are reminiscent to those in elderly humans, including reduced 
movement, sarcopenia (muscle loss), immunosenescence (reduced resistance to 
infection), reduced fertility, pathogenicity caused by commensal or symbiotic bacteria, 
and reduced stress resistance [9,30–34]. Importantly, many of these changes are greatly 
delayed or attenuated by daf-2/IGFR mutation. This maintained youthfulness in aged daf-
2 mutants is often termed extended “health span.” As the causes of death in C. elegans 
are not well-studied, it is possible that many of the changes that occur in aged C. elegans 
might not contribute to mortality, at least under laboratory conditions. In that case, many 
of the gene regulatory events that we identified may promote extended health span, but 
not longevity. It will be interesting to determine the extent of overlap between DAF-
16/FoxO target genes that promote health span and those that promote longevity. 
Implications for aging and longevity 
Given that aging does cause numerous changes in an organism, how can a single DAF-
16/FoxO target gene such as sodh-1 or hsp-12.3 have a major effect on longevity? It is 
more intuitive that dramatic life span extension requires alterations in many biological 
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processes each involving many genes. There are several possible explanations for how a 
small set of genes can have a disproportionate effect on longevity (Figure 6.2). 
A straightforward explanation is that these genes might be involved in the regulation of 
many other genes, a model that applies to the daf-2 and daf-16 genes themselves. Indeed, 
it has been hypothesized that DAF-16/FoxO acts as a “regulator of regulators” [35], and 
secondary regulators may play a disproportionate role in life span control. Another 
explanation is that target genes might be required for full DAF-16/FoxO function, acting 
in a positive feedback loop. Previous experiments indicate that DAF-16/FoxO targets 
aakg-4 and tcer-1 bolster DAF-16/FoxO transcriptional activity [36,37]. However, these 
explanations are not readily suggested by annotated functions of sodh-1 and hsp-12.3. 
Another possible explanation is that genes like sodh-1 and hsp-12.3 are directly affecting 
the major causes of mortality. It is not clear what aged worms die of, and it is possible 
that only a few causes of death are relevant in the laboratory setting. In that case, the 
majority of DAF-16/FoxO target genes might instead function to delay death in the wild 
where animals more frequently die of external threats such as predators and extreme 
environmental conditions. In contrast, in the laboratory it is plausible that a handful of 
target genes protect against a handful of causes of death, and therefore those are the genes 
that are strongly required for longevity. 
Perhaps the most interesting (though speculative) possibility is that sodh-1 and hsp-12.3 
protect against the negative consequences of DAF-16/FoxO activation. It seems unlikely 
that all changes effected by DAF-16/FoxO are neutral or beneficial for longevity 
assurance. One open question in the aging field is why “reduced IIS” (insulin/IGF 
signaling), for example by daf-2/IGFR mutation in C. elegans or by fat-specific insulin 
receptor knockout in mice [38], greatly improves longevity and health span. If these 
mutations truly cause “reduced IIS” then they should cause insulin resistance, a defining 
feature of type 2 diabetes which reduces longevity and health span in humans. Indeed, 
reduced IIS in pancreatic beta cells and liver cause a diabetes-like phenotype in mice, 
which is reversed by FoxO1 haploinsufficiency [39,40]. This suggests that FoxO and 
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reduced IIS promote diabetes and therefore have negative effects on health, yet they 
promote longevity and health span in a conserved manner.  
hsp-12.3 and sodh-1 offer a potential solution to this apparent paradox. The human 
orthologs alpha-crystallin and sorbitol dehydrogenase are involved in cellular responses 
to type 2 diabetes and hyperglycemia [41,42]. If daf-2 mutation and DAF-16/FoxO 
activation causes negative effects reminiscent of diabetes in C. elegans, but 
simultaneously upregulate hsp-12.3 and sodh-1, then the negative effects may be 
counteracted. In this case, perhaps many genes involved in other mechanisms act in a 
cumulative manner to extend life span, but a few genes are permissive for life span 
extension because they protect against the negative effects of DAF-16/FoxO activation.  
Figure 6.2. Hypothetical model of how single DAF-16/FoxO target genes might play 
a disproportionate role in life span control. 





However, we should be cautious and agnostic about the functions of these genes until 
more definitive analysis is carried out. For example, the free radical theory of aging, 
where aging is the result of accumulated damage from free radicals, predicts that genes 
that defend against oxidative stress will extend life span and delay aging [43]. However, 
many studies reviewed in [44–46] call the role of free radicals in aging into question. One 
study found that superoxide dismutases can promote longevity, but they do so not by 
protecting against oxidative stress but rather by activating transcription factors including 
DAF-16/FoxO [47]. Therefore, traditional ideas about how specific processes influence 
life span are in question. Now that we have identified a handful of DAF-16/FoxO target 
genes that are strongly required for life span extension, it is now feasible to perform 
detailed studies of gene function, rather than inferring function from gene ontology 
annotations. As IIS reduction and DAF-16/FoxO activation dramatically increase life 
span and slow aging, the critical DAF-16/FoxO target genes identified in this dissertation 
may shed light on the fundamental nature of aging and suggest strategies to prevent and 
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